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Immune system
The human body is constantly exposed to different micro-organisms and 
pathogens. The immune system protects organisms from these invading pathogens 
but is also involved in the eradication of tumour cells. It can detect a wide variety 
of pathogens such as viruses, bacteria and parasites and is also able to distinguish 
between an organism's healthy and malignant cells. The huge variety of cells of the 
immune system and their sophisticated interplay make up a highly developed and 
complex defence system.
The innate and adaptive immune system
The immune response is based on two distinct yet linked responses, the 
innate and the adaptive immune responses. The innate immune response acts 
immediately, is predominantly non-specific and remains largely unaltered after a 
second encounter with the same pathogen. Im portant players orchestrating the 
innate immune response are natural killer cells, m ast cells, eosinophils, basophils, 
macrophages, neutrophils and dendritic cells (DCs). Innate immune cells respond 
to conserved structures derived from micro-organisms, the pathogen-associated 
molecular patterns (PAMPs), via so-called Pattern Recognition Receptors (PRRs). 
Four functionally distinct classes of PRR exist, one of which are the Toll-like 
receptors (TLRs). TLRs are transm em brane receptors that are located on the cell 
surface or within endosomal compartments. The primary function of TLRs is to 
trigger intracellular signalling cascades leading to activation of the immune system 
in response to pathogens [1]. Another class of PRRs are the nucleotide-binding 
oligomerization domain (NOD)-like receptors (NLRs). NLRs are cytoplasmic 
proteins involved in sensing the presence of intracellular micro-organisms. A third 
class of PRR are the C-type lectin receptors (CLRs), which recognize conserved 
carbohydrate residues. The last class is formed by the Retinoic acid-inducible gene 
(RIG)-I-like receptors (RLRs). They are localized in the cytoplasm of the cell and 
recognize the genomic RNA of dsRNA viruses and dsRNA generated as the replication 
intermediate of ssRNA viruses [2]. The recognition of PAMPs or other endogenous 
molecules called danger-associated molecular patterns (DAMPs) by PRRs leads to 
activation of the innate immune cells and ultimately the elimination of the pathogens. 
In addition, activated innate immune cells can elicit, steer and regulate adaptive 
immune responses [3]. Key players in the adaptive immune system are the B and T 
lymphocytes. In contrast to the innate immune cells, B and T lymphocytes recognize 
only one specific antigen via their B- or T-cell receptor (BCR and TCR, respectively) 
at the cell surface. Although the response generated after a first encounter with an
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antigen can take longer than a week, repeated exposure to the same antigen induces 
a more rapid memory response.
The B lymphocytes, when activated by a specific antigen via their BCR, 
differentiate into plasma cells that secrete antibodies and form the humoral arm 
of the adaptive immune system. The cellular arm of the adaptive immune response 
is mediated by the T lymphocytes. This response is initiated by antigen presenting 
cells (APCs) such as DCs, that recognize, take up, process and present antigens in the 
context of the major histocompatibility complex (MHC) to the TCR on T lymphocytes
[4]. Two different classes of MHC exist, MHC class I and MHC class II. Both classes of 
MHC are involved in presenting processed antigens in the form of peptides on the 
cell surface. MHC class I complexes present processed endogenous antigens (either 
self or viral proteins) and are recognized by CD8 positive T lymphocytes. These CD8 
positive T lymphocytes are specialized in killing the cells that present this complex 
which will lead to eradication of the infected or “transform ed” (tumour) cells. In 
contrast, MHC class II complexes present exogenous antigens and are recognized 
by the CD4 positive T helper lymphocytes (Th). These CD4 positive Th lymphocytes 
are specialized in the secretion of cytokines and thereby involved in activating and 
directing other cells of the immune system [5, 6].
Dendritic cells and their life cycle
An im portant cell in our immune system is the professional antigen presenting 
DC. This cell forms the bridge between innate and adaptive immunity. They are 
essential mediators of immunity and tolerance as they play a crucial role in the 
initiation and modulation of the immune response. DCs were first discovered in 
1973 [7], are derived from hematopoietic bone m arrow progenitor cells and form 
a heterogeneous group of cells after differentiation that consists of several distinct 
subpopulations. The heterogeneity among DCs is of particular interest due to the 
specialized functional properties of each DC subset. There are two major types of DCs: 
the myeloid DCs (mDCs), and the plasmacytoid DCs (pDCs). mDCs act as sentinels 
in the periphery and have a specialized function depending on their location and 
the expression profile of PRRs. The cellular cues present in different locations, for 
example in the gut, skin or other organs, and the array of PRR expressed by the cell 
skews the mDC towards a specific response against particular invading pathogens. 
pDCs are considered to be the front line of defence in anti-viral immunity as they 
rapidly produce massive amounts of type I interferon in response to viral infection 
and prime T cells against viral antigens [8-10].
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DCs residing in the tissue are in a so-called ‘immature’ state and have a high 
capacity to recognize and capture microbial antigens through specific receptors. 
Upon infection or inflammation, they undergo a complex process of maturation, 
whereby they change from an antigen-capturing cell into an antigen-presenting cell. 
During this process the DC changes in morphology by losing adhesive structures, 
the cytoskeleton is reorganized and high cellular motility is acquired. These changes 
allow the DC to migrate from the periphery towards the lymph nodes where they are 
able to present antigens to T lymphocytes (signal 1). In addition to these changes, 
they also lose phagocytic capacity, begin secreting chemokines and expression of 
co-stimulatory molecules such as CD40, CD80 and CD86 is upregulated (signal
2). Moreover, MHC class II compartments translocate to the cell surface and the 
DC begins secreting cytokines that differentiate and polarize attracted immune 
effector cells (signal 3) [11, 12]. Furthermore, DCs have the unique capacity to also 
present internalized antigens from exogenous antigens, such as from necrotic and 
apoptotic tum our cells via MHC class I. This process is term ed cross-presentation 
and is necessary in evoking an immune response against m ost tumours and against 
viruses that do not infect DCs [5, 6].
Role of DCs in immunity and tolerance
DCs not only activate immune cells, they can also skew the immune response 
towards tolerance. In the steady-state condition, DCs remain immature. They 
express only small amounts of MHC class II and co-stimulatory molecules and after 
T cell stimulation this will lead to T cell anergy [13, 14]. The role played by DCs in the 
outcome of T cell stimulation (tolerance or immunity) is largely dependent on the 
activation status of the DC and the surrounding environmental stimuli (Figure 1).
Inflammation and molecules derived from bacterial or viral products promote 
the production of cytokines by DC that will induce Th1 responses. In contrast, 
anti-inflammatory molecules such as IL-10, TGF-0, prostaglandin (PG)E2 and 
corticosteroids will inhibit DC maturation and cytokine production. Regulatory T 
cell (Treg) responses are therefore promoted, leading to maintenance of immune 
system homeostasis and tolerance [14, 15]. Tregs occur in various forms, all of which 
possess a suppressive function on the immune system. They include the naturally 
occurring CD4+CD25+FoxP3+, IL-10 producing Tr1 and TGF-0 producing Tr3 Tregs 
[16].
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Figure 1. Schem atic re p re se n ta tio n  of th e  ro le  o f DCs in  Th-cell lineage d ifferen tia tion
Th-cell differentiation of naive T-cells is initiated through interaction with a DC. DCs can skew differentiation 
towards specific T cell subsets depending on different environmental signals and stimuli. These and other 
signals are m ediated via the expression of Toll-Like Receptors (TLRs), NOD-like receptors (NLRs), C-type 
lectin receptors (CLRs), RIG-I-like receptors (RLRs) and Nuclear Receptors (NRs). Differentiation of T 
cells is m ediated via the expression of particular cytokine profiles by the DC. The specific T cell subsets 
(Th1, Th2, Th17 or Treg) are characterized by the expression of key transcription factors indicated in 
parentheses. The resulting expression of cytokines by the different T-cell subsets will ultimately lead to a 
specific type of immune response. Thus, DCs orchestrate the induction of a specific immune response via 
the skewing of differentiation of naive T-cells to a particular Th-cell subset specialized in the eradication 
of specific pathogens (immunity) or to maintain hom eostasis (tolerance).
As DCs can generate immunity as well as tolerance, they are essential mediators 
in defending the host against invading pathogens and in the prevention for 
excessive inflammation. Since an effective immune response is also crucial in the 
eradication of malignant tum our cells, DCs are also studied and applied to induce 
anti tum our immunity. Different tumours have already been treated with DC-based 
immunotherapy including melanoma, RCC, breast and prostate cancer [6], however 
currently no DC vaccination regimen is indicated as a standard anticancer therapy 
yet.
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Transcriptional control of DC developm ent and differentiation
Although a growing number of transcription factors, including Irf8, Batf3, RelB, 
E2-2, Id2, Ikaros, Gfi-1, STAT3 and STAT5, have been implicated in the development 
and /o r homeostasis of specific DC populations, no transcription factor has yet been 
shown to be required for the development of all DC lineages, except for PU.1 [10]. 
The cytokine fms-like thyrosine kinase 3 ligand (Flt3L) and its receptor (Flt3) are 
key regulators of DC commitment in hematopoiesis. Flt3 is expressed on short-term 
re-populating hematopoietic stem cells and its expression is progressively lost in 
m ost hematopoietic lineages with the exception of the DC precursors [10, 17]. Mice 
with a deficiency in Flt3 or Flt3L exhibited reduced DC numbers [18, 19], indicating 
an essential role for this factor in DC development. It has recently been demonstrated 
that PU.1 directly controls Flt3 gene expression on hematopoietic progenitors in a 
dose-dependent manner [20]. The regulation of the essential cytokine receptors 
Flt3 and GM-CSFR by PU.1 demonstrates that PU.1 is necessary and sufficient for 
the development of all DC lineages, PU.1 has also been shown to be required for 
the maintenance of normal HSC function and the regulation of commitment of adult 
hematopoietic progenitors [20].
Another transcription regulator putatively im portant in DC biology is DC-SCRIPT 
(DC Specific transCRIPT), also known as ZNF366. DC-SCRIPT is expressed in all DC 
subsets tested so far, including moDCs, mDCs, pDCs and Langerhans Cells (LCs). DC- 
SCRIPT mRNA expression is an early hallmark of DC differentiation from monocytes, 
suggesting an essential role in DC immunobiology. This is further emphasized by 
the fact that in both mouse and human, transcription factors with a profound role 
in haematopoiesis and DC biology can bind with high probability to the 300 bp 
preceding the first exon of DC-SCRIPT, like GATA-1, AP-1 and Spi B [21]. DC-SCRIPT 
is not expressed among other leukocyte populations [22] and is located to human 
chromosomes 5q13.2 [23]. DC-SCRIPT is well conserved in evolution, the human and 
mouse gene are located in syntenic chromosomal regions and at the protein level the 
human and mouse protein are more than 80% homologous [21]. The DC-SCRIPT 
gene is encoded by an 8 kb messenger RNA and the protein consists of a proline rich 
region, 11 C2H2-type zinc fingers and an acidic region (see figure 2). Beyond its zinc 
fingers it does not share homology with proteins alike. DC-SCRIPT bears a functional 
CtBP1 motif and a putative LxxLL Nuclear Receptor (NR) interaction motif [22, 24]. 
Recently, DC-SCRIPT has been shown to be an im portant co-regulator of multiple 
NRs [25].
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Figure 2. Schem atic re p re se n ta tio n  of th e  h u m an  DC-SCRIPT gene  a n d  p ro te in
Introns are represented as lines and exons as boxes. UTRs and codings sequences are marked. The regions 
of the protein that are encoded from each exon are also shown. The binding sites for CtBP and the LxxLL 
nuclear receptor interaction motif (NR) are also indicated.
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Nuclear Receptors
The superfamily of Nuclear Receptors (NRs) consists of ligand-inducible 
transcription factors. They can bind to specific DNA-regulatory response elements 
and act as cell-type- and promoter-specific regulators of transcription [26, 27]. 
The activity of NRs is dependent on binding to their corresponding ligands -  small 
lipophilic molecules that easily penetrate biological membranes [26]. The NRs play 
an im portant role in physiological processes such as the immune response, control 
of embryonic development, metabolism and homeostasis. Beyond this, the NRs 
are also involved in many pathological conditions such as diabetes, rheumatoid 
arthritis, asthma and cancer. The family of NRs has a common evolutionary history as 
evidenced by their sequence similarity and their cellular function [28]. In mammals, 
49 family members have been described that all share common functional domains: 
they contain an amino-terminal trans-activation domain, a DNA binding domain 
(DBD) and a carboxy-terminal ligand-binding domain [27, 29, 30]. Based on their 
mode of action, NRs are divided into two main subclasses, as described in figure 3.
Type I NRs comprise the steroid receptors, including the hormone receptors, 
Estrogen Receptor (ER), Glucocorticoid Receptor (GR), Progesterone Receptor 
(PR), and Androgen Receptor (AR). Steroid receptors are classically sequestered 
in the cytoplasm of cells by binding to heat shock proteins. Upon ligand binding, 
they homodimerize and translocate to the nucleus where they bind to specific DNA 
sequences. Binding to these DNA response elements will lead to recruitm ent of co­
activator complexes, ultimately resulting in transcriptional activation of the target 
gene. Type II NR consists of the Retinoid X Receptor (RXR) heterodimers. Well-
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Figure 3. N uclear R eceptor dom ain  s tru c tu re  and  classification
A) Domain structure of NRs. N represent the amino and C the carboxyl termini. AF1 is a variable 
amino-terminal transactivation domain. The ligand-binding domain (LBD) also mediates dimerization, 
transcriptional activation, and transcriptional repression functions. DBD, DNA-binding domain. B) The 2 
main subclasses of NR. The Type I NR involve the steroid receptors, generally binding as homodimers in a 
ligand-dependent m anner to horm one Response Elements (RE) th at consist of palindromic arrangements 
of core recognition motifs (arrows). Type II NR, the RXR heterodim ers, bind in the presence or absence 
of ligands (shown here in the presence of ligand) to similar core recognition elements arranged as direct 
repeats. Both the specific sequence of the core recognition motif and the spacing between motifs are 
determ inants of DNA-binding specificity. Modified from [31].
C
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known members of this class are the Retinoic Acid Receptor (RAR), peroxisome 
proliferator-activated receptors (PPAR) and vitamin D receptors (VDR). In contrast 
to type I NRs, type II receptors generally reside in the nucleus in the absence of ligand. 
They bind to their response elements and are often complexed with co-repressor 
proteins. Upon ligand binding, conformational changes occur, co-repressor proteins 
are released, co-activators are recruited and transcription is initiated [27, 29, 30, 32, 
33]. Another subclass of NRs are the orphan NRs, including the RAR-related orphan 
receptors (RORs). For these NRs no natural ligands have been identified as yet. The 
processes regulated by NRs are the result of the interplay between the receptors, 
their ligands, their respective response elements, and their co-regulators [26, 34]. 
The importance of NRs and the 300 known NR co-regulators is emphasized by the 
finding that at least 165 co-regulators have so far been directly associated with 
human diseases [35-37].
Nuclear Receptors in the Immune System
The immune system is known to be profoundly affected by the endocrine 
system. NRs are im portant players in the endocrine system, they are expressed by 
immune cells and have been reported to play an im portant role in haematopoiesis 
[38] and proper function of the immune system [39]. Multiple members of type
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I, type II as well as the orphan receptors have been implicated in modulating 
inflammatory responses [40]. A well-known member of the NR super-family 
implicated in modulating the immune response is GR. GR is known to repress 
pro-inflammatory genes via a number of mechanisms [39, 40]. Besides GR, also 
ER, PPARy, VDR and liver X Receptors (LXR) have been shown to be implicated in 
pro-inflammatory gene repression [39, 40]. The manner in which immune cells 
respond to antigens is greatly influenced by the presence of multiple NR ligands 
in the surrounding microenvironment. In the intestinal mucosa for instance, it is 
im portant that the immune cells do not elicit an immune response against food and 
commensal bacteria. Therefore, in the gut DCs are present that have unique mucosal 
functions specific for intestinal tissues. These functions include the ability to induce 
Treg responses which is regulated by retinoic acid (RA; a metabolite of vitamin A 
degradation, ligand for RAR) and TGF-0 which are both present in the gut tissue 
(reviewed in [41]). Also during pregnancy, hormones play an im portant role on 
cells of the immune system; there is a physiological regulation of the innate immune 
response to prevent the rejection of the foetus. An im portant hormone herein is 
progesterone (ligand for PR), a potent immunomodulator that blocks mitogen- 
stimulated lymphocyte proliferation and prolongs allograft survival (reviewed in 
[42]). Another im portant NR in the immune system is RORyt, which has been shown 
to be critical to the development of secondary lymphoid tissues and in the regulation 
of lineage specification to Th17 cells [43, 44]. Altogether this implies that NRs and 
their ligands play a pivotal role in the proper function of different immune cells in 
specific microenvironments.
Nuclear Receptors in Cancer
A strong association also exists between NRs and cancer. Clinically and 
biochemically, there is a well-recognized connection between hormone dependent 
NR function and cancer development. Malfunction of NR and /o r their co-regulators 
has been implicated in a wide variety of cancers. Many breast cancers are due in 
part to excess levels of activity of ER. AR has been implicated in the initiation and 
progression of prostate cancer. Bone cancer has been linked to the nor-1 receptor, 
and colon cancer to PPARy. The NRs RORy, nur77 and nor-1 have been implicated in a 
wide variety of leukaemia's (American Association for Cancer Research www.AACR. 
org). Dominant pathways affected by NRs in oncogenic cells include the apoptosis 
pathway, cell cycle regulation and growth factor signalling. The most extensively 
studied cancers involving NR are breast and prostate cancer.
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Breast cancer is the second m ost common cancer overall. It is by far the most 
frequent cancer among women with an estimated 1.38 million new cancer cases 
diagnosed in 2008 (23% of all cancers) [45]. Im portant hormone-related risk 
factors for breast cancer include early menarche, nulliparity or late age at first birth 
and late menopause [46]. The type I hormone-inducible NRs play an im portant role 
in the tumourigenesis of breast cancer. Estrogens proliferative and anti-apoptotic 
effects are held to be responsible for its role as a causative agent in breast cancer 
[47-50]. ER and PR expression is preserved or increased in approximately 70% of 
breast tumours and anti-estrogens such as tamoxifen have profound pro-apoptotic 
effects and are highly effective in the treatm ent of breast cancer [51]. Breast 
tum our tissue expressing the type I NRs, ER and /or PR exhibit a well-differentiated 
phenotype indicative for a good prognosis. Furthermore, ER/PR status is predictive 
for tamoxifen sensitivity and the response to aromatase inhibitors that block the 
synthesis of estrogens [52, 53]. In line with the importance of ER and PR in breast 
cancer, the expression of transcriptional co-regulators of ER and PR are also of 
prognostic significance in breast cancer [54, 55].
While the importance of type I NRs in breast cancer is well accepted, much 
less is known regarding the role of type II NRs. Both low vitamin D ingestion and 
low circulating 25-hydroxyvitamin D3 levels are associated with increased breast 
cancer risk, indicating a protective role of the type II NR VDR in breast cancer 
tumourigenesis [56]. In early studies, stimulation of the NRs RAR/RXR and PPAR/ 
RXR has been explored [57, 58] and synthetic RAR ligands have been shown to 
reduce second breast cancers [59]. Treatment efficacy of these studies has so far 
been limited because of retinoic acid resistance acquired by the cancerous cells 
[60, 61]. No adjuvant treatm ents directed at type II NRs are routinely available for 
breast cancer. More recent data indicate that type II NRs do have clinical relevance 
in breast cancer. RARa mRNA expression has very recently shown to be associated 
with a good prognosis in endocrine treated breast cancer patients [27], and Hua et 
al. [62] were able to define a RA-induced gene expression profile associated with a 
favourable prognosis. Furthermore, increased expression in the primary tum our of 
another type II NR, PPARy, also correlated with improved survival [63]. In addition 
to these hormone related factors an increasing number of other prognostic factors 
are studied to predict survival in breast cancer. Few of them are currently well- 
established prognostic markers and are worldwide used in decision making for 
selecting patients for the type of therapy they will receive. These factors include 
lymph node status, tum our size, histological grade, her2 positivity and age [64].
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Prostate cancer is the second most frequently diagnosed cancer of men (914.000 
cases, 13.8% of the total) and the 5th m ost common cancer overall [45]. Hormone- 
related factors are very im portant in prostate cancer biology, deregulation of AR 
and AR co-regulators, expression, or activity is involved in the initiation of prostate 
cancer and contributes to the transition of the disease to hormone-refractory stage 
[65-67]. In addition to the type I NR, AR the type II NR, VDR is also im portant in
Proliferation
W
Fibroblasts
« / fc>  
< 4
Metastasis
Endothelial cells
Growth factors 
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Chemokines 
NR ligands
Immune cells
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Differentiation
Figure 4. T um our m icroenv ironm en t
In the tum our m icroenvironment there is a complex interaction between the tum our cells, endothelial 
cells, fibroblasts and leukocytes present. They all secrete factors that will influence the function of the 
other cells. Therefore the environmental cues present, such as growth factors, cytokines, NR ligands etc 
will influence tum our cell proliferation, survival, differentiation and m etastatic capacity.
the aetiology of prostate cancer. In 1997, Ingles et al. reported an association with 
variants of the VDR gene with prostate cancer [68]. Most studies of VDR and cancer 
have focused on polymorphisms in VDR [69]. The ligands for VDR are shown to 
reduce the growth of several prostate cancer cell lines in vitro, as well as tumour 
growth in vivo [70-73]. Another im portant risk factor in prostate cancer is age (www. 
AACR.org). In addition, many different genes have been implicated in the aetiology 
of prostate cancer. Mutations in BRCA1, BRCA2 and Hereditary Prostate cancer gene 
1 (HPC1), but also fusion of TMPRSS2 with ETS transcription factors such as ERG 
and ETV1 has often been dem onstrated in prostate carcinoma cells.
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Further understanding of the mechanism of NRs and their co-regulators in breast 
and prostate cancer and the discovery of potential new ligands and antagonists 
could provide new targets to trea t these types of cancer [74].
Tumourmicroenvironment & treatm ent
Multiple studies investigating the role of individual NRs in cancer have led to 
novel insights into genome-wide transcription factor binding patterns and gene 
regulation. In a physiological context, however, cells communicate with surrounding 
cells, receive a multitude of signals and interact with the extracellular matrix (ECM). 
Within their local environment they experience complex mixtures of compounds 
and substrates, including growth factors, hormones, vitamins, organic constituents 
and their metabolic products. An emerging challenge is to unravel how NR family 
members act in concert to regulate complex cellular processes in tissues where 
multiple NR ligands are present and how their deregulation relates to malignant 
transformation. For many tissues it is known that this complex interaction between 
epithelial and stromal cell such as endothelial cells, fibroblasts, myofibroblasts, 
adipocytes, pericytes, and leukocytes exist. Many reports have already suggested 
that the tum our microenvironment can modify the proliferation, survival, polarity, 
differentiation, invasive and metastatic capacity of cancer cells [75-79] (figure 
4). NRs and their ligands in the various microenvironments play a pivotal role in 
these processes and constitute an im portant factor influencing cancer development 
and progression. The tumour microenvironment is also an im portant factor in 
determining the failure or success of immune therapy of cancer [80, 81].
Cancer is usually first treated with a combination of surgery, chemotherapy and 
radiotherapy. Surgery aims at removal of the primary tumour, chemotherapy acts 
mainly via killing the cells that divide rapidly, which is one of the main properties 
of cancer cells and radiotherapy is the use of ionizing radiation to control the 
growth of malignant cells. However, cancers such as breast and prostate cancer 
are often treated with targeted hormone therapies by inhibiting the function of ER 
(in ER positive breast cancers) or blocking the function of AR in prostate cancer. 
The treatm ent efficacy greatly depends on the type of cancer, as different cancers 
have different microenvironments and respond differently to the type of treatment. 
Therefore, knowledge regarding the exact subtype of cancer is essential for deciding 
which treatm ent or combination of treatm ent offers the best chance for successful 
treatm ent of cancer
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Scope of this thesis
In this thesis we investigated the function of the versatile NR co-regulator DC- 
SCRIPT in DC biology and in carcinomas. There is a complex interplay between NRs, 
their ligands and their co-regulators within the immune system but they also play a 
crucial role in the development and aetiology of cancer. Understanding the function 
and regulation of DC-SCRIPT in these different settings and in the complex tumour 
microenvironment where they all come together is a major challenge. However, such 
an endeavour may be highly rewarding as the processes putatively orchestrated by 
DC-SCRIPT in the different cell types are at the heart of cell growth, cell-survival, 
cell-death and cell-behaviour. In this thesis we aimed to investigate the role of DC- 
SCRIPT in the immune system, in carcinoma and in the interplay with NRs.
In Chapter 2 we characterised the mRNA and protein expression of DC-SCRIPT 
during differentiation of DCs and in different DC subsets. We investigated its mRNA 
expression during differentiation of monocytes into DC and during the complete 
lifecycle of the DC. Furthermore we investigated the protein expression of DC- 
SCRIPT in moDC, mDC and pDC as well as its localization. To study its function in 
DCs we performed knock-down experiments.
Chapter 3 deals with the expression of DC-SCRIPT in breast carcinoma. In 
this chapter we describe the interaction of DC-SCRIPT with multiple NR and we 
investigated the effects of DC-SCRIPT expression in a breast carcinoma cell line. In 
addition we studied the expression levels of DC-SCRIPT in breast cancer patients 
and related this to disease free survival.
In Chapter 4 we investigated the prognostic value of DC-SCRIPT mRNA 
expression in a large breast cancer cohort (n=1505) and related this to other 
prognostic markers known for breast cancer such as age, menopausal status, grade, 
PR and ER status and tum our size. In addition, we related the DC-SCRIPT mRNA 
expression to ERa and ER0 positivity.
In Chapter 5 we studied the role of DC-SCRIPT in prostate cancer. We analyzed 
the interaction of DC-SCRIPT with AR and VDR known to be im portant in prostate 
cancer. In addition we examined its expression in frozen tissue sections of prostate 
(cancer) epithelium.
Chapter 6 discusses the role of NR crosstalk and the effect of DC-SCRIPT 
expression in breast carcinoma.
Finally, in Chapter 7 the results, the importance of our findings and the future 
plans are described.
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Dendritic cells (DC) are the professional antigen presenting cells of the immune system and proper function of DCs is crucial to elicit an effective immune response. Therefore, molecular understanding of DC biology will 
lead to a more rational design of DC based immunotherapies and is especially crucial 
for optimal clinical applications in vaccination settings. Previously, we isolated and 
characterized the cDNA encoding DC-SCRIPT (dendritic cell-specific transcript, 
also known as ZNF366). DC-SCRIPT mRNA expression in the immune system was 
confined to DCs and was reported to be an early hallmark of DC differentiation. 
Recently we showed that DC-SCRIPT is also expressed by breast ductal epithelial 
cells and plays an im portant role in breast carcinoma by modulation of nuclear 
receptor (NR) mediated transcriptional regulation. Here, we demonstrate that IL-4 
is the dominant factor for DC-SCRIPT expression in monocyte derived DCs (moDCs), 
in addition we show endogenous DC-SCRIPT protein expression in DC for the first 
time. In vitro and in situ  DC-SCRIPT protein is detected early upon differentiation 
of monocytes into DCs and is also present in multiple freshly isolated DC subsets. 
The cellular localization of DC-SCRIPT, nuclear and cytoplasmic, differs between 
different subsets but also between different donors. Moreover, we demonstrate that 
knock-down of DC-SCRIPT in m ature DCs impedes IL-6, IL-12 and TNF-a production, 
suggesting an im portant function of DC-SCRIPT in DC maturation.
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Introduction
Dendritic cells (DC) are the m ost im portant antigen presenting cells of the 
immune system. DCs reside in the tissue in an immature state, and are capable of 
recognizing and capturing microbial antigens through specific receptors. Upon 
infection or inflammation, they undergo a complex process of maturation, where 
they change from an antigen-capturing cell into an antigen-presenting cell [1, 2]. 
Mature DC play an essential role in the initiation and modulation of the immune 
response. By the expression of co-stimulatory molecules and the secretion of pro­
or anti-inflammatory cytokines, DCs generate either immunity or tolerance through 
T-lymphocyte stimulation [3]. W hether immunity or tolerance occurs greatly 
depends on the activation status of the DC and is subjected to environmental stimuli 
[4-6]. In vivo, a t least 2 major subsets of DCs have been described, the myeloid 
and the plasmacytoid DCs (mDC and pDC, respectively). mDCs act as sentinels in 
the periphery and have a specialized function depending on their location and the 
expression profile of Pattern Recognition Receptors (PRR). The cellular cues present 
a t different locations, e.g. gut, skin or other organs, inflicted by local invading 
pathogens skews the mDCs towards a specific response against the particular 
invading pathogens there. pDCs are considered the front line of defence in anti-viral 
immunity as they rapidly produce massive amounts of type I interferon in response 
to viral infection and prime T cells against viral antigens [7-9]. In vitro, monocytes can 
be differentiated into DCs in the presence of IL-4 and GM-CSF [10]. Stimulation with 
these cytokines triggers DC differentiation from monocytes while potently inhibiting 
macrophage and osteoclast differentiation [11-13]. The fate of DC precursors is 
believed to be determ ined at the genetic level by differential gene expression. 
Genetic analyses have identified for example IRF4, RelB and PU.1, to be crucial for 
development of specific DC subsets in lymphoid organs [14-18]. DC differentiation 
and m aturation requires a complete change in the DC gene expression profile, this 
process is the result of the combinatorial effect of a few key transcriptional factors 
and chromatin re-organization [19]. In 2006 we identified and characterized a new 
DC expressed transcription factor, term ed dendritic cell-specific transcript (DC- 
SCRIPT; also known as ZNF366). DC-SCRIPT mRNA is expressed in all DC subsets 
tested so far, including monocyte derived DC (moDC), mDC, pDC and LC (Langerhans 
cells). Interestingly, expression was not detected among other leukocyte populations 
[20], suggesting an essential role of DC-SCRIPT in DC immunobiology. DC-SCRIPT is 
located on human chromosomes 5q13.2 [21] and is encoded by an 8 kb messenger 
RNA. DC-SCRIPT is well conserved in evolution, with the human and mouse gene
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both located in syntenic chromosomal regions and sharing 80% amino acid 
sequence homology [22]. The protein consists of a proline rich region, 11 C2H2-type 
zinc fingers and an acidic region. In addition, it bears a functional CtBP1 motif and a 
putative LxxLL Nuclear Receptor (NR) interaction m otif [20, 23]. Recently, we have 
dem onstrated DC-SCRIPT to be a unique modulator of NR function [24]. NRs are 
ligand-inducible transcription factors that bind specific DNA-regulatory response 
elements. NRs and their co-regulators, have been described to play an im portant 
role in a wide variety of biological processes including immunobiology and cancer 
biology [25-30]. We dem onstrated that DC-SCRIPT can repress transcription 
mediated by the type I NRs (the steroid NRs), whereas it enhances transcription 
mediated by the type II NRs (the RXR heterodimer NRs). Moreover, we found that 
expression of DC-SCRIPT is not limited to DCs, but could also be detected in prostate 
and breast epithelial cells. Importantly, we showed that DC-SCRIPT is a strong and 
independent prognostic m arker in breast carcinoma [24, 31]. Thus far, DC-SCRIPT 
expression in DCs was only investigated at the mRNA level. Here we characterized 
the endogenous DC-SCRIPT protein expression dynamics in in vitro derived as well 
as in primary blood derived DCs and studied its role during DC maturation.
Materials & Methods
Generation of human DC
Human monocyte derived Dendritic Cells (moDC) were generated from PBMCs as described 
previously [32]. Monocytes were derived from buffy coats. Plastic-adherent monocytes were 
cultured for 6 days in Phenolred free RPMI-1640 medium (Life Technologies, Breda, The 
Netherlands) supplemented with 1% ultra-glutamine (Cambrex, Wiesbaden, Germany), 0,5% 
antibiotic-antimycotic (Invitrogen, Breda, The Netherlands), 10% (v/v) FCS (Greiner, Krems- 
muenster, Austria), IL-4 (300 U/ml), and GM-CSF (450 U/ml) both from cellgenix. During day 
3 moDC were supplemented with new IL-4 (300 U/ml) and GM-CSF (450 U/ml). Mature moDC 
were generated from day 6 immature moDC through 48 hour stimulation with 200 ng/ml LPS 
(InvivoGen, Toulouse, France). Tolerogenic moDC were generated from day 6 immature moDC 
through 24 hour stimulation with 100 nM Dexamethasone and subsequent 24 hours with 
200 ng/ml LPS. Human Myeloid Dendritic Cells (MDC) were isolated from PBMCs using the 
CD1c (BDCA-1)+ Dendritic Cell Isolation Kit (Miltenyi Biotec, Leiden, The Netherlands). Hu­
man Plasmacytoid Dendritic Cells (PDC) were isolated from PBMCs using the CD304 (BDCA- 
4/Neuropilin-1)+ MicroBead Kit (Miltenyi Biotec, Leiden, The Netherlands). Purity (>90%) of 
the freshly isolated mDC and pDC were ensured by FACS staining.
RNA isolation and quantitative PCR
Total RNA for RT-PCR was isolated from cells using an RNA isolation kit (Zymo research). RNA
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quantity and purity were determined on a NanoDrop spectrophotometer. RNA was treated 
with DNase I (amplification grade; Invitrogen) and reverse-transcribed into cDNA by using 
random hexamers and Moloney murine leukemia virus reverse transcriptase (Invitrogen). 
mRNA levels for the genes of interest were determined with a PRISM 7000 sequence detec­
tion system (Applied Biosystems, Foster City, CA) with SYBR Green (Roche) as the fluorophore 
and the following oligonucleotide primers (forward, reverse): DC-SCRIPT (5 ' -AAGCATG- 
GAGTCATGGAG-3 ', 5 ' -TTCTGAGAGAGGTCAAAGG-3 ' ), PBGD (5 ' -GGCAATGCGGCTGCAA-3 ', 
5 ' -GGGTACCCACGCGAATCAC-3 '). Reaction mixtures and program conditions were used that 
were recommended by the manufacturer (Applied Biosystems). Quantitative PCR data were 
analyzed with 7000 Systems SDS Software v1.2.3 (Applied Biosystems) and checked for cor­
rect amplification and dissociation of the products. mRNA levels of the genes of interest were 
normalized to mRNA levels of the housekeeping gene porphobilinogen deaminase (PBGD) 
and were calculated according to the cycle threshold method [33].
Immunohistochemistry
Snap-frozen tonsil specimens were obtained from the Department of Pathology, RUNMC St, 
Radboud and approved by the institutional ethics committee of the RUNMC. The specimens 
were embedded in OCT embedding matrix (CellPath, Newtown, UK) and sectioned in 5 |iM 
thick tissue sections. The sections were placed on Superfrost slides (Thermo Scientific, Etten- 
Leur , the Netherlands), fixed with acetone, and incubated with 4 ng/mL goat anti-human 
DC-SCRIPT antibody (R&D Systems, Abingdon, UK), 4 ng/mL mouse anti-human DC-SIGN 
(AZN-D1), followed by incubation with a biotinylated horse anti-goat IgG or horse anti-mouse 
(Vector Laboratories), and signal development was performed using a Vectastain ABC-HRP 
Kit (Vector Laboratories, Burlingame, CA) and DAB (Sigma). Isotype-matched goat IgG (R&D 
Systems) and mouse IgG1 (BD Bioscience) were used as controls. Sections were counter­
stained with hematoxylin to visualize the cell nuclei and analyzed by using a Leica DM LB 
microscope (Leica Microsystems B.V., Rijswijk, the Netherlands).
Western blotting
Cells were lysed in 1% SDS and 62,5mM Tris pH 6.8. Cell lysates were mixed with sample buf­
fer containing 5% glycerol, 6% sodium dodecyl sulfate, 125 mM Tris -  HCl (pH 6.8), 0.1 mg/ 
mL bromophenol blue (Gebr . Schmid GmbH + Co, Freudenstadt, Germany), and 10%-mercap- 
toethanol (Sigma); heated at 95°C for 5 minutes; and then cooled on ice. The proteins were re­
solved by electrophoresis on an 8% polyacrylamide gel (ratio of acrylamide to bisacrylamide, 
37.5:1) and transferred overnight to Protran nitrocellulose transfer membranes (Schleicher 
and Schuell , 's-Hertogenbosch, the Netherlands) at 30 mA and 4°C. To block nonspecific pro­
tein binding, the membranes were incubated in 1% skimmed milk powder and 3% bovine 
serum albumin in PBST. The membranes were then incubated for 1 hr with 2,5ug/ml goat 
anti-human DC-SCRIPT antibody (R&D Systems, Abingdon, UK), washed three times in PBST, 
and subsequently incubated for 1 hour with the secondary antibody IRDye 800CW donkey 
anti goat IgG (1:5000 dilution; Li-cor Biosciences, Bad Homburg, Germany ) to detect DC-
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SCRIPT. To detect actin, the membranes were incubated with a mouse anti-actin (1:20.000 
dilution, Sigma clone AC/40), washed three times in PBST, and incubated for 1 hour with the 
secondary antibody Alexa Fluor 680 -  conjugated Donkey-anti-mouse IgG (1:5000 dilution; 
Invitrogen). All membranes were then washed three times in PBST. After staining, the mem­
branes were scanned by using an Odyssey Infrared Imaging System (Li-cor Biosciences) to 
visualize the proteins.
Confocal Laser Scanning Microscopy
Round 0 12 mm cover slides (Thermo Scientific, Braunschweig, Germany) were coated with 
Poly-L-Lysine (Sigma Aldrich, Zwijndrecht, the Netherlands). Immature and mature moDC 
(day 6), MDC and PDC were seeded on cover slides (50.000 cell/slide) and adhered for 2 
hours in serum free, phenolred free RPMI-1640 supplemented with 1% ultra-glutamine, 
0,5% antibiotic-antimycotic, IL-4 (300 U/ml) and GM-CSF (450 U/ml). DC were fixed using 
1% paraformaldehyde extra pure DAC 1 (Merck, Haarlem, The Netherlands) in PBS for 15 min 
at RT. DC were permeabilized with 100% ice cold Methanol (Boom, Meppel, The Netherlands) 
for 5 minutes at 4oC, washed with PBS, blocked for 1 hour with 3% BSA (Roche, Woerden, 
The Netherlands) and 1% Normal Donkey Serum (Sigma Aldrich) in PBS, stained 1 hour with 
2,5 ng/ml Goat-anti-human DC-SCRIPT (R&D Systems, Abingdon, UK) and 1 hour with 1/400 
Alexa Fluor 488 Donkey anti-Goat IgG (Invitrogen). The nucleus was stained 5 minutes with 
0,3 ng/ml DAPI (Sigma Aldrich) or 1 ng/|il Propidium Iodide (ITK, Uithoorn, The Nether­
lands), washed with PBS and mounted on 76 x 26 mm microscope slide (Thermo Scientific) 
with mowiol + 2,5% azide (Calbiochem, San Diego, US). Confocal laser scanning microscopy 
(CLSM) was carried out with an Olympus FV1000 Confocal Laser Scanning Microscope with 
an Argon (457, 488, 515nm), and 405, 559 and 635 diode lasers at the Microscopic Imaging 
Facility of the Department of Cell Biology, Nijmegen Centre for Molecular Life Sciences, Rad­
boud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
DC-SCRIPT silencing
For DC-SCRIPT silencing a 21 nucleotide Custom ZNF366 termed SC1 targeting the DC- 
SCRIPT gene at position 2352-2370 and a 23 nucleotide Custom ZNF366 siRNA termed SC38 
targeting the DC-SCRIPT gene at position 2349-2369 (Dharmacon, Lafayette, Colorado, US). 
Human immature moDC day 3 were seeded 1106 cells/ml, 0,5 ml/well in 24-wells plate in 
Phenolred free RPMI-1640 medium supplemented with 1% ultra-glutamine and 10% (v/v) 
FCS and adhered for 2 hours prior to transfection. DC were transfected using a transfection 
mix containing 20 |il of 2 |iM Custom ZNF366 SC1, Custom siRNA SC38, or ON-TARGETplus 
Non-Targeting siRNA#1 (Dharmacon) plus 20 |il 1/16,7 DharmaFECT 4 (Dharmacon) in se­
rum free Phenolred free RPMI-1640 medium. Cell cultures were supplemented with IL-4 (300 
U/ml), and GM-CSF (450 U/ml) 18 hours after transfection. Day 6 (72 hours after transfec­
tion) DC were stimulated with vehicle or 200 ng/ml LPS (InvivoGen) for 24 hours, after which 
supernatant was harvested for cytokine measurements. Total lysates were prepared 48-, 72-, 
and 96 hours after transfection, lysing 50.000 cells in 50 |il 1% SDS lysis buffer containing 1%
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SDS and 62,5 mM TRIS pH 6,8 plus the protease inhibitors 2 n g/mL leupeptin (Sigma, Zwijn- 
drecht, the Netherlands), 2 n g/mL aprotinin (Roche, Woerden, the Netherlands), and 1 mM 
phenylmethylsulfonyl fluoride (Sigma, Zwijndrecht, the Netherlands).
ELISA
Cytokines were measured in the supernatants 24 hours after induction of maturation. IL- 
12p70 production was measured using a standard sandwich enzyme-linked immunosorbent 
assay (ELISA; Pierce Biotechnology, Etten-Leur, The Netherlands). IL-6 was measured using 
PeliPair human IL-6 ELISA kit (Sanquin, Amsterdam, The Netherlands), TNF was measured 
using Human TNF ELISA Set (BD Biosciences, Breda, The Netherlands), IL-10 was measured 
using Human IL-10 Module Set (Bender MedSystems, Vienna, Austria). Differences in cyto­
kine production were assessed using t tests. Two-sided P values less than .05 were a priori 
considered to be statistically significant.
Results
DC-SCRIPT mRNA expression during DC differentiation
Within the immune system, human DC-SCRIPT mRNA has been found to be 
preferentially expressed by DCs [20]. To obtain more insight into the expression 
characteristics of DC-SCRIPT, we investigated DC-SCRIPT mRNA expression during 
differentiation of monocytes into DCs. Hereto, adherent monocytes were cultured 
in the presence of IL-4, GM-CSF or the combination of both cytokines. Cells were 
analyzed at different time points after s tart of differentiation. In the absence of 
cytokines (vehicle) essentially no DC-SCRIPT mRNA expression could be detected. 
In the presence of GM-CSF alone, only small amounts of DC-SCRIPT mRNA could 
be discerned. Incubation of IL-4 and GM-CSF or IL-4 alone resulted in DC-SCRIPT 
mRNA expression within 2 hrs after the start of stimulation, indicating IL-4 as the 
dominant factor for DC-SCRIPT induction. An increase in DC-SCRIPT mRNA levels was 
observed up to 8 hours after induction (Figure 1A). At later time points, DC-SCRIPT 
mRNA levels decreased somewhat but remained stable from day 3 to day 8. After 
m aturation with LPS or after stimulation with the combination of dexamethasone 
and LPS to obtain tolerogenic DCs, mRNA levels remain relatively stable (Figure 1B).
DC-SCRIPT protein expression
To confirm endogenous DC-SCRIPT protein expression, cell lysates were 
prepared from monocytes at different time points after the onset of differentiation 
towards DCs. Within 4hrs, DC-SCRIPT protein expression could be observed. Protein 
levels steadily increased during differentiation to DCs and remained constant 
from day 6 onwards (Figure 2A). In line with its mRNA expression, DC-SCRIPT
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Figure 1. DC-SCRIPT mRNA ex p ress io n  in  moDCs
A) DC-SCRIPT mRNA expression relative to PBGD mRNA in monocytes as determined by quantitative 
polymerase chain reaction. Monocytes were cultured in the presence of vehicle (white bars), IL-4 (light 
grey bars), GM-CSF (dark grey bars) or IL-4 and GM-CSF (black bars) and harvested at the indicated time 
points. B) DC-SCRIPT mRNA expression relative to PBGD mRNA at the indicated time points after start 
of differentiation as determined by quantitative polymerase chain reaction. A and B) representative data 
from 1 out of 3 donors.
protein expression is also dependent on IL-4 (data not shown). To prove that DC- 
SCRIPT protein is also present in freshly isolated blood mDC and pDC, cell lysates 
were prepared from purified mDC and compared to total PBMC (peripheral blood 
mononuclear cells). DC-SCRIPT protein could not be detected in total PBMCs (Figure 
2B, lane 1), nor could it be detected in the mDC negative fraction (Figure 2B, lane 2). 
However, in the mDC fraction DC-SCRIPT protein expression was readily observed 
(Figure 2B, lane 3). Similarly, DC-SCRIPT protein was present in pDCs (Figure 2C, lane
3), whereas no DC-SCRIPT expression could be detected in the total PBL (peripheral 
blood leukocytes) fraction (Figure 2C, lane 1) and the pDC negative fraction (Figure 
2C, lane 2). These data show for the first time that DC-SCRIPT is endogenously 
expressed at protein level in in vitro differentiated moDC, and in freshly isolated 
mDC and pDC.
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Figure 2. DC-SCRIPT p ro te in  expression  in  moDCs, mDC and  pDC
Proteins from cell lysates of the indicated cell fractions were subjected to immunoblotting with anti-DC- 
SCRIPT antibodies and anti-actin as loading control. A) Cell lysates of moDCs harvested at the indicated 
time points. B) Cell lysates of the indicated fractions of a mDC isolation procedure C) Cell lysates of the 
indicated fractions of pDC isolation procedure
DC-SCRIPT localization in different DC subsets
The subcellular localization of endogenous DC-SCRIPT protein in the different 
subsets of DCs was investigated with confocal laser scanning microscopy (CLSM). 
Hereto, DCs were stained with anti-DC-SCRIPT antibodies recognizing the C-terminal 
part of DC-SCRIPT. The specificity of the antibody was validated by DC-SCRIPT 
peptide blocking experiments (data not shown). Our data show that DC-SCRIPT is 
predominantly localized in the nucleus of moDC and localization does not change 
upon maturation of the cells (Figure 3A). In fresh mDC, DC-SCRIPT localization is 
also most pronounced in the nucleus of the cells (Figure 3B). In both, moDC and 
mDCs, all donors show some DC-SCRIPT expression in the cytoplasm. In pDC, DC- 
SCRIPT expression could be found in the cytoplasm (Figure 3C) as well as in both 
the cytoplasm and nucleus (Figure 3D) depending on the donor. In total pDC were 
isolated from 6 different donors, of which 4 donors showed primarily cytoplasmic 
staining and 2 donors showed cytoplasmic as well as nuclear localization. Within 
one donor, the localization of DC-SCRIPT was uniform among cells. These data 
show that the DC-SCRIPT localization varies in the different DC subsets but also 
between different donors. To further confirm DC-SCRIPT protein expression in 
DCs in immunological tissue, frozen tonsil sections were analyzed for DC-SCRIPT 
expression. The presence of DCs was confirmed by staining the consecutive section
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Figure 3. DC-SCRIPT localization  in d ifferen t DC su bsets
CLSM analysis of DC-SCRIPT expression in different DC subsets. A) DC-SCRIPT in imm ature and mature 
DCs is stained with a goat-anti-DC-SCRIPT (green), the nucleus is visualized by staining with DAPI (blue) 
B) DC-SCRIPT in myeloid DCs is stained with a goat-anti-DC-SCRIPT (green), the nucleus is visualized by 
staining with PI (red), C) and D) plasmacytoid DCs are stained with a goat-anti-DC-SCRIPT (green) and 
the nucleus is visualized by staining with DAPI (blue). The scalebar represents 20^m.
DC-SCRIPT in Dendritic Cells | 35
with the DC m arker DC-SIGN (Figure 4). As expected, DCs were mainly present in the 
T cell areas in between the germinal centres. DC-SCRIPT expression was observed in 
cells with DC morphology, further substantiating its protein expression in DCs. DC- 
SCRIPT expression in these cells is mostly confined to the nucleus. These data show 
that DC-SCRIPT is differentially distributed in the cell in various DC subsets.
Figure 4. DC-SCRIPT expression  in tonsil tissue
Immunohistochemistry staining of DC-SIGN and DC-SCRIPT in frozen tonsil sections. Cells were 
counterstained with hematoxiline to visualize the nuclei.
Function of DC-SCRIPT in moDC
DC-SCRIPT mRNA and protein is expressed during the complete lifecycle of 
moDCs. To investigate whether DC-SCRIPT expression is im portant in the maturation 
process of DC, DC-SCRIPT expression was silenced at day 3 of differentiation and 
cells were matured with LPS at day 6 for 24hrs. DC-SCRIPT protein expression was 
silenced with two different siRNA oligos (s il and si38) targeting the DC-SCRIPT gene 
at position 2352-2370 (sil) and at position 2349-2369 (si38), both located in the 
acidic region of DC-SCRIPT. Our data showed that both oligos effectively repressed 
DC-SCRIPT protein expression (figure 5A). To obtain more insight into the effect of 
DC-SCRIPT expression on the DC maturation process, both cell surface m aturation 
m arker expression and cytokine secretion in the supernatant were investigated
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24 hrs after LPS stimulation. Our data showed that upon LPS stimulation the 
expression of the m aturation markers CD40, CD83 and CD86 was increased and 
also led to significant enhanced production of the pro-inflammatory cytokines IL- 
12, IL-6 and TNF-a. Silencing of DC-SCRIPT expression resulted in a slight reduction 
of the m aturation markers CD40, CD83 and CD86 upon LPS stimulation (data not 
shown). Interestingly, secretion of IL-12, IL-6 and TNF-a was reduced for more than 
60% when DC-SCRIPT expression was silenced (Figure 5B). Secretion of the anti­
inflammatory cytokine IL-10 was not significantly altered. Also no significant effects 
were observed on cytokine secretion in the cells that were not treated with LPS. 
These data demonstrate that DC-SCRIPT expression is im portant for TLR induced 
pro-inflammatory cytokine production.
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Figure 5. DC-SCRIPT p ro te in  ex p ress io n  in fluences p ro -in flam m ato ry  cytokine p ro d u c tio n  by 
moDC
Day 3 moDCs are transfected with the indicated siRNA DC-SCRIPT oligos. At day 6 LPS is added to 
m ature the DC. 24 hrs later A) DC-SCRIPT expression is analyzed by w estern blot analysis. DC-SCRIPT 
is visualized by immunoblotting with anti-DC-SCRIPT and anti-actin is used as a loading control. NT = 
Non-targeting control siRNA B) Cytokine secretion in the supernatant is measured by ELISA. Data are 
expressed as the mean value of five donors relative to the NR control treated with LPS. Absolute values for 
the NT control samples treated with LPS were as follows: IL-12: 900-4200 pg/ml, IL-6: 3000-12000 pg/ 
ml, TNF-a: 2100-12000 pg/m l and IL-10: 160-850 pg/m l for. Error bars correspond to +/- SEM.
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Discussion
Previously, we have isolated and characterized the cDNAs encoding the human 
and mouse DC-SCRIPT [20, 22]. To get further insight into human DC-SCRIPT 
expression in different DC subsets, and its function during DC development, 
endogenous DC-SCRIPT mRNA and protein expression was further investigated. DC- 
SCRIPT was readily expressed upon differentiation of monocytes towards DCs. In 
addition we identified IL-4 as the dominant factor for DC-SCRIPT induction in moDC 
and we showed endogenous DC-SCRIPT protein expression in moDC as well as 
freshly isolated mDC and pDC. DC-SCRIPT is predominantly expressed in the nucleus 
of the myeloid DC subsets, which is in line with the presence of a nuclear localization 
motif. Remarkably, in pDC DC-SCRIPT was most often detected in the cytoplasm, 
albeit nuclear expression was also seen in some donors, suggesting a possible 
cytoplasmic function for DC-SCRIPT. Furthermore our data dem onstrated that RNAi 
mediated knockdown of DC-SCRIPT expression strongly impairs IL-12, IL-6 and 
TNF-a production in LPS m atured DCs, suggesting that DC-SCRIPT expression in an 
im portant factor for TLR-4 induced cytokine production.
Transcription factors play a decisive role in cell commitment. During DC 
development, differentiation and m aturation different sets of genes are activated 
and silenced depending on environmental signals. Culturing human monocytes 
with IL-4 and GM-CSF skews their differentiation towards DC. Our data show that 
IL-4 plays a predom inant role in DC-SCRIPT induction in these moDCs. In contrast, 
IL-4 stimulation of MCF-7 breast carcinoma cells or total PBLs did not induce DC- 
SCRIPT expression (data not shown), suggesting that the induction mediated by 
IL-4 is specific for moDCs. DC-SCRIPT mRNA expression has been reported in all 
DC subsets including LC, mDC and pDC. Here we show for the first time endogenous 
DC-SCRIPT protein expression in mDCs and pDCs. Interestingly, whereas DC-SCRIPT 
is predominantly localized in the nucleus in moDCs and mDCs, the localization in 
pDC greatly varies between donors. Despite its nuclear localization motif, DC- 
SCRIPT is also localized in the cytoplasm of DCs. Many factors and environmental 
stimuli may play an im portant role in the differential subcellular location of DC- 
SCRIPT. Fascinatingly, we recently reported on the function of DC-SCRIPT as an NR 
co-regulator. NRs and their co-regulators are known to be localized in the nucleus 
as well as in the cytoplasm. The type I NRs are classically sequestered in the 
cytoplasm, upon ligand binding they homodimerize, translocate to the nucleus and 
bind to specific DNA sequences [26, 34-37]. The NR co-regulators N-CoR and SMRT 
are predominantly nuclear proteins, but recent evidence suggests that changes in
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signalling at the cell surface can ultimately lead to nuclear-cytoplasmic shuttling 
of the co-repressors [38]. Further research is necessary to fully elucidate the 
pattern and dynamics of DC-SCRIPT expression in different DC subsets. To elucidate 
the mechanism of DC-SCRIPT localization in different cellular compartments it 
is im portant to understand the underlying biochemical basis for this. It would 
therefore be interesting to investigate whether DC-SCRIPT localization is affected by 
extracellular signals, such as hormones and vitamins that are ligands for NRs.
DC-SCRIPT knock-down was employed to investigate its function during 
maturation. Our data showed that normal physiological expression of DC-SCRIPT 
is essential for proper production of the pro-inflammatory cytokines IL-12, IL-6 
and TNF-a. DC m aturation is a complex process and depends on the type of signal 
a DC receives. In addition to LPS, also stimulation with R848 and poly(I:C) led to 
a significant lower production of IL-12 when DC-SCRIPT expression was silenced 
(data not shown). As cytokine production by DCs is crucial for DC induced T cell 
stimulation, these data suggest that DC-SCRIPT is a very im portant factor for 
efficient m aturation of moDC upon stimulation with different TLR ligands. It will be 
interesting to further elucidate the underlying molecular mechanisms by which DC- 
SCRIPT can regulate pro-inflammatory cytokine production by DCs. It is tempting 
to speculate that DC-SCRIPT plays also an im portant role as NR co-regulator in DCs 
and thereby may affect DC maturation. A well-known member of the NR superfamily 
implicated in modulating the immune response is GR (Glucocorticoid Receptor). GR 
is known to repress proinflammatory genes via a number of mechanisms [27, 39]. 
Interestingly, recent preliminary data demonstrate that DC-SCRIPT can be present 
in a protein complex together with GR and represses transcription mediated by 
GR. Upon stimulation with glucocorticoids, DC-SCRIPT knockdown enhances the 
expression of the well-known GR target gene GILZ in DCs (data not shown). GILZ 
expression is known to redirect m ature DC function towards a tolerogenic mode 
[40]. The observation that knockdown of DC-SCRIPT leads to lower proinflammatory 
cytokine production is completely in line with the upregulation of GILZ and its 
described tolerogenic properties [41]. These data suggest that the modulating role 
of DC-SCRIPT on NRs may extend beyond breast and prostate epithelial cells and is 
also present in DCs. Therefore we hypothesize that DC-SCRIPT may also be a key 
regulator of NRs in DCs, thereby playing an essential role in balancing the response 
to hormones and vitamins known to be im portant in DC development, differentiation 
and maturation. It will be of great interest to further characterize the role of DC- 
SCRIPT as NR modulator in DC in future experiments.
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Nuclear receptors, including estrogen receptor (ER), progesterone receptor (PR-B), peroxisome proliferator-activated receptor gamma (PPARy), and retinoic acid receptor alpha (RARa), have been implicated in breast 
cancer etiology and progression. We investigated the role of dendritic cell- 
specific transcript (DC-SCRIPT) as coregulator of these nuclear receptors and as a 
prognostic factor in breast cancer. The effect of DC-SCRIPT on the transcriptional 
activity of nuclear receptors was assessed by luciferase reporter assays. DC-SCRIPT 
expression in normal and tum or breast tissue was analyzed by PCR assays and 
immunohistochemistry. The prognostic value of tum or DC-SCRIPT mRNA expression 
was assessed in three independent cohorts of breast cancer patients: a discovery 
group (n = 47) and a validation group (n = 97) (neither of which had received 
systemic adjuvant therapy), and a second tamoxifen-treated validation group 
(n = 68). Univariate and multivariable Cox proportional hazards model analyses 
were performed. DC-SCRIPT suppressed ER- and PR-mediated transcription in a 
ligand-dependent fashion, whereas it enhanced the RARa- and PPARy-mediated 
transcription. In breast tissue samples, DC-SCRIPT mRNA was expressed at lower 
levels in tum or than in corresponding normal tissues (P = .010). Patients with high 
tum or DC-SCRIPT mRNA levels (66%) had a longer disease-free interval than those 
with a low DC-SCRIPT mRNA level (34%) (hazard ratio [HR] of recurrence for high 
vs low DC-SCRIPT level = 0.23, 95% confidence interval [CI] = 0.06 to 0.93, P = .039), 
which was confirmed in the validation group (HR of recurrence = 0.50, 95% CI = 
0.26 to 0.95, P = .034). This prognostic value was confined to patients with ER- and/ 
or PR-positive tumors (discovery group: HR of recurrence = 0.16, 95% CI = 0.03 
to 0.89, P = .030; validation group: HR of recurrence = 0.42, 95% CI = 0.19 to 0.91, 
P = .028), and was also observed in the second validation group (HR = 0.46, 95% 
CI = 0.22 to 0.97, P = .040). DC-SCRIPT was an independent prognostic factor after 
correction for tum or size, lymph node status, and adjuvant therapy (n = 145; HR = 
0.50, 95% CI = 0.29 to 0.85, P = .010). In conclusion, DC-SCRIPT is a key regulator of 
nuclear receptor activity that has prognostic value in breast cancer.
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Introduction
Nuclear receptors form a unique class of phylogenetically conserved 
transcriptional regulators [1]. They execute a transcriptional program upon binding 
to a ligand. Ligands for the nuclear receptor family of proteins vary from hormones 
to vitamins and metabolic products. In accordance with the wide variety of ligands, 
nuclear receptors are key regulators in a diversity of physiological functions, 
including development, metabolism, cell differentiation, and immune responses [2]. 
Malfunction of nuclear receptors has been associated with diseases such as diabetes, 
chronic inflammatory diseases, and cancer [2-4].
Clinically, a connection between horm one-dependent nuclear receptor function 
and breast cancer development has long been recognized. Most research has focused 
on the expression and function of two nuclear receptors, estrogen receptor-a (ER) 
and progesterone receptor (PR), which are preserved or increased in approximately 
70% of breast tumors [5]. Estrogens, the ligands for the ER, are often associated 
with the initiation and progression of breast cancer [6], and are well known for 
their proliferative effect on breast cancer cells [7-9]. Anti-estrogen therapy with 
tamoxifen has been applied successfully in the treatm ent of breast cancer patients
[5]. In line with the importance of the ER and PR in breast cancer, the expression 
of transcriptional co-regulators of ER and PR are also of prognostic significance in 
breast cancer [10, 11]. For example, the genes encoding nuclear receptor coactivator 
3 (NCOA3; also known as AIB1) and nuclear receptor co-repressor 2 (NCOR2; also 
known as SMRT) have been shown to serve as a tum or suppressor gene and an 
oncogene for breast cancer, respectively [12-17].
Another class of nuclear receptors, the retinoid X receptor alpha (RXRa) 
heterodimers (ie, RXRa-retinoic acid receptor alpha [RARa] and RXRa-peroxisome 
proliferator-activated receptor gamma [PPARy]), have recently been implicated in 
breast cancer. For example, whereas the presence of ER and PR is associated with 
breast tum or development and breast tum or cell proliferation, RARa and PPARy 
play a predominantly antitumorigenic role in human breast cancer by inhibiting cell 
growth and inducing apoptosis [7, 18]. These properties imply that an imbalance 
in the activity of nuclear receptors may contribute to the development and 
progression of breast cancer. How the activity of the nuclear receptor repertoire in 
cells is regulated and which factors determine the response of the nuclear receptor 
repertoire to environments in which multiple nuclear receptor ligands are present 
are still open questions.
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We previously identified and characterized a novel protein, dendritic cell-specific 
transcript (DC-SCRIPT; also known as ZNF366), that is preferentially expressed 
by dendritic cells in the immune system [19, 20]. DC-SCRIPT contains an amino- 
terminal proline-rich domain, 11 Cys2His2-type zinc fingers, and a carboxyl-terminal 
acidic region. The acidic region of DC-SCRIPT contains a functional binding motif for 
the corepressor protein CtBP [19, 21] and an LXXLL nuclear receptor interaction 
motif, which is thought to be involved in ER function [22]. Herein, we investigate 
the effect of DC-SCRIPT on the function of multiple members of the nuclear receptor 
family as well as the prognostic relevance of DC-SCRIPT expression in breast cancer 
patients.
Materials and Methods
Cells
Human embryonic kidney 293 (HEK293) cells were cultured in Dulbecco's modified Eagle 
(DMEM) medium containing GlutaMAX (Invitrogen, Breda, the Netherlands) supplemented 
with 10% heat-inactivated fetal calf serum (FCS; Greiner Bio-one, Alphen a/d Rijn, the Neth­
erlands), 1% non-essential amino acids (Invitrogen), and 0.5% antibiotic-antimycotic (In­
vitrogen). Human hepatocellular carcinoma Hep3b cells were cultured in Iscove's modified 
Dulbecco's medium (Invitrogen), 10% heat-inactivated FCS, and 0.5% antibiotic-antimycotic. 
Human breast adenocarcinoma MCF-7 cells were cultured in RPMI-1640 medium (Invitro­
gen), 10% heat-inactivated FCS, and 0.5% antibiotic-antimycotic. Schneider's Drosophila 
Line 2 (SL2) cells were grown in Schneider’s drosophila medium (Invitrogen) and 10% heat- 
inactivated FCS. All cell lines were originally obtained from American Type Culture Collection 
(Manassas, VA). Cells were regularly checked morphologically to verify the identity of each 
cell line.
Co-immunoprecipitation Assay
The nuclear receptors (National Center for Biotechnology Information [NCBI] accession 
number) ERa (NM_000125), PR-B (NM_000926), RARa (NM_000964), RXRa (NM_002957), 
and PPARy (NM_138712) were each cloned into the expression vector pHA-n1 to enable ex­
pression of fusion proteins that contain a carboxyl-terminal haemagglutinin (HA) epitope 
tag. pHA-n1 was generated by replacing the green fluorescent protein (GFP) DNA sequence 
from the plasmid pEGFP-n3 (Clontech) with the HA DNA sequence. The DNA for DC-SCRIPT 
(NM_152625) was cloned into the mammalian expression vector pEYFP (Clontech) to enable 
expression of a DC-SCRIPT fusion protein tagged with enhanced yellow fluorescent protein 
(YFP). HEK293 cells were plated in 10-cm dishes (6 x 106 cells per dish) and incubated for 
24 hours. The cells were cotransfected with 5 ng pDC-SCRIPT-EYFP or pEYFP (control) and 5 
Hg of a vector expressing HA-tagged ERa, PR-B, RARa, or PPARy by using Metafectene trans­
fection reagent (Biontex, Germany) according to the manufacturer's protocol. The cells were
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stimulated 8 hours after transfection with the following ligands (all from Sigma, Zwijndrecht, 
the Netherlands): 10 nM p-estradiol for cells expressing HA-tagged ER; 1 |iM all-trans-reti- 
noic acid (AtRA) for cell expressing HA-tagged RAR; 1 |iM GW1929 (a PPARy ligand) for cells 
expressing HA-tagged PPARy; or the PR ligand 10 nM R5020 (Perkin Elmer, Groningen the 
Netherlands) for cells expressing HA-tagged PR-B. For all ligands, a 1000-times stock dilution 
in ethanol was used. Twenty-four hours after transfection, the cells were lysed in radioim- 
munoprecipitation assay buffer (50 mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate 
[SDS], and 50 mM Tris-HCl [pH 7.5]) containing the protease inhibitors 2 ng/mL leupeptin 
(Sigma, Zwijndrecht, the Netherlands), 2 ng/mL aprotinin (Roche, Woerden, the Nether­
lands), and 1 mM phenylmethylsulfonyl fluoride (Sigma, Breda, the Netherlands). The cell ly­
sates were used for immunoprecipitation of YFP-tagged proteins with anti-green fluorescent 
protein (GFP) antibody-coupled protein G beads (GE Healthcare) (this antibody recognizes 
YFP-tagged proteins). Cells transfected with YFP and HA-tagged ERa, PR-B, RARa, or PPARy 
were used as controls for nonspecific binding. Immunoprecipitated proteins were mixed with 
sample buffer containing 5% glycerol, 6% SDS, 125 mM Tris-HCl [pH 6.8], 0.1 mg/mL bromo- 
phenol blue (Gebr. Schmid GmbH + co, Freudenstad, Germany), and 10% p-mercaptoethanol 
(Sigma, Breda, the Netherlands), heated at 95°C for 5 minutes, and then cooled on ice. The 
proteins were resolved by electrophoresis on an 8% polyacrylamide gel (ratio of acrylamide 
to bisacrylamide, 37.5:1) and transferred overnight to Protan nitrocellulose transfer mem­
branes (Schleicher and Schuell, 's Hertogenbosch, the Netherlands) at 30 mA and 4 °C. To 
block nonspecific protein binding, the membranes were incubated in 2% skimmed milk pow­
der (Campina, Eindhoven, the Netherlands) and 1% bovine serum albumin (BSA) (Roche, 
Woerden, the Netherlands) in phosphate-buffered saline with 0.01% Tween (PBST) for de­
tecting HA-tagged proteins or in 1% skimmed milk powder and 3%BSA in PBST for detecting 
YFP-tagged proteins. The membranes were then incubated for 2 hours with a mouse anti-GFP 
antibody (1:1000 dilution; Roche Applied Science), washed three times in PBST, and subse­
quently incubated for 1 hour with the secondary antibody IRDye 800CW goat anti-mouse 
IgG (1:5000 dilution; Li-cor Biosciences) to detect YFP-tagged proteins. To detect HA-tagged 
proteins, the membranes were incubated with a rat monoclonal anti-HA antibody (1:1000 di­
lution, clone 3F10; Roche), washed three times in PBST, and incubated for 1 hour with the sec­
ondary antibody Alexa Fluor 680-conjugated goat anti-rat IgG (1:5000 dilution; Invitrogen). 
All membranes were then washed three times in PBST. After staining the YFP- or Ha-tagged 
proteins, the membranes were scanned by using an Odyssey Infrared Imaging system (Li-cor 
Biosciences) to visualize the YFP- or Ha-tagged proteins.
Transcription Assays
The transcription reporter plasmids pTk-RARE3-luc, which contains three RAR response ele­
ments (RAREs) upstream of a firefly luciferase reporter, and pTk-luc were described previous­
ly [23]. pAc5.1 (Invitrogen), which contains the Drosophila actin 5C (Ac5) promoter for high- 
level expression of the gene of interest in SL2 cells [24], was used to generate the following 
plasmids for expression in insect cells: pAc-RAR containing RARa, pAc-RXR containing RXRa,
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and pAc-DCSCRIPT containing DC-SCRIPT. The mammalian expression plasmids pCATCH and 
pCATCH-DCSCRIPT were described previously [19] and were used in the transcription assays 
in Hep3b and MCF-7 cells. MMTV-luc, a transcription reporter plasmid containing the mouse 
mammary tumor virus (MMTV) promoter, which is positively regulated by several classes of 
steroid hormones including ligands for the PR [25, 26], was kindly provided by Prof. Dr. Stun- 
nenberg (NCMLS, Nijmegen, the Netherlands). MMTV-luc was used to generate MMTV-RLuc, a 
reporter plasmid in which Renilla luciferase expression is under the control of the MMTV pro­
moter, which was used in the MCF-7 transcription assay. The transcription reporter PPRE-luc 
(Addgene plasmid number 1015) contains the PPAR response elements upstream of a firefly 
luciferase reporter and has been described previously [27]. The PR expression plasmid pSG5- 
PR-B [28] was kindly provided by Prof. Dr. Horwitz (University of Colorado Health Sciences 
Center) and was used in the transcription assays in Hep3B and MCF-7 cells. The transcription 
reporter ERE3-TATA-luc (Addgene plasmid number 11354), which contains three copies of 
the vitellogenin estrogen response element (ERE), has been described previously [29] and 
was used in the transcription assays in Hep3b cells.
Hep3b cells were plated in 24-well plates (6 x 104 cells per well) 8 hours before transfection 
and all plasmids were transfected into these cells by using a calcium phosphate precipitation 
kit (Invitrogen) according to the manufacturers protocol. SL2 cells were plated in medium 
without FCS in 24-well plates (1 x 106 cells per well) just before transfection by using a cal­
cium phosphate precipitation kit (Invitrogen). MCF-7 cells were plated in 24-well plates (5 x 
104 cells per well) 8 hours before transfection and all plasmids were transfected into these 
cells by the use of Metafectene reagent (Biontex, Germany). Twenty-four hours after trans­
fection, Hep3B, MCF-7, and SL2 cells were stimulated with the RAR ligand AtRA (1 |iM) or 
vehicle (ethanol) for 16 hours. Transfected Hep3B and MCF7 cells were stimulated 16 hours 
after transfection with the following ligands or vehicle (ethanol) for 24 hours: the ER ligand 
p-estradiol (10 nM; Sigma, Zwijndrecht, the Netherlands); the PR ligands progesterone (100 
nM; Sigma Zwijndrecht, the Netherlands) or R5020 (10 nM; PerkinElmer, Groningen, the 
Netherlands); or the PPARy ligands GW1929 (1 |iM; Sigma, Zwijndrecht, the Netherlands) or 
troglitazone (10 |iM; Sigma, Zwijndrecht, the Netherlands). Forty hours after transfection, the 
cells were lysed in 100 |il Passive Lysis buffer (Promega) and the lysates were analyzed for 
luminescence with the use of the Dual-Luciferase Reporter Assay System (Promega, Leiden, 
the Netherlands) according to manufacturer's protocol and a Victor 3 luminometer (PerkinEl- 
mer, Groningen, the Netherlands). Relative light units (RLU) were calculated after correction 
for transfection efficiency based on the activity of a co-transfected reporter plasmid encoding 
Renilla luciferase under the control of the SV40 promoter (pRL-SV40; Promega). The data are 
expressed as the mean relative luciferase activity of at least three independent experiments 
with 95% confidence intervals (CIs).
Dissociation and Purification of Epithelial Cells from Breast Biopsy Samples
Normal breast tissue located distally from the tumor was obtained during surgical resection 
of the primary tumor at the Radboud University Nijmegen Medical Centre (RUNMC) from six
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anonymous breast tumor patients and was macrodissected within 12 hours of surgical re­
moval and dissociated as previously described [30]; tissue procurement was approved by the 
institutional ethics committee of the RUNMC. In short, the tissue was minced with a scalpel 
and dissociated in 0.1% DNase (Roche, Woerden, the Netherlands) and 0.14% collagenase A 
(Roche) in RPMI-1640 medium, by incubating the minced tissue three times for 45 minutes 
each time in fresh DNase-collegenase-containing medium. The cell suspension was passed 
through a 30-^M MACS preseparation filter (Miltenyi Biotec, Utrecht, the Netherlands) washed 
to remove tissue debris, and stored overnight at 4 °C. The cell suspension was incubated with 
allophycocyanin (APC)-conjugated anti-human CD326 antibody (Miltenyi Biotec), which re- 
congnizes the epithelial cell surface marker Epithelial Cell Adhesion Molecule (Epcam) fol­
lowed by incubation with anti-APC MACS beads (Miltenyi Biotect), and the CD326-positive 
and CD326-negative cells were fractionated by magnetic separation. The CD326-positive and 
CD326-negative cell fractions were lysed for RNA isolation, and analyzed for the expression 
of the leukocyte marker CD45, the dendritic cell marker CD11c, the epithelial cell marker 
CD326, and DC-SCRIPT by means of quantitative polymerase chain reaction (PCR) analysis.
Complementary DNA (cDNA) Synthesis and Quantitative Polymerase Chain Reaction 
(PCR) Analysis
For quantitative PCR analysis of DC-SCRIPT, PBGD, CD45, CD11c, and CD326 mRNA levels, 
total RNA was isolated from fresh normal breast tissue or cell lines with the use of Trizol 
reagent (Gibco BRL) according to the manufacturer's protocol. RNA was treated with DN­
ase I (amplification grade, Invitrogen) and reverse-transcribed into cDNA by using random 
hexamers and Moloney murine leukemia virus reverse transcriptase (Invitrogen). mRNA 
levels for the genes of interest were determined with a PRISM 7000 sequence detection 
system (Applied biosystems, Foster City, CA) with SYBR Green (Applied Biosystems) as 
the fluorophore and the following oligonucleotide primers (forward, reverse): DC-SCRIPT 
(5'-AAGCATGGAGTCATGGAG-3', 5'-TTCTGAGAGAGGTCAAAGG-3'); PBGD (5'-GGCAATGCG- 
GCTGCAA-3', 5'-GGGTACCCACGCGAATCAC-3'); CD326 (5'-TGTCTGTGAAAACTACAAGCTGG-3', 
5'-AGCCATTCATTTCTGCCTTCATC-3'); CD45 (5'-ACCACAAGTTTACTAACGCAAGT-3', 5'-TTT 
GAGGGGGATTCCAGGTAAT-3'); and CD11c (5'-ATCACCTTCTTGGCTACCT-3', 5'-TGAGGTATTT- 
GGTGAATTGT-3'). We used reaction mixtures and program conditions that were recommend­
ed by the manufacturer (Applied Biosystems).
Quantitative PCR data were analyzed with 7000 Systems SDS Software v1.2.3 (Applied Bio­
systems) and checked for correct amplification and dissociation of the products. mRNA levels 
of the genes of interest were normalized to mRNA levels of the housekeeping gene porphobi­
linogen deaminase (PBGD) [31], and were calculated according to the cycle threshold method 
[32].
Immunohistochemistry
Snap-frozen breast cancer specimens from eight anonymous breast cancer patients were ob­
tained from the Rijnstate Hospital (Arnhem, the Netherlands; approved by the institutional
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ethics committee of the Radboud University Nijmegen Medical Centre) and embedded in OCT 
embedding matrix (CellPath, Newtown, UK) and sectioned (5-^M thick tissue sections). The 
sections were placed on Superfrost slides (Thermo Scientific, Ettenleur, the Netherlands), 
fixed with acetone, and incubated with 4 ng/mL goat anti-human DC-SCRIPT antibody (R&D 
Systems) followed by incubation with a biotinylated horse anti-goat IgG (Vector Laboratories) 
and signal development was performed using a Vectastain ABC-AP kit (Vector Labs, Brunswig, 
Amsterdam) and fast red (Sigma). The epithelial cell surface marker epithelial cell adhesion 
molecule (Epcam) was detected with a mouse monoclonal anti-CD326 antibody (Miltenyi 
Biotec) and a biotinylated horse anti-mouse IgG (Vector Laboratories). Isotype-matched goat 
IgG (R&D Systems) and mouse IgG1 (BD Bioscience) were used as controls. Sections were 
counterstained with hematoxylin to visualize the cell nuclei and analyzed by using a Leica DM 
LB microscope (Leica Microsystems B.V., Rijswijk, the Netherlands).
Patients
Our use of coded tumor tissues in this study was performed in accordance with the Code of 
Conduct of the Federation of Medical Scientific Societies in the Netherlands (http://www. 
federa.org/) [a link to the English version is available at this site]) and was approved by the 
institutional ethics committee of the Radboud University Nijmegen Medical Centre. All steps 
in tissue processing and marker assaying were performed by individuals who blinded to the 
clinical outcomes, and, as much as possible, in accordance with the guidelines for biomarker 
characterization described by Pepe et al. [33].
From nine anonymous patients who underwent surgery in the early 1990s, both breast tumor 
and distally located normal breast tissue was macrodissected, and stored in liquid nitrogen 
until RNA isolation as described below. No other information on these patients or tissues is 
available.
Other tumor tissues were from patients who had operable unilateral breast cancer and had 
undergone resection of their primary tumor between November 1987 and December 1997. 
We included patients who had no previous carcinoma diagnosis, no distant metastases at 
diagnosis, and no evidence of disease within 1 month after primary surgery. We excluded 
patients who had received neoadjuvant systemic therapy or who were diagnosed with carci­
noma in situ only.
The discovery group (n = 47) was selected from among a previously described cohort of pa­
tients [34] based on the availability of tumor RNA and consisted of stage pT1 or pT2 [35] 
ductal (n = 42) or lobular (n = 5) node-negative breast tumors that had received no adjuvant 
systemic therapy. The tumors were collected, snap frozen, and embedded in OCT compound 
(Tissue-Tek) as soon as possible after surgical resection (breast conserving lumpectomy: n = 
34; modified radical mastectomy: n = 13) at the Rijnstate Hospital (Arnhem, the Netherlands). 
Tumors in the validation (n = 97) and tamoxifen-treated (n = 68) groups were also selected 
based on tumor RNA availability and receipt of adjuvant treatment (no adjuvant systemic 
treatment [validation group] or adjuvant systemic treatment with tamoxifen) from among a 
different cohort of patients that was also described earlier [36]. The tumors from this cohort
DC-SCRIPT: Nuclear R eceptor M odulation and Breast Cancer | 51
of patients were obtained from a tumor bank in the Department of Chemical Endocrinology 
(Radboud University Nijmegen Medical Centre) that contains frozen tumor tissue collected 
from breast cancer patients who were treated at the nine hospitals that form the Comprehen­
sive Cancer Center East in the Netherlands. The tumor tissues were collected by these hospi­
tals for the central measurement of estrogen receptor (ER) and progesterone receptor (PR) 
levels by ligand binding assay. Patients were defined as ER- and/or PR-positive (level of either 
or both receptors >10 fmol/mg protein) or as ER- and PR-negative (levels of both receptors 
< 10 fmol/mg protein).
All patients were followed up once every 3 months during the first 2 years after surgery once 
every 6 months for the next 5 years, and once a year thereafter by means of a medical his­
tory, physical examination, and routine laboratory investigations. Each patient received once 
yearly x-ray mammography, and for those with suspicious results, magnetic resonance imag­
ing of the breast.
Tumor Tissue RNA isolation
Aliquots of frozen tissue were pulverized using a microdismembrator (Braun, Melsungen, 
Germany) and the resulting tissue powder was stored in liquid nitrogen. Total RNA was iso­
lated from 20 mg of tissue powder with the use of an RNeasy Mini kit (Qiagen, Hilden, Ger­
many) with on-column DNase I treatment. Aliquots of RNA were stored at -80 °C. RNA quality 
was verified by examining the ribosomal RNA bands after agarose gel electrophoresis of each 
RNA sample and by PCR amplifying PBGD mRNA. RNA concentrations were determined from 
the spectrophotometric absorption at 260 nm by using a Genequant spectrophotometer (Am- 
ersham, Eindhoven, the Netherlands). We observed no effect of storage time in liquid nitrogen 
on the quality of the RNA.
Statistical Analyses
Statistical analyses were carried out using SPSS software (version 16.0; SPSS, Benelux BV). 
The normality of distributions was tested by the method of Kolmogorov-Smirnov [37]. A nor­
mal distribution for DC-SCRIPT mRNA expression values was achieved after taking the 10log 
of each value. Differences in the proportions of clinicopathological characteristics among the 
three patient groups were assessed with Pearson chi-square tests. Differences in PBGD-nor- 
malized DC-SCRIPT mRNA expression levels between normal breast tissue and tumor tissue 
from the same patient were assessed using paired t tests, and between tumor tissues and cell 
lines by unpaired Student t tests. Differences in DC-SCRIPT mRNA levels for variables with 
more than two groups were assessed by analysis of variance. Because data on histological 
grading were missing for a substantial number of patients, patients with missing data were 
included in all analyses as a separate group. The disease-free interval (defined as the time 
from surgery until the diagnosis of recurrent disease) was used as follow-up end point. Con­
tralateral breast cancer or second malignancies were not considered to be recurrent disease. 
Overall survival was not evaluated because data on breast cancer-specific causes of death 
were difficult to retrieve from the patient records and, thus, the number of events was too
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small for reliable statistical analysis. Survival curves were generated by using the Kaplan­
Meier method. Cox proportional hazards modeling was used to assess the prognostic value 
of DC-SCRIPT mRNA expression after dichotomization of the patient group. The proportional 
hazard assumption was confirmed by examination of the Schoenfeld residuals. An optimal 
cutpoint was selected in a discovery group at the lowest possible P value at such cutpoint, 
thus representing the best dichotimization of the patient group. The cutpoint was selected 
by multiple testing and validated in the two other independent patient cohorts. Multivariable 
Cox proportional hazards modeling was then used to assess the independent prognostic value 
of DC-SCRIPT mRNA expression in the combined validation and tamoxifen-treated patient 
cohorts. All clinicopathological variables were entered into the Cox regression model. Sub­
sequently variables that did not contribute to the model (P > .1) according to the likelihood 
ratio statistic were removed in a stepwise fashion until only statistically significant variables 
remained in the model. Interactions between DC-SCRIPT mRNA expression and ER and PR 
status and between DC-SCRIPT mRNA expression and tamoxifen treatment were assessed by 
entering an interaction variable into the model. Two-sided P values less than .05 were a priori 
considered to be statistically significant.
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Figure 1. A ssociation of DC-SCRIPT w ith  m ultip le  n u c lear recep to rs  in  tran sfec ted  Hek293 cells
Lysates from Hek293 cells th at were co-transfected with YFP-DC-SCRIPT or YFP and with the indicated 
HA-tagged nuclear receptors, were imm unoprecipitated (IP) with mouse monoclonal anti-GFP antibody- 
coupled beads (the antibody recognizes YFP-tagged proteins). The immunoprecipitated proteins were 
subjected to immunoblotting (WB) with the anti-GFP antibody to detect YFP-tagged proteins or with a 
ra t monoclonal anti-HA antibody to detect the co-immunoprecipitated HA-tagged nuclear receptors (NR- 
HA). Data shown are from one of a t least three experiments that produced similar results. YFP-DC-SCRIPT 
protein degradation products are indicated with an asterisk.
DC-SCRIPT: Nuclear R eceptor M odulation and Breast Cancer | 53
Results
Interaction Between DC-SCRIPT and Multiple Nuclear Receptors
We performed co-immunoprecipitation experiments to examine whether DC- 
SCRIPT interacts with the steroid nuclear receptors ERa and PR-B or with the 
RXR heterodimers RARa and PPARy. For this experiment, whole-cell lysates were 
prepared from HEK293 cells that had been co-transfected with expression vectors 
encoding YFP-tagged DC-SCRIPT or YFP (control) and HA-tagged nuclear receptors 
ERa, PR-B, RARa, or PPARy. YFP-DC-SCRIPT was immunoprecipitated with anti- 
GFP antibody-coupled beads, and the immunoprecipitated fraction was subjected 
to immunoblotting with an anti-GFP antibody. Equal expression of the HA-tagged 
nuclear receptors was dem onstrated by immunoblotting of total lysates of the 
transfected cells with an anti-HA antibody (Figure 1, top panels). YFP-DC-SCRIPT 
and the control protein YFP were both effectively immunoprecipitated by the anti- 
GFP antibody-coupled beads (Figure 1). In addition to the intact YFP-DC-SCRIPT 
protein, some additional protein bands were also observed that correspond to 
YFP-DC-SCRIPT breakdown products (Figure 1 and data not shown). Interestingly, 
in cells transfected with YFP-DC-SCRIPT, the HA-tagged nuclear receptor ERa 
was efficiently co-immunoprecipitated by the anti-GFP antibody-coupled beads
RAR RXR ER
- P ZnAc - P ZnAc - P ZnAc
CtBP1
S up p lem en tary  F igure 1. DC-SCRIPT in te rac tio n s in  y eas t tw o-hybrid  assays
Yeast two-hybrid assays w ere perform ed using bait (- = the negative control empty plasmid, P = proline- 
rich region of DC-SCRIPT, or ZnAc = the zinc acidic region of DC-SCRIPT) and prey (RAR, RXR, ER, or 
CtBPl [positive control for binding to DC-SCRIPT] plasmids in the absence (white bars) and presence 
(black bars) of ligand (10 ^M all-trans-retinoic acid for RAR and RXR prey and 10 nM p-estradiol for ER 
prey). The physical interaction between the bait and prey proteins activates transcription of a reporter 
gene that encodes p-galactosidase. p-Galactosidase activity was used as an indicator of protein-protein 
interactions. p-Galactosidase activity from the yeast clones containing bait and prey was assayed with 
the use of a Yeast p-Galactosidase Assay Kit (Pierce) and measured using the following equation: (1000 
x A 420)/(t x V x 0D660), where A420 = absorbance value at 420 nm, t = time (in m inutes) of incubation, 
V = volume of cells (mL), and 0D660 = optical density at 660 nm. We analyzed 10 colonies per each bait- 
prey combination per experiment for their p-galactosidase activity, and the data are expressed as the 
mean values of three experiments; error bars correspond to 95% confidence intervals.
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(Figure 1, lane 2). HA-tagged PR-B (lane 4), RARa (lane 6), and PPARy (lane 8) 
were also specifically co-immunoprecipitated with YFP-DC-SCRIPT, but not with 
the control protein YFP. We repeated these co-immunoprecipitation experiments 
using the same stringent lysis conditions in the presence or absence of the ligand 
and observed no substantial effect on the efficiency of the co-immunoprecipitation 
experiments (data not shown). Additional yeast two-hybrid experiments showed 
no direct interaction between DC-SCRIPT and RAR, RXR, or ER (Supplementary 
Figure 1). These co-immunoprecipitation data combined with the yeast-two-hybrid 
results dem onstrate that DC-SCRIPT is present in a protein complex with either of 
these nuclear receptors, and imply that these interactions are indirect and ligand 
independent.
Effect of DC-SCRIPT on ER- and PR-B-Mediated Transcription
Next, we used luciferase reporter assays to assess the effect of DC-SCRIPT on the 
transcriptional activity of the steroid-induced nuclear receptors ER and PR. Hep3B
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Figure 2. Effect o f DC-SCRIPT o n  e s tro g en  re ce p to r (ER)- a n d  p ro g estero n e  re ce p to r (PR)-B-m edi- 
a te d  tran sc rip tio n
A) ER-mediated transcription. Hep3b cells were transfected with the firefly luciferase reporter plasmid 
ERE3-TATA-luc in the absence (-) or presence (+) of a cotransfected ER expression plasmid and 
increasing amounts of DC-SCRIPT expression plasmid. The cells were treated for 24 hours with vehicle 
(white bars) or 10 nM p-estradiol (black bars), and luciferase activity was m easured with a luminometer.
B) PR-B-mediated transcription. Hep3b cells were transfected with the firefly luciferase reporter plasmid 
MMTV-luc, co-transfected expression vector encoding for PR-B as indicated, and increasing amounts of 
co-transfected DC-SCRIPT expression vector. The cells were treated for 24 hours with vehicle (white 
bars), 100 nM progesterone (grey bars), or with 10 nM R5020 (black bars), and luciferase activity was 
m easured with a luminometer. All data w ere corrected for transfection efficiency by dividing the firefly 
luciferase values by the value of a co-transfected Renilla luciferase reporter construct. Luciferase data are 
expressed relative to luciferase production in cells transfected with the nuclear receptor, stimulated with 
the appropriate ligand, and in the absence of co-transfected DC-SCRIPT. Data are expressed as the mean 
values of at least four independent experiments; error bars correspond to 95% confidence intervals.
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cells were transfected with a reporter construct containing response elements for 
ER (ERE3-TATA-luc) [29] and stimulated with the ER ligand estradiol. In the absence 
of exogenous ER very little luciferase was produced by transfected cells that were 
exposed to estradiol (Figure 2, A, left). By contrast, Hep3B cells that were co­
transfected with a mammalian expression vector encoding ER displayed luciferase 
activity in an estradiol-dependent manner (Figure 2, A, right). Introduction of 
increasing amounts of an expression vector encoding DC-SCRIPT into cells expressing 
exogenous ER revealed a dose-dependent repression of estradiol-dependent ER- 
mediated luciferase activity (Figure 2, A, right). These data are in agreem ent with 
previous findings that dem onstrated that DC-SCRIPT can repress expression levels 
of endogenous targets of ER (ie, cathepsin D and pS2) [22]. Similarly, DC-SCRIPT 
strongly repressed the hormone-induced (ie, progesterone and R5020) transcription 
mediated by PR-B on the MMTV prom oter in a dose dependent m anner (Figure 2, B). 
These data indicate that DC-SCRIPT specifically represses transcription mediated 
by the steroid receptors ER and PR-B in a dose- and hormone ligand-dependent 
manner.
Effect of DC-SCRIPT on RARa/RXRa- and PPARy/RXRa-Mediated 
Transcription
To examine the effect of DC-SCRIPT on transcription mediated by two members 
of the RXR subclass of nuclear receptors, the RXR heterodimers with RARa and 
PPARy, we performed additional luciferase reporter assays in Hep3B cells. Hep3B 
cells transfected with the luciferase reporter construct ptk-RARE3-luc [23], which 
contains three response elements for the heterodimer RARa/RXRa, exhibited 
luciferase activity after stimulation with the RARa/RXRa ligand AtRA (Figure 3, A). 
Strikingly, co-expression of increasing amounts of DC-SCRIPT resulted in a dose- 
dependent increase in luciferase activity upon addition of AtRA (Figure 3, A), which 
is in contrast to the repressive effect of DC-SCRIPT on the transcriptional activity 
of the steroid receptors. To unequivocally demonstrate that the observed increase 
in luciferase activity was mediated by RARa/RXRa, we repeated the experiment 
in insect SL2 cells, which do not express RARa or RXRa [38] (Figure 3, B). DC- 
SCRIPT activated AtRA-dependent transcription in a dose-dependent fashion in 
SL2 cells only when RAR/RXR was co-expressed. In addition, removal of the RARa/ 
RXRa response elements in the reporter construct completely abolished luciferase 
production in both Hep3b and SL2 cells (data not shown). We further demonstrated 
that DC-SCRIPT enhanced the transcriptional activity of PPARy/RXRa in Hep3B cells.
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and PPARv/RXRa-mediated transcription
A) RARa/RXRa-mediated transcription in Hep3b 
cells. Hep3b cells were transfected with the firefly 
luciferase reporter ptk-RARE3-luc and increasing 
amounts of a co-transfected DC-SCRIPT expression 
vector. The cells were treated for 16 hours with 
vehicle (white bars) or 1 all-trans-retinoic acid 
(AtRA) (blackbars). Luciferase activity was m easured 
with a luminometer and is expressed relative to 
luciferase production upon stimulation with AtRA 
and in the absence of DC-SCRIPT. B) RARa/RXRa- 
mediated transcription in SL2 cells. SL2 cells were 
transfected with the reporter firefly reporter ptk- 
RARE3-luc, the co-transfected expression plasmids 
RARa and RXRa as indicated and increasing 
amounts of the expression vector for DC-SCRIPT. The 
cells were treated for 16 hours with vehicle (white 
bars) or 1 ^M AtRA (black bars). Luciferase activity 
was m easured with a luminometer. C) PPARy/RXRa- 
mediated transcription in Hep3b cells. Hep3b cells 
were transfected with the firefly luciferase reporter 
PPRE2-luc, the PPARy expression plasmid as 
indicated, and increasing amounts of the expression 
plasmid for DC-SCRIPT. Cell were treated for 24 
hours with vehicle (white bars), the PPARy ligand 1 
HM GW1929 (grey bars), or the PPARy ligand lO^M 
troglitazone (black bars) Luciferase data (B-C) are 
expressed relative to luciferase production in the 
presence of cotransfected nuclear receptor, upon 
stimulation with the ligand, and in the absence of cotransfected DC-SCRIPT. All data (A-C) are corrected 
for transfection efficiency by dividing the firefly-luciferase values by the value of a co-transfected 
Renilla luciferase reporter construct. The data are expressed as the mean of at least four independent 
experiments; error bars correspond to 95% confidence intervals,
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Hep3B cells transfected with a reporter construct containing the response elements 
for PPARy/RXRa (PPRE-luc [27]) failed to display luciferase activity when exposed 
to the PPARy ligands GW1929 and troglitazone. However, co-expression of PPARy/ 
RXRa in these cells resulted in ligand-dependent induction of luciferase activity that 
was enhanced by DC-SCRIPT in a dose-dependent m anner (Figure 3, C). These data 
indicate that in contrast to the repressive effect of DC-SCRIPT on the transcriptional 
activity of the steroid receptors ER and PR-B, DC-SCRIPT enhances transcription 
mediated by the RXR heterodimers RARa and PPARy.
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Effect of DC-SCRIPT on nuclear receptor-induced transcription in breast 
carcinoma MCF7 cells
Our finding that DC-SCRIPT can repress transcription mediated by the steroid 
receptors ER and PR-B, whereas on the other hand it can enhance the transcriptional 
activity of the RXR heterodimers RARa and PPARy, implies that DC-SCRIPT may 
be a key regulator that balances the cell’s response to multiple nuclear receptor 
ligands such as vitamins, fatty acids, and hormones. To corroborate these findings, 
we examined the effect of DC-SCRIPT on nuclear receptor-induced transcription 
in human breast carcinoma MCF-7 cells which endogenously express both PR and
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A  Figure 4. Effect o f DC-SCRIPT on nuclear receptor-
induced transcription in  breast carcinom a MCF7 
cells
A) RARa/RXRa-mediated transcription. MCF7 cells 
were transfected with the AtRA sensitive reporter ptk- 
RARE3-luc (firefly luciferase) and in the presence or 
absence of an expression plasmid of DC-SCRIPT. Cells 
were treated for 24 hours with vehicle (white bars), 
w ith 1 nM AtRA (grey bars), or 1 AtRA and 10 nM 
R5020 simultaneously (black bars). B) PR-B mediated 
transcription. MCF7 cells were transfected with the 
progesterone-sensitive Renilla luciferase reporter 
plasmid MMTV-RLuc and with a DC-SCRIPT expression 
plasmid as indicated. Cells were treated for 24 hours 
with vehicle (white bars), with the PR-B ligand 10 nM 
R5020 (grey bars), or with 1 AtRA and 10 nM R5020 
simultaneously (black bars). The luciferase data in A 
and B are expressed relative to luciferase activity in 
the absence of DC-SCRIPT and upon stimulation with 
AtRA and R5020. C) RARa/RXRa- and PR-B-mediated 
transcription. MCF7 cells were co-transfected with 
the AtRA sensitive ptk-RARE3-luc (firefly luciferase 
reporter) and with the progesterone-sensitive MMTV- 
RLuc (renilla luciferase reporter) and with increasing 
amounts of DC-SCRIPT and stimulated simultaneously 
for 24 hours w ith 10nM R5020 and 1 ^M AtRA. White 
bars indicate AtRA-mediated luciferase production 
(firefly luciferase) and black bars R5020-mediated 
luciferase production (Renilla luciferase). Luciferase 
activity is expressed relative to luciferase production 
upon stimulation with AtRA and R5020 and in the 
absence of DC-SCRIPT. All luciferase data are expressed as the mean of a t least three independent 
experiments; error bars correspond to 95% confidence intervals.
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RARa. Therefore, MCF-7 cells were cotransfected with MMTV-Rluc, a progesterone- 
inducible reporter construct that drives the expression of Renilla luciferase, and ptk- 
RARE3-luc, an AtRA-inducible reporter construct that drives the expression of firefly 
luciferase. Control experiments showed that both types of luciferase are induced in 
cells that are exposed to either the corresponding specific nuclear receptor ligand 
(PR ligand: R5020 and RARa/RXRa ligand: AtRA) or both nuclear receptor ligands 
compared with MCF-7 cells treated with vehicle (Figure 4A and B). In addition, 
the effect of DC-SCRIPT on the activity of these endogenously expressed nuclear 
receptors was in agreement with our findings in transfected Hep3b cells (Figure 2, 
B and Figure 3, A). Interestingly, co-expression of DC-SCRIPT together with both the 
AtRA-inducible reporter and the progesterone-inducible reporter enhanced RARa/ 
RXRa-mediated transcription (white bars) and concurrently repressed the activity 
of PR (black bars) (Figure 4, C). We further found that DC-SCRIPT overexpression 
inhibited MCF-7 cell growth, as did treatm ent of MCF-7 cells with the known ER 
antagonist tamoxifen (Supplementary Figure 2). These data dem onstrate that the 
presence of DC-SCRIPT can simultaneously modulate the activity of endogenously 
expressed PR and RARa/RXRa in MCF-7 cells and affects MCF-7 cell growth.
Supplem entary Figure 2. Effect o f DC-SCRIPT on the 
growth of MCF-7 cells
Human breast cancer MCF-7 cells were transfected 
with pEYFP (control, white bars) or pEYFP-DCSCRIPT 
(black bars) and incubated for 16 hours. The cells were 
incubated in the presence or absence of 1 ^M tamoxifen 
for 96 hours, harvested and counted using a Biirker cell 
counting chamber (Optik Labor, Germany) and analyzed 
for YFP expression by means of fluorescence-activated 
cell sorting on a FACS-Calibur (BD bioscience) and 
analyzed using WinMDI 2.8 software by J. Trotter (The 
Scripps institute). Thereafter, the num ber of transfected cells was calculated. Number of cells plotted in the 
graph is relative to the num ber of cells at the start of incubation in the presence or absence of tamoxifen. 
Data are expressed as the mean values of three independent experiments; error bars correspond to 95% 
confidence intervals.
DC-SCRIPT Expression in Breast Epithelial Cells
Among immune cells, DC-SCRIPT expression appears to be restricted to the 
dendritic cell lineage [19]. Less is known about DC-SCRIPT expression in non­
immune cells. Because DC-SCRIPT regulates transcription mediated by multiple 
nuclear receptors that play an im portant role in breast cancer and affects growth of 
the breast carcinoma MCF-7 cells, we examined DC-SCRIPT mRNA levels in normal
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breast tissue and corresponding breast tum or tissue from nine patients. DC-SCRIPT 
mRNA expression was readily detected in normal breast tissue by quantitative 
PCR. Statistically significantly lower DC-SCRIPT mRNA levels were present in the 
corresponding breast tum or samples (P = .010 [paired t test]; Figure 5, A) DC-SCRIPT 
mRNA was essentially undetectable in more than 50 different cell lines analyzed, 
including a panel of 16 breast tum or cell lines (data not shown).
A B
Figure 5. DC-SCRIPT expression  in b re a s t
A) DC-SCRIPT mRNA expression in paired tissue samples. DC-SCRIPT mRNA levels in healthy tissues 
(black bars) and corresponding b reast tum or (white bars) tissue (n = 9 patients) relative to PBGD mRNA 
as determined by quantitative RT-PCR. B) mRNA expression in CD326-positive and CD326-negative 
b reast cells. Expression of CD326, CD45, CD11c, and DC-SCRIPT mRNA in CD326-positive (white bars) 
and CD326-negative (black bars) cells purified from b reast tissue relative to PBGD mRNA as determined 
by quantitative real-time RT-PCR. Data from one of the two DC-SCRIPT-positive patients out of six are 
shown. Data are expressed as the mean of at least three independent quantitative PCR assays; error bars 
correspond to 95% confidence intervals C,D) DC-SCRIPT and CD326 protein expression in b reast tumor 
sections. Epcam was stained with an anti-CD326 (red), DC-SCRIPT with anti-DC-SCRIPT (red) or matched 
isotypes (red) as control staining on frozen b reast tum or sections as detected by immunohistochemistry 
staining. Nuclei are counter-stained with hematoxylin (blue). Magnification is indicated by size bars (C) 
0.1 |im and D) 1 |im) in lower left corner. Representative sections are shown.
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Table 1. P a tie n t a n d  tu m o r ch arac te ris tics  by study  group*
Characteristic
Discovery 
No. (%)
Validation 
No. (%)
Tamoxifen-treated 
No. (%) Pt
Menopausal status
Premenopausal 9 (19) 26 (27) 0 (0) <.001
Postmenopausal 38 (81) 71 (73) 68 (100)
Tumor type
Ductal 42 (89) 61 (63) 34 (50) <.001
Lobular 5 (11) 10 (10) 6 (9)
Other/unknown 0 (0) 26 (27) 28 (41)
Tumor graded
1 7 (15) 3 (3) 5 (7) .026
2 15 (32) 27 (28) 20 (29)
3 19 (40) 33 (34) 29 (43)
Unknown/missing 6 (13) 34 (35) 14 (21)
Tumor stage§ (size in mm)
pT1 (<20) 31 (66) 33 (34) 17 (25) <.001
pT2 (20-50) 16 (34) 55 (57) 39 (58)
pT3 (>50) 0 (0) 8 (8) 11 (16)
Unknown/missing 0 (0) 1 (1) 1 (1)
No. of positive lymph nodes
0 47 (100) 74 (76) 5 (7) <.001
1-3 0 (0) 7 (7) 38 (56)
>4 0 (0) 10 (10) 12 (18)
Unknown/missing 0 (0) 6 (6) 13 (19)
ER and PR status
ER and PR negative 10 (21) 32 (33) 21 (31) .342
ER and/or PR positive 37 (79) 65 (68) 47 (69)
Type of surgery
Lumpectomy 34 (72) 29 (30) 21 (31) <.001
Mastectomy 13 (28) 68 (70) 47 (69)
Radiotherapy
No 14 (30) 35 (36) 7 (10) .001
Yes 33 (70) 62 (64) 61 (90)
Systemic adjuvant therapy
No 47 (100) 97 (100) 0 (0) <.001
Yes 0 (0) 0 (0) 68 (100)
DC-SCRIPT mRNA level |||
Low 16 (34) 33 (34) 18 (26) .543
High 31 (66) 64 (66) 50 (74)
*ER = estrogen receptor; PR = progesterone receptor 
t  Chi-square test (two-sided). 
t  Bloom-Richardson grade (39).
§ American Joint Committee on Cancer staging (35).
Ill DC-SCRIPT/PBGD ratio higher or lower than 0.15, the optimal prognostic cutpoint in the discovery 
group.
DC-SCRIPT: Nuclear Receptor Modulation and Breast Cancer | 61
To identify w hich cells in the breast tissu e sam ples expressed  DC-SCRIPT mRNA, 
total cells isolated  from fresh norm al breast tissu e b iopsy sam ples w ere separated  
into an epithelial ce ll-p ositive and an epithelial ce ll-d ep leted  fraction by m agnetic  
bead sorting using the epithelial cell marker EpCaM (CD326). Quantitative PCR 
analysis o f  these sam ples sh ow ed  that, as expected, DC-SCRIPT mRNA w as present 
in the C D 326-depleted leukocyte-containing fraction, as w ere the mRNAs encoding  
the dendritic cell-sp ecific  marker CD11c and the leukocyte marker CD45 (Figure 
5, B). Importantly, DC-SCRIPT mRNA w as also detected  in the CD326-positive 
epithelial cell fraction. The absence o f CD11c mRNA in the CD 326-positive fraction 
indicates that epithelial cells and n ot contam inating dendritic cells w ere the cells 
that expressed  DC-SCRIPT mRNA. Im m unohistochem istry on frozen breast tumor 
sections confirm ed that m orphologically norm al and m alignant CD326-positive 
ductal epithelial cells express DC-SCRIPT protein (Figure 5, C and D). In concordance 
w ith the PCR data (Figure 5, A), a w ide range o f DC-SCRIPT protein expression  levels 
w as observed  in the breast tum or b iopsy sam ples (data n ot show n).
Prognostic Significance of DC-SCRIPT mRNA Expression in Breast Cancer
Next, w e explored the prognostic value o f DC-SCRIPT mRNA expression  in three 
cohorts o f breast cancer patients. Characteristics o f these patient cohorts and tumor 
tissu es used  in this study are described in Table 1. Most patients (70% -80% ) in the 
untreated patient (ie, the discovery and validation) cohorts w ere postm enopausal at 
the tim e o f prim ary surgery, w hereas all patients that w ere treated w ith  tam oxifen  
w ere postm enopausal (P < .001). The discovery group consisted  only o f pT1 or 
pT2 tum ors w ithout axillary nodal involvem ent, w hereas both the validation and 
the tam oxifen cohorts consisted  o f larger tum ors (8% -16%  w ere pT3; P  < .001) 
and included patients w ith  positive lym ph nodes (validation vs tamoxifen: 17%  vs 
74%, P < .001). The discovery group m ostly (72% ) underw ent breast-conserving  
lumpectom y, w hereas m ost patients in both the non-treated and tam oxifen-treated  
cohorts underw ent m odified  radical m astectom y (69% -70% , P  < .001). Patients 
treated w ith  endocrine therapy received tam oxifen 40  m g tw ice daily for at least 2 
years. The three study groups did n ot differ in the relative size o f their subgroups as 
defined by DC-SCRIPT expression (chi-square P  = .543) (Table 1).
First, w e m easured the DC-SCRIPT mRNA levels in prim ary breast tum ors from a 
cohort o f patients w ho had n ot received system ic adjuvant treatm ent (the discovery  
group; n= 47). The DC-SCRIPT mRNA level in this patient group w as n ot associated  
w ith any o f the clinicopathological param eters [ie, m enopausal status, tum or type,
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Figure 6. DC-SCRIPT expression  as  a  p rognostic  m ark e r in  ER- a n d  PR-positive b re a s t  cancer
A) Kaplan-Meier analysis of disease-free interval according to DC-SCRIPT mRNA expression in tumors 
from breast cancer patients who did not have axillary lymph node metastases and did not receive 
systemic adjuvant therapy (discovery group; n = 47). B) Kaplan-Meier analysis of disease-free interval 
according to DC-SCRIPT mRNA expression in tumors from an independent validation group that included 
patients with larger tum ors than those in the discovery group and with axillary lymph node metastases 
(n = 97). C) Kaplan-Meier analysis of disease-free interval according to DC-SCRIPT mRNA expression in 
tum ors from patients in the validation group with ER- and PR-positive tum ors (n = 65). D) Kaplan-Meier
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analysis of disease-free interval according to DC-SCRIPT mRNA expression in tum ors from patients in 
the validation group with ER- and PR-negative tum ors (n = 32). E) Kaplan-Meier analysis of disease-free 
interval according to DC-SCRIPT mRNA expression in tum ors from patients treated with tamoxifen (n = 
68). (A-E) Patients with high DC-SCRIPT expression were compared with patients with lower DC-SCRIPT 
expression. High DC-SCRIPT expression (dotted line) indicates expression above the optimal cutoff of DC- 
SCRIPT/PBGD transcript ratio of 0.15; low DC-SCRIPT expression (solid line) indicates expression below 
DC-SCRIPT/PBGD transcript ratio of 0.15. F) Kaplan-Meier analysis of disease-free interval according 
to tum or ER and PR status among patients treated with tamoxifen (n = 68). Dotted line corresponds to 
patients with ER- an d /o r PR-positive tumors; solid line corresponds to patients with ER- and PR-negative 
tumors. All P values are two-sided (Cox proportional hazards tests). Tick marks indicate censored events, 
and vertical lines indicate 95% confidence intervals. Numbers below graphs are the num ber of patients 
a t risk a t that time point.
grade [39], tum or size, lym ph node status, horm one receptor status, or type of 
surgery or therapy] or w ith  the percentage o f tum or cells in the b iopsy sam ple (data 
n ot show n). We then analyzed the prognostic value o f DC-SCRIPT mRNA level in the 
discovery group after dichotom ization o f the patients according to an optim al DC- 
SCRIPT to PBGD transcript ratio cutoff o f  0.15, w hich resu lted  in 16 (34% ) patients 
w ith low  levels o f DC-SCRIPT mRNA and 31 (66% ) patients w ith  high levels o f DC- 
SCRIPT mRNA in their prim ary tum ors. In a Kaplan-M eier survival analysis, these  
tw o groups o f patients differed statistically significantly w ith  resp ect to d isease-free  
interval: those w ith  a high DC-SCRIPT mRNA level had a statistically significantly  
longer d isease-free interval than those w ith  a low  DC-SCRIPT mRNA level (hazard  
ratio [HR] o f recurrence = 0.23, 95%  confidence interval [CI] = 0.06 to 0.93, P  = .039) 
(Figure 6, A).
To validate this finding, w e analyzed DC-SCRIPT expression in an independent 
cohort o f patients w ho also had n ot received adjuvant system ic treatm ent (the 
validation group; n = 97). Overall, the validation group included m ore patients with  
advanced d isease than the d iscovery group (eg, pT3 tumors: 8% vs 0%; axillary nodal 
involvem ent: 17% vs 0%) (Table 1). Nevertheless, w hen w e applied the sam e cutoff, 
the 64  patients (66% ) w ith  a high tum or DC-SCRIPT mRNA level had statistically  
significantly better prognosis than the 33 patients (34% ) w ith  low  tum or DC-SCRIPT 
mRNA level (HR o f recurrence = 0.50, 95%  CI = 0.26 to 0.95, P  = .034) (Figure 6, B).
Because DC-SCRIPT represses the activity o f both ER and PR, w e explored the 
prognostic value o f DC-SCRIPT in relation to the ER and PR status o f the primary 
tumor. We found that the tum or DC-SCRIPT mRNA level had statistically significant 
prognostic value for patients in the discovery and validation groups w ith  ER- an d / 
or PR-positive tum ors but n ot for th ose w ith  ER- and PR-negative tum ors (discovery
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Table 2. U nivariate  a n d  m ultivariab le  Cox p ro p o rtio n a l h aza rd s  m odeling  of facto rs assoc ia ted  
w ith  d isease-free  survival in  th e  com bined  va lid a tio n  a n d  tam ox ifen -trea ted  p a tie n t groups 
(n=165)*
Factor and comparison Univariate analysis Multivariable analysis
HR of recurrence 
(95% CI)
Pt HR of recurrence 
(95% CI)
Pt
Postmenopausal vs 
prem enopausal
0.69 (0.38 to 1.26) .224 0.58 (0.27 to 1.24) .157
Tumor type
Lobular vs ductal
Other or unknown vs ductal
1.94 (0.96 to 3.92) 
1.03 (0.61 to 1.75)
.216 1.18 (0.45 to 3.10) 
1.25 (0.67 to 2.32)
.771
Tumor grade t
2 vs 1
3 vs 1
0.94 (0.21 to 4.19) 
2.29 (0.55 to 9.57)
.022 0.86 (0.18 to 4.03) 
1.67 (0.38 to 7.33)
.337
Tumor stage §
pT2 vs pT1 
pT3 vs pT1
1.73 (0.96 to 3.13) 
2.97 (1.39 to 6.37)
.020 1.74 (0.91 to 3.32) 
2.19 (0.96 to 5.02)
.133
No. of positive lymph nodes
1-3 vs 0 
>4 vs 0
1.63 (0.89 to 2.97) 
4.68 (2.48 to 8.84)
<.001 4.13 (1.86 to 9.16) 
11.6 (5.17 to 26.2)
<.001
ER- an d /or PR-positive vs ER- 
and PR-negative
0.81 (0.49 to 1.33) .411 0.95 (0.52 to 1.75) .879
Mastectomy vs lumpectomy 1.93 (1.09 to 3.43) .018 0.71 (0.29 to 1.70) .439
Radiotherapy (yes vs no) 1.23 (0.69 to 2.17) .480 0.59 (0.29 to 1.21) .149
Systemic adjuvant therapy (yes  
vs no)
1.14 (0.71 to 1.84) .593 0.33 (0.16 to 0.67) .002
DC-SCRIPT mRNA level (high vs 
low) I
0.49 (0.30 to 0.80) .004 0.50 (0.29 to 0.85) .010
DC-SCRIPT interaction
With systemic adjuvant therapy 
With ER and PR status
0.83 (0.49 to 1.39) 
0.56 (0.34 to 0.91)
.470
.017
NA
NA
* HR = Hazard ratio; ER = estrogen receptor; PR = progesterone receptor; NA = not applicable. 
t  Cox proportional hazards 
t  Bloom-Richardson Grade(39).
§ American Joint Committee on Cancer staging (35)
III DC-SCRIPT/PBGD ratio higher or lower than 0.15, the optimal prognostic cutpoint in the discovery 
group.
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group, patients w ith  ER- an d /or PR-positive tumors: HR o f recurrence = 0.16, 95%  CI 
= 0.03 to 0.89, P  = .030; discovery group, patients w ith ER- and PR-negative tumors: 
HR of recurrence = 0.73, 95%  CI = 0.07 to 8.07, P  = .797; validation group, patients 
w ith ER- an d /or  PR-positive tumors: HR of recurrence = 0.42, 95%  CI = 0.19 to 0.91, 
P  = .028 [Figure 6, C]; validation group, patients w ith  ER- and PR-negative tumors: 
HR o f recurrence = 0.68, 95%  CI = 0.21 to 2.22, P  = .519 [Figure 6, D]).
We next assessed  the prognostic value o f DC-SCRIPT expression and tum or ER 
and PR status in a third cohort o f patients w ho received anti-estrogen therapy with  
tam oxifen (n = 68). Strikingly, w hen w e applied the sam e cutoff that w as established  
in the discovery group, DC-SCRIPT expression had approxim ately the sam e 
prognostic value in the tam oxifen-treated cohort as w as found in the validation  
group (HR o f recurrence = 0.46, 95%  CI = 0.22 to 0.97, P  = .040) (Figure 6, E). As 
expected, tum or ER and PR status predicted the response to endocrine therapy in 
this group of patients (P = .011, Figure 6, F).
DC-SCRIPT expression
Va lidation and Tam oxifen-treated groups com bined
0- P < 
0
Patients at risk:
.001 log-rank
20 40  60 80
Time after primary surgery (months)
Q3
Q1
Supplementary Figure 3. DC-SCRIPT ex­
pression as a prognostic marker in breast 
cancer
Kaplan-Meier estimates of disease-free 
interval according to quartiles of DC-SCRIPT 
mRNA expression in tumors from patients 
in the combined validation and tamoxifen- 
treated groups (n = 165). Q1 is the lowest 
quartile of DC-SCRIPT mRNA expression, and 
Q4 is the highest quartile.
We next perform ed univariate and m ultivariable Cox regression analyses in the 
com bined validation and tam oxifen cohorts (n = 165) to assess the independence of 
the prognostic value of DC-SCRIPT mRNA expression after correction for standard  
clinicopathological param eters (Table 2). In the univariate analysis, tum or grade (P  
= .022), tum or size (P = .020), lym ph node status (P < .001), the type of surgery (P = 
.018), and DC-SCRIPT mRNA level (P = .004) w ere statistically significantly associated  
w ith prognosis but tum or ER and PR status w as not. In this com bined cohort, DC- 
SCRIPT mRNA level w as statistically significantly associated  w ith prognosis w hen  
entered as a continuous variable in a Cox regression  analysis independent of 
cutpoint (P = .013; data n ot show n) and after dividing the patients into quartiles
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of DC-SCRIPT mRNA level (P = .001, log-rank test for trend; Supplem entary Figure 
3). The m ultivariable analysis (Table 2) revealed that DC-SCRIPT is an independent 
factor contributing to prognosis after correction for tum or size, lym ph node status, 
system ic adjuvant treatm ent (n = 145; HR o f recurrence = 0.50, 95%  CI = 0.29 to 
0.85, P  = .010).
The interaction b etw een  DC-SCRIPT mRNA level and tam oxifen treatm ent was 
n ot statistically significant (P = .470), w hereas the interaction b etw een  DC-SCRIPT 
mRNA level and tum or ER and PR status w as (P = .017) (Table 2). These data indicate 
that the prognostic value o f DC-SCRIPT mRNA level is in dependent o f w hether or 
n ot the patient received tamoxifen, but does depend on w hether or n ot the tum or 
expresses ER and PR.
Discussion
Here w e have identified  DC-SCRIPT as a regulator o f the activity o f several 
subclasses o f nuclear receptors and as a prognostic marker for ER- an d /or PR- 
positive breast cancer. We have show n that expression  o f DC-SCRIPT in Hep3B 
cells and MCF-7 cells represses the horm one-induced  activity o f ER and PR while 
it  concurrently enhances RARa/RXRa-and PPARy/RXR-mediated transcription. 
In addition, w e show ed  that ductal epithelial cells express DC-SCRIPT mRNA, that 
breast tum ors express low er levels o f DC-SCRIPT than norm al breast tissu e from  
the sam e patient, and that breast tum or cell lines do n ot express DC-SCRIPT mRNA. 
Moreover, quantification o f DC-SCRIPT mRNA expression in three cohorts o f  breast 
cancer patients revealed that DC-SCRIPT mRNA expression  is an independent 
prognostic factor for breast cancer patients w ith  ER- an d /or PR-positive tumors.
To our know ledge, w e have provided the first evidence for the presence o f DC- 
SCRIPT in m ultiple nuclear receptor protein com plexes based  on data from co- 
im m unoprecipitation experim ents. Results o f yeast tw o-hybrid experim ents imply 
that DC-SCRIPT, unlike its direct binding to CtBP1 [19], does n ot bind directly to 
nuclear receptors. This finding suggests that the interaction b etw een  DC-SCRIPT and 
nuclear receptors is likely to be m ediated  by other nuclear receptor co-regulators 
that are presen t in these large m ulti-protein com plexes [14]. Because DC-SCRIPT 
w as previously show n to interact w ith  m ultiple proteins know n to be p resen t in 
th ese  protein com plexes [19, 22], it w ill be in teresting to investigate the m olecular 
m echanism  by w hich DC-SCRIPT differentially m odulates the activity o f m ultiple 
classes o f nuclear receptors.
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Because m alfunction o f nuclear receptors and their co-regulators has been  
associated  w ith  breast cancer [2-4], w e evaluated the expression  o f DC-SCRIPT 
in breast tissue. We found that DC-SCRIPT is expressed  by norm al breast tissue  
w hereas less DC-SCRIPT mRNA could be detected  in the corresponding breast 
tum or tissue. Combined w ith  our finding that DC-SCRIPT inhibits cell growth o f the 
breast carcinom a cell line MCF-7, th ese  data su ggest that DC-SCRIPT m ay act as a 
tum or suppressor in breast cancer developm ent. Such a function for DC-SCRIPT is 
also con sistent w ith  our finding that DC-SCRIPT overexpression in Hep3B and MCF- 
7 cells inhibits the activity o f  ER and PR, w hich w ere previously show n [6] to exhibit 
proliferative and anti-apoptotic activities in breast cancer cells. In contrast, RARa/ 
RXRa and PPARy/RXR, the transcriptional activities o f w hich are enhanced by DC- 
SCRIPT, are reported to have anti-proliferative and pro-apoptotic effects in breast 
cancer cells [40-42]. Moreover, a recent report sh ow ed  that expression  o f RARa/ 
RXRa target genes identified  in MCF-7 cells predicted a positive clinical outcom e 
in breast cancer patients [43]. Our findings in MCF-7 cells indicate that DC-SCRIPT 
affects the balance in the activities o f endogenous PR and RARa/RXRa in favor of 
RARa/RXRa activity w hen the breast cancer cells are sim ultaneously stim ulated  
w ith the respective ligands. To directly dem onstrate a tum or suppressor function for 
DC-SCRIPT and to assess the im pact o f DC-SCRIPT expression  on transcription at a 
genom e-w ide level is very difficult because prolonged overexpression o f DC-SCRIPT 
in all o f the cell lines tested  thus far resu lted  in grow th inhibition and death o f the DC- 
SCRIPT-expressing cells (data n ot show n). Moreover, none o f the cell lines analyzed  
endogenously  expressed  DC-SCRIPT, w hich prevented us from perform ing the 
obvious knock-dow n experim ents o f en dogenous DC-SCRIPT to further investigate 
its anti-proliferative effect. It w ill therefore be im portant to define the conditions 
and factors that regulate DC-SCRIPT expression, from both a physiological and a 
therapeutic perspective.
To our know ledge, this is the first tim e that DC-SCRIPT mRNA expression has 
b een  identified  as a prognostic marker in breast cancer. Over the years, m olecular 
profiling has yielded  gen etic signatures for m any solid  tum ors [44-49] including  
breast cancer [50], h ow ever DC-SCRIPT w as n ot p resen t in these signatures. The 
absence o f DC-SCRIPT from these signatures can be explained by the fact that on 
older m icroarrays used  to determ ine breast cancer signatures, the DC-SCRIPT 
gene w as n ot yet presen t and the relatively low  DC-SCRIPT mRNA expression  may 
have prevented its detection  in m ore recent studies. Our discovery o f DC-SCRIPT 
as an independent prognostic marker for breast cancer patients w ith  ER- a n d /
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or PR-positive tum ors w as p ossib le because w e used  a unique cohort o f patients  
w ho w ere treated w ith system ic adjuvant therapy and follow ed up for 10 years [34, 
36]. Prognostic significance can only be ascertained in such patient groups [51, 
52], w hich are becom ing increasingly scarce because currently even patients with  
negative axillary lym ph nodes alm ost all receive system ic adjuvant therapy. Our 
finding that DC-SCRIPT has prognostic value independent o f  a specific treatm ent 
suggests that DC-SCRIPT m ay contribute to tum or grow th characteristics and is  
con sistent w ith  the proposed  tum or suppressor function o f DC-SCRIPT. The potential 
clinical significance o f DC-SCRIPT extends beyond untreated patients given that we 
sh ow ed  that high DC-SCRIPT expression, like ER and PR status, is also prognostic 
in tam oxifen-treated patients. In line w ith  this finding is our dem onstration that 
DC-SCRIPT inhibited the growth MCF-7 cells treated w ithou t tam oxifen or with  
tam oxifen to block ER function. These data im ply that DC-SCRIPT expression  may  
be used  to se lect ER- an d /or PR-positive patients w ho m ight be candidates for m ore 
aggressive adjuvant therapy.
This study has several lim itations. First, w e have n ot found independent validation  
of DC-SCRIPT mRNA expression  as a prognostic marker in breast cancer in publicly  
available databases; the absence o f the DC-SCRIPT gene on older m icroarrays and 
the relatively low  abundance o f  DC-SCRIPT mRNA m ay have prevented its detection. 
Second, our clinical conclusions are therefore based  on nonrandom ized retrospective  
analyses. To attain a higher level o f evidence, independent m ulticenter an d/or  
random ized prospective studies o f DC-SCRIPT expression  analyses are n ecessary
It w ill be extrem ely interesting to a ssess in future validating studies w hether the 
RARa an d /or PPARy status o f the tum ors is o f relevance regarding the prognostic 
value o f DC-SCRIPT. The presence o f RARa/RXRa target genes in the genetic  
signature o f breast tum or sam ples predicts a positive clinical outcom e in breast 
cancer patients [43]. Stim ulation o f the nuclear receptors RAR/RXR and PPARy/ 
RXR has b een  explored as a novel therapy for breast cancer [53, 54]. So far these  
therapies have show n only lim ited success due to retinoic acid resistance [18, 55]. 
Intriguingly, our data dem onstrate that DC-SCRIPT is able to sim ultaneously enhance 
the activities o f RARa/RXRa and PPARy/RXRa and repress the activities o f  ERa 
and PR-B. On the basis o f these findings w e hypothesize that the anti-proliferative 
effect o f  DC-SCRIPT in breast cancer cells is m ediated by m odulating the activity  
of m ultiple nuclear receptors. It w ill be interesting therefore to also exam ine DC- 
SCRIPT expression levels in clinical trials that have explored the effect o f stim ulation  
of the RAR/RXR and PPARy/RXR on the clinical outcom e in breast cancer patients.
DC-SCRIPT: Nuclear Receptor Modulation and Breast Cancer | 69
Acknowledgments
We thank G. Nikoloski and J. Heuvel for technical assistance and Drs. J. Moiling,
H. van Krieken, H. Stunnenberg, and C. Figdor for critically reading the manuscript. 
This w ork w as supported by the Netherlands Organization for Scientific Research  
[918 .66 .615  to G.J.A].
References
I. Laudet V, Hanni C, Coll J, Catzeflis F, Stehelin D: Evolution of the  nuclear receptor gene superfamily. Embo J 
1992, 11(3):1003-1013.
2. Nagy L, Schule R, Gronemeyer H: Twenty years of nuclear receptors: Conference on Nuclear Receptors: 
from Chromatin to Disease. EMBO Rep 2006, 7(6):579-584.
3. Sonoda J, Pei L, Evans RM: Nuclear receptors: decoding metabolic disease. FEBS L e tt  2008, 582(1):2-9.
4. Wang K, Wan YJ: Nuclear receptors and inflammatory diseases. Exp Biol M ed (M aywood) 2008, 233(5):496- 
506.
5. Turner NC, Jones AL: Management of b reast cancer--Part II. B m j 2008, 337:a540.
6. Yager JD, Davidson NE: Estrogen carcinogenesis in b reast cancer. N  Engl J  M ed  2006, 354(3):270-282.
7. Conzen SD: Minireview: nuclear receptors and b reast cancer. M ol Endocrinol 2008, 22(10):2215-2228.
8. Bourdeau V, Deschenes J, Laperriere D, Aid M, White JH, Mader S: Mechanisms of prim ary and secondary 
estrogen target gene regulation in b reast cancer cells. Nucleic Acids Res 2008, 36(1):76-93.
9. Turner NC, Jones AL: Management of b reast cancer--part I. B m j 2008, 337:a421.
10. Epping MT, Hart AA, Glas AM, Krijgsman O, Bernards R: PRAME expression and clinical outcome of breast 
cancer. Br J  Cancer 2008, 99(3):398-403.
11. Girault I, Lerebours F, Amarir S, Tozlu S, Tubiana-Hulin M, Lidereau R, Bieche I: Expression analysis of estrogen 
receptor alpha coregulators in breast carcinoma: evidence th a t NCOR1 expression is predictive of the 
response to tamoxifen. Clin Cancer Res 2003, 9(4):1259-1266.
12. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, 
Meltzer PS: AIB1, a steroid receptor coactivator amplified in b reast and ovarian cancer. Science 1997, 
277(5328):965-968.
13. Lonard DM, Lanz RB, O'Malley BW: Nuclear receptor coregulators and hum an disease. Endocr Rev 2007, 
28(5):575-587.
14. Lonard DM, O'Malley B W: Nuclear receptor coregulators: judges, juries, and executioners of cellular 
regulation. M ol Cell 2007, 27(5):691-700.
15. O'Malley BW: Coregulators: from whence came these "m aster genes". M ol Endocrinol 2007, 21(5):1009- 
1013.
16. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SAW, Wong JM, Allred DC, Clark GM, Schiff 
R: Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in 
b reast cancer. Journal o f  the N a tiona l Cancer In stitu te  2003, 95(5):353-361.
17. Green AR, Burney C, Granger CJ, Paish EC, El-Sheikh S, Rakha EA, Powe DG, Macmillan RD, Ellis IO, Stylianou 
E: The prognostic significance of steroid receptor co-regulators in b reast cancer: co-repressor NCOR2/ 
SMRT is an independent indicator of poor outcome. B reast Cancer Res T reat 2008, 110(3):427-437.
18. Schug TT, Berry DC, Toshkov IA, Cheng L, Nikitin AY, Noy N: Overcoming retinoic acid-resistance of 
m am m ary carcinomas by diverting retinoic acid from PPARbeta/delta to RAR. Proc N a tl Acad Sci U S  A 
2008, 105(21):7546-7551.
19. Triantis V, Trancikova DE, Looman MW, Hartgers FC, Janssen RA, Adema GJ: Identification and 
characterization of DC-SCRIPT, a novel dendritic cell-expressed m em ber of the  zinc finger family of 
transcriptional regulators. J  Im m unol 2006, 176(2):1081-1089.
20. Triantis V, Moulin V, Looman MW, Hartgers FC, Janssen RA, Adema GJ: Molecular characterization of the 
m urine homologue of the DC-derived protein  DC-SCRIPT. JL eukoc Biol 2006, 79(5):1083-1091.
C
ha
pt
er
70 | Chapter 3
21. Chinnadurai G: CtBP family proteins: m ore than  transcriptional corepressors. Bioessays 2003, 25(1):9-12.
22. Lopez-Garcia J, Periyasamy M, Thomas RS, Christian M, Leao M, Jat P, Kindle KB, Heery DM, Parker MG, Buluwela 
L e t  al: ZNF366 is an estrogen receptor corepressor th a t acts through CtBP and histone deacetylases. 
Nucleic Acids Res 2006, 34(21):6126-6136.
23. de The H, Chomienne C, Lanotte M, Degos L, Dejean A: The t(15;17) translocation of acute promyelocytic 
leukaem ia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. N ature  1990, 
347(6293):558-561.
24. Chung YT, Keller EB: Regulatory elem ents m ediating transcription from the Drosophila m elanogaster 
actin 5C proximal prom oter. M ol Cell Biol 1990, 10(1):206-216.
25. Cato AC, Miksicek R, Schutz G, Arnemann J, Beato M: The horm one regulatory elem ent of mouse mammary 
tum our virus m ediates progesterone induction. Em bo J  1986, 5(9):2237-2240.
26. Cato AC, Henderson D, Ponta H: The horm one response elem ent of the  mouse m am m ary tum our virus 
DNA m ediates the progestin and androgen induction of transcription in the proviral long term inal 
repeat region. Em bo J  1987, 6(2):363-368.
27. Kim JB, Wright HM, Wright M, Spiegelman BM: ADD1/SREBP1 activates PPARgamma through the 
production of endogenous ligand. Proc N a tl A cad Sci U S  A 1998, 95(8):4333-4337.
28. Tung L, Abdel-Hafiz H, Shen T, Harvell DM, Nitao LK, Richer JK, Sartorius CA, Takimoto GS, Horwitz KB: 
Progesterone receptors (PR)-B and -A regulate transcrip tion  by different mechanisms: AF-3 exerts 
regulatory control over coactivator binding to PR-B. M ol Endocrinol 2006, 20(11):2656-2670.
29. Hall JM, McDonnell DP: The estrogen receptor beta-isoform  (ERbeta) of the hum an estrogen receptor 
m odulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens 
and antiestrogens. Endocrinology 1999, 140(12):5566-5578.
30. Sombroek CC, Stam AG, Masterson AJ, Lougheed SM, Schakel MJ, Meijer CJ, Pinedo HM, van den Eertwegh 
AJ, Scheper RJ, de Gruijl TD: Prostanoids play a m ajor role in the prim ary tum or-induced inhibition of 
dendritic cell differentiation. J  Im m unol 2002, 168(9):4333-4343.
31. de Kok JB, Roelofs RW, Giesendorf BA, Pennings JL, Waas ET, Feuth T, Swinkels DW, Span PN: Normalization 
of gene expression m easurem ents in tum or tissues: com parison of 13 endogenous control genes. Lab 
Invest 2005, 85(1):154-159.
32. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-tim e quantitative PCR and 
the 2(-Delta Delta C(T)) Method. M ethods 2001, 25(4):402-408.
33. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD: Pivotal evaluation of the accuracy of a b iom arker used for 
classification or prediction: standards for study design. J  N a tl Cancer In st 2008, 100(20):1432-1438.
34. Foekens JA, Atkins D, Zhang Y, Sweep FC, Harbeck N, Paradiso A, Cufer T, Sieuwerts AM, Talantov D, Span PN 
e t  a l: M ulticenter validation of a gene expression-based prognostic signature in lymph node-negative 
prim ary b reast cancer. J  Clin Oncol 2006, 24(11):1665-1671.
35. Greene F, Page D, Fleming I, Fritz A, Balch C, Haller D, Morrow M, eds.: American Joint Committee on Cancer: 
AJCC Cancer Staging Manual, 6th edn: Springer; 2002.
36. Span PN, Sweep FC, Wiegerinck ET, Tjan-Heijnen VC, Manders P, Beex LV, de Kok JB: Survivin is an independent 
prognostic m arker for risk  stratification of b reast cancer patients. Clin Chem 2004, 50(11):1986-1993.
37. Massey FJ, Jr.: The Kolmogorov-Smirnov tes t for goodness of fit. Journal o f  the Am erican Sta tistica l 
A ssociation  1951, 46:68-78.
38. Mangelsdorf DJ, Ong ES, Dyck JA, Evans RM: Nuclear receptor th a t identifies a novel retinoic acid response 
pathway. N ature  1990, 345(6272):224-229.
39. Bloom HJ, Richardson WW: Histological grading and prognosis in b reast cancer; a study of 1409 cases of 
which 359 have been followed for 15 years. Br J  Cancer 1957, 11(3):359-377.
40. Zhou Q, Stetler-Stevenson M, Steeg PS: Inhibition of cyclin D expression in hum an b reast carcinom a cells 
by retinoids in vitro. Oncogene 1997, 15(1):107-115.
41. Liu R, Takayama S, Zheng Y, Froesch B, Chen GQ, Zhang X, Reed JC, Zhang XK: Interaction of BAG-1 with 
retinoic acid receptor and its inhibition of retinoic acid-induced apoptosis in cancer cells. J  Biol Chem 
1998, 273(27):16985-16992.
42. Bonofiglio D, Cione E, Qi H, Pingitore A, Perri M, Catalano S, Vizza D, Panno ML, Genchi G, Fuqua SA e t  al: 
Combined low doses of PPARgamma and RXR ligands trigger an intrinsic apoptotic pathway in human 
b reast cancer cells. A m  J  Pathol 2009, 175(3):1270-1280.
DC-SCRIPT: Nuclear Receptor Modulation and Breast Cancer | 71
43. Hua S, Kittler R, White KP: Genomic antagonism betw een retinoic acid and estrogen signaling in breast 
cancer. Cell 2009, 137(7):1259-1271.
44. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton 
MJ e t  al: A gene-expression signature as a predictor of survival in b reast cancer. N  Engl J  M ed 2002, 
347(25):1999-2009.
45. Jansen MP, Foekens JA, van Staveren IL, Dirkzwager-Kiel MM, Ritstier K, Look MP, Meijer-van Gelder ME, 
Sieuwerts AM, Portengen H, Dorssers LC e t al: Molecular classification of tam oxifen-resistant breast 
carcinomas by gene expression profiling. J  Clin Oncol 2005, 23(4):732-740.
46. Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, Sherlock G, Lewicki J, Shedden K, Clarke MF: The 
prognostic role of a gene signature from tum origenic breast-cancer cells. N  Engl J  M ed 2007, 356(3):217- 
226.
47. Smid M, Wang Y, Klijn JG, Sieuwerts AM, Zhang Y, Atkins D, Martens JW, Foekens JA: Genes associated with 
b reast cancer m etastatic to bone. J  Clin Oncol 2006, 24(15):2261-2267.
48. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, Dai H, He YD, van't Veer LJ, Bartelink H e t al: 
Robustness, scalability, and integration of a wound-response gene expression signature in predicting 
b reast cancer survival. Proc N a tl A cad Sci U S  A 2005, 102(10):3738-3743.
49. Pharoah PD, Antoniou AC, Easton DF, Ponder BA: Polygenes, risk  prediction, and targeted prevention of 
b reast cancer. N  Engl J  M ed  2008, 358(26):2796-2803.
50. Massague J: Sorting out breast-cancer gene signatures. N  Engl J  M ed 2007, 356(3):294-297.
51. Hayes DF, Bast RC, Desch CE, Fritsche H, Jr., Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton 
L e t al: Tumor m arker utility grading system: a fram ew ork to evaluate clinical utility of tum or markers. 
J  N a tl Cancer In st 1996, 88(20):1456-1466.
52. Hayes DF: M arkers of increased risk  for failure of adjuvant therapies. B reast 2003, 12(6):543-549.
53. Tari AM, Lim SJ, Hung MC, Esteva FJ, Lopez-Berestein G: H er2/neu induces all-trans retinoic acid (ATRA) 
resistance in b reast cancer cells. Oncogene 2002, 21(34):5224-5232.
54. Papadaki I, Mylona E, Giannopoulou I, Markaki S, Keramopoulos A, Nakopoulou L: PPARgamma expression in 
b reast cancer: clinical value and correlation with ERbeta. H istopathology 2005, 46(1):37-42.
55. Freemantle SJ, Spinella MJ, Dmitrovsky E: Retinoids in cancer therapy and chemoprevention: promise 
m eets resistance. Oncogene 2003, 22(47):7305-7315.
C
ha
pt
er

Chapter 4
Clinical Significance of the Nuclear 
Receptor Co-Regulator DC-SCRIPT in 
Breast Cancer: an Independent 
Retrospective Validation Study
Anieta M. Sieuwerts* 
Marleen Ansems* 
Maxime P. Look 
Paul N. Span 
Vanja de Weerd 
Anne van Galen 
John A. Foekens 
Gosse J. Adema 
John W. Martens
*Authors contributed equally
Breast Cancer Research (2010) 12(6):R103
74 | Chapter 4
In this study w e aim ed to validate the prognostic value o f DC-SCRIPT mRNA expression  in a large in dependent breast cancer cohort. In addition, since DC-SCRIPT is a transcriptional co-regulator o f nuclear receptors, w e explored  
its prognostic value in relation to estrogen-receptor-a (ESR1) and -0 (ESR2) and 
evaluated its predictive value for resp onse to tam oxifen treatm ent. DC-SCRIPT mRNA 
levels w ere m easured by real-tim e PCR in 1 ,505 prim ary invasive breast cancers 
and associated  w ith  outcom e (disease-free survival (DFS), m etastasis-free survival 
(MFS) and overall survival (OS)) using univariate and m ultivariable Cox regression  
analysis. Logistic and Cox regression  w ere used  to associate DC-SCRIPT levels with  
clinical benefit and progression-free survival (PFS) for 296  patients treated with  
first-line system ic tam oxifen for advanced disease. In univariate and m ultivariable 
analysis higher DC-SCRIPT levels w ere associated  w ith  a favorable outcom e for both  
the entire cohort and patients w ith lym ph node-negative (LNN) d isease that did 
n ot receive adjuvant therapy (DFS, MFS and OS; all, P<0.001). This association  was 
m ost pronounced in sm all (pT1) tum ors, in ESR1 -positive tum ors and in tum ors 
w ith low  ESR2 expression. For first-line endocrine therapy for advanced d isease no 
predictive association  w as seen  w ith clinical benefit or PFS. This study provides a 
higher level o f  evidence that DC-SCRIPT is in deed  an independent, pure prognostic, 
factor for prim ary breast cancer and sh ow s that DC-SCRIPT mRNA expression is 
m ost inform ative for either ESR1 -positive an d /or ESR2-low pT1 tumors.
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Introduction
Estrogens influence the aggressiveness o f breast cancer through their cognate 
nuclear receptors. In particular the estrogen  receptor alpha (ERa, ESR1) -present 
in tum or cells o f about 70-75%  o f all breast tum ors- is considered  crucial due to its 
proliferation-inducing actions and for that reason  is an im portant target for therapy. 
Next to ESR1 a second  ER exists, ERE (ESR2). ESR2 counteracts the activity o f  ESR1 
in m any system s [1, 2] and is also expressed  in the m ajority o f breast cancers. Apart 
from breast epithelial tum or cells, ESR2 is also expressed  in adjacent infiltrating 
lym phocytes, fibroblasts and endothelial cells, all o f w hich are know n to influence 
tum or growth [3]. However, its precise role in breast cancer progression is less well 
defined.
DC-SCRIPT (ZN F366) is a recently identified  nuclear receptor co-regulator first 
identified  in im m une cells [4-6]. Nuclear receptor coregulators are proteins that can 
activate or repress the transcriptional activity o f nuclear receptors. DC-SCRIPT is in 
this resp ect a unique co-regulator as w e have show n that it enhances the activities 
o f the nuclear retinoic acid receptor (RAR) and peroxisom e proliferator-activated  
receptor (PPAR) heterodim ers, RARa/RXRa and PPARy/RXRa, but represses the 
activities o f ESR1 and progesterone receptor (PGR) [7]. We also sh ow ed  that DC- 
SCRIPT w as an in dependent prognostic factor, particularly for horm one receptor- 
positive breast cancer. This led  us to postulate that the anti-proliferative effect o f 
DC-SCRIPT in breast cancer cells could be m ediated  by sim ultaneous m odulation of 
the activity o f m ultiple nuclear receptors.
To provide a higher level o f evidence for DC-SCRIPT mRNA expression as a 
prognostic marker, w e n ow  report on the expression  and significance o f DC-SCRIPT 
expression  in a retrospective validation study on 1 ,505 breast cancer patients with  
know n ESR1, ESR2 and PGR expression  levels. The prim ary objective o f this study  
w as to confirm  the relationship b etw een  DC-SCRIPT mRNA levels m easured in 
prim ary breast cancers and tum or aggressiveness in a m uch larger and independent  
breast cancer cohort. The m ain clinical endpoints for assessin g  the prognostic value 
o f DC-SCRIPT expression  w ere DFS, MFS and OS in lymph node-negative (LNN) 
patients w ho had n ot received adjuvant system ic therapy, w hich allow ed us to 
determ ine tum or aggressiveness during the natural course o f the disease. As DC- 
SCRIPT m odulates ER receptor activity, w e also analyzed the prognostic value o f DC- 
SCRIPT  separately in tum ors stratified by ESR1 and ESR2 expression. Since several 
co-regulators o f nuclear receptors also m odulate response to therapy [8, 9], w e also 
assessed , as secondary aim o f this study, the predictive value o f DC-SCRIPT using
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clinical benefit and PFS after first-line tam oxifen for advanced d isease as the main 
endpoints.
Materials and Methods
Patients
The protocol to study biological markers associated with disease outcome was approved by 
the medical ethics committee of the Erasmus Medical Center Rotterdam, the Netherlands (MEC 
02.953). This retrospective study used 1,505 M0 and an additional 32 M1 blind-coded freshly 
frozen primary tumor tissues of female patients with primary operable breast cancer from 
1978 through 2000. The study was performed in accordance with the Code of Conduct of the 
Federation of Medical Scientific Societies in the Netherlands [10], consent was not required, 
and, wherever possible, has been reported in line with the Reporting Recommendations for 
Tumor Marker Prognostic Studies guidelines [11]. The primary breast tumors were from pa­
tients with detailed clinical follow-up as previously described [12-14]. ER protein status was 
determined by routine ligand-binding assays or enzyme immunoassays [15] and ESR1, ESR2 
and PGR mRNA status by real-time reverse transcriptase PCR [14],[16, 17]. Follow-up, tumor 
staging, and response to therapy was defined by standard International Union Against Cancer 
(Geneva, Switzerland) classification criteria [18] and applied previously by Foekens et al [19]. 
All 1,537 patients underwent breast conserving lumpectomy (44%) or modified mastectomy 
(56%). Of the 1,505 patients included for the evaluation of tumor aggressiveness, 462 lymph 
node-positive patients (31%) were treated with adjuvant systemic therapy, 207 patients re­
ceived hormonal, 233 chemo- and 22 combination therapies. Disease recurrence occurred in 
836 patients and 703 developed a distant metastasis. The median follow-up time of patients 
alive was 90 months (range 4 to 260 months).
Eight hundred thirty seven patients had no involved nodes and did not receive systemic adju­
vant therapy. Of these 837 LNN patients, 383 had a disease relapse, 300 developed a distant 
metastasis and 273 had died during follow-up. Of the 703 patients who developed a distant 
metastasis, 296 ER-positive patients, including the additional 32 M1 patients, received hor­
monal therapy as first line therapy for advanced disease. Clinical benefit of first-line tamoxi­
fen treatment was observed in 185 patients. Median follow-up time for treatment of advanced 
disease was 38 (4 to 120) months. Two-hundred nineteen patients had died at the end of the 
follow-up. None of these patients had received prior adjuvant hormonal therapy while 19% 
received prior adjuvant chemotherapy. Patient and tumor characteristics combined with DC- 
SCRIPT mRNA expression and clinical outcome are listed in Table 1.
Patient samples.
Frozen tumor samples were originally submitted to our reference laboratory from regional 
hospitals for measurements of steroid hormone receptors and have been stored in our liquid 
nitrogen tumor bank at the Erasmus Medical Center (Rotterdam, The Netherlands). Guide­
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lines for primary treatment were similar for all hospitals. All available frozen tumor speci­
mens from female patients with breast cancer who entered the clinic during 1978-2000 and 
from whom detailed clinical follow-up was available [19, 20], were processed for mRNA anal­
ysis. Further inclusion criteria were: >100 mg frozen tissue available, invasive breast cancer, 
no previous other cancer (except basal cell skin cancer or early-stage cervical cancer stage Ia/ 
Ib), no second contralateral primary breast tumor as first relapse for first-line studies, at least 
30% invasive tumor cell nuclei, and good RNA quality with both the 18S and 28S bands visible 
on gel. Thirty percent of the samples were rejected because of a too low percentage tumor 
cells and/or poor RNA quality and/or because the RNA yield was less than 2 ug.
The primary breast tumors used for this study were from patient with detailed clinical follow- 
up information as described previously [12-14, 21]. Fifteen hundred and five patients were 
included in the prognosis analyses. Of these 1,505 M0 patients 264 were included for the anal­
ysis of recurrent disease combined with an additional 32 M1 patients. All 1,537 patients were 
treated with breast conserving lumpectomy (44%) or modified mastectomy (56%). Axillary 
dissection was performed in most cases (99%). Adjuvant radiotherapy was given to 98% and 
46% of the patients undergoing lumpectomy or modified mastectomy, respectively, and 379 
(25%) of all patients received adjuvant radiation at the nodes. ER status was determined by 
routine ligand-binding assays or enzyme immunoassays. Pathological review was performed 
in the various participating regional hospitals as described previously [15].
For the analysis of MFS, 1,505 patients, of whom 837 LNN, were included. None of the 837 
LNN patients received systemic adjuvant therapy. Patients were evaluated every three months 
for the first 2 years, every 6 months for the next 3 years and once a year thereafter. Median 
follow-up time of patients alive was 90.3 months. Of the 837 LNN patients 383 had a disease 
relapse, 300 developed a distant metastasis and 273 had died during follow-up.
For the evaluation of PFS and clinical benefit after start of first-line tamoxifen for metastatic 
disease, 296 patients with ER protein-positive primary breast tumors (264/1,505 of whom 
127/837 patients LNN were also included in the analysis of MFS and experienced a relapse) 
who received tamoxifen monotherapy as first-line treatment for recurrent disease were in­
cluded [16]. Basic characteristics of these patients at diagnosis were: median age at diag­
nosis 58 years (range 26 to 89) and 61 (29 to 90) at start of therapy of whom 35% were 
pre-menopausal at diagnosis and 26% at start of therapy; 44% node negative; grade poor 
(54%), good/moderate (13%), or unknown (33%). None of these patients had received prior 
adjuvant hormonal therapy and 19% had received prior adjuvant chemotherapy (21 patients 
anthracycline-based ((F)AC/FEC) and 34 patients non-anthracycline-based (CMF)).
Patients were routinely followed at the outpatient clinic, generally once every 3 weeks during 
the first 6 months, and in case of objective response approximately every 6 weeks [22, 23]. All 
participating hospitals used the same guidelines for disease detection and progression, how­
ever, subtle differences may have existed due to the interpretation by individual physicians. 
Skin metastases were assessed clinically by palpation, measured and documented by photog­
raphy; lymph node metastases were assessed by palpation or when necessary by ultrasound; 
lung metastases were routinely followed by X-thorax (once every 6-12 weeks), and by CT-tho-
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rax where applicable; liver metastases were always followed by ultrasound or CT of the liver, 
in general once every 12 weeks; brain metastases were assessed by CT or magnetic resonance 
imaging if indicated; bone metastases were followed by X-rays (every 6-12 weeks) and bone 
scan (every 6-12 months) as a standard, and by magnetic resonance imaging if indicated. 
Furthermore, plasma tumor marker levels (CA15.3 and/or CA125) were measured regularly. 
The type of response to therapy was recorded as defined by standard International Union 
Against Cancer criteria [18]. For the patients treated with first line tamoxifen, no clinical 
benefit occurred in 111 patients (94 progressive disease (i.e., 25% or more increase) and 17 
stable disease shorter or equal than 6 months). Clinical benefit of first-line tamoxifen treat­
ment was observed in 185 patients, of whom 12 showed a complete remission (i.e., complete 
disappearance of all metastases), 39 a partial remission (i.e., at least 50% reduction) and the 
remaining 134 patients experienced stable disease for longer than 6 months. Median follow- 
up time for treatment of recurrent disease was 38 (4 to 120) months. Two-hundred nineteen 
patients had died at the end of the follow-up.
Tissue Processing
Primary tumor tissue was processed as described previously [16]. In summary, 20 to 60 cryo­
stat sections of 30 |im, corresponding to 30 to 100 mg, were cut from snap-frozen tissues for 
RNA isolation. To assess the amount of invasive tumor cell nuclei relative to the amount of 
surrounding stromal cells, 5 |im sections were cut for hematoxylin and eosin staining, before, 
in between, and after cutting the sections for RNA isolation. For this study, only specimen with 
at least 30% invasive tumor cell nuclei, distributed uniformly over at least 70% of the section 
area, were included.
RNA isolation and Quantitative RT-PCR
Tissue processing, RNA isolation, cDNA synthesis and quantitative reverse transcriptase 
polymerase chain reaction (RT-PCR) were performed as previously described [16]. Real-time 
quantitative PCR reactions were performed in a 25 |iL reaction volume in a Mx3000PTM Real­
Time PCR System (Agilent, Amsterdam, The Netherlands). In addition to a SYBR-based assay 
to detect a 129 bp DC-SCRIPT transcript covering exon 4 to 5 (forward primer: 5'-AAAGT- 
CAAGCATGGAGTCATG-3'; reverse primer: 5'-GCTTCTGAGAGAGGTCAAAG-3'), a commercially 
available Taqman Gene Expression Assay from Applied Biosystems (Nieuwerkerk aan den 
IJssel, the Netherlands) covering exon 3 to 4 and generating a 62 bp product and was used 
(Hs00403536_m1, RefSeq NM_152625.1). DC-SCRIPT levels were readily detected with both 
assays and data generated with these assays correlated significantly (Spearman's Rho=0.87; 
P<0.0001). We therefore performed our analyses on the real-time RT-PCR data generated 
with the Taqman assay which is generally considered to be more specific. Intron-spanning 
primer sequences for the three reference genes, i.e., hydroxymethylbilane synthase (HMBS), 
hypoxanthine-guanine phospho-ribosyltransferase (HPRT1) and fé-2-microglobulin (B2M) 
and for ESR1, ESR2, PGR and real time PCR conditions for these SYBR-based assays were as 
described previously [16, 17]. Forty rounds of amplification were performed and fluorescent
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signals of the Taqman probe or SYBR green signal were used to generate Cycle threshold (Ct) 
values from which mRNA expression levels were calculated. Ct-values of HPRT1 and B2M 
were adjusted to the higher HMBS Ct-values. Next, the expression levels of DC-SCRIPT were 
normalized against the average expression levels of the thus same ranged three reference 
genes as follows: mRNA target = 2 (mean Ct reference genes - mean Ct Target) [16].
Tissue Processing
Primary tumor tissue was processed as described previously [16]. To assess the amount of 
invasive tumor cell nuclei relative to the amount of surrounding stromal cells, 5 |im sections 
were cut for hematoxylin and eosin staining, before, in between, and after cutting the sections 
for RNA isolation. Only specimen with at least 30% invasive tumor cell nuclei were included 
in this study.
Data analysis and statistics
The relationship between DC-SCRIPT with patient and tumor characteristics were investigat­
ed with the use of nonparametric methods (Spearman rank correlations for continuous vari­
ables and Wilcoxon rank-sum for dichotomized or Kruskal-Wallis test for ordered variables). 
To reduce skewness DC-SCRIPT levels were transformed using the Box-Cox transformation. 
DC-SCRIPT levels were dichotomized using the previously identified 66.7% high versus 33.3% 
low cut off for DC-SCRIPT [7]. To test for an association with tumor aggressiveness and the 
time to progression during first-line therapy, Cox regression analysis was applied on the Box- 
Cox-transformed and dichotomized DC-SCRIPT mRNA levels.The hazard ratio (HR) and its 
95% confidence interval (95% CI) was computed to correlate the expression levels with DFS, 
MFS, OS and PFS, respectively. In multivariable analysis, Cox proportional-hazards models for 
DFS, MFS, OS and PFS were applied to test DC-SCRIPT levels added to models with traditional 
factors. The proportional hazards assumptions were checked using Schoenfeld residuals. The 
analyses were stratified if necessary. The models for DFS, MFS and OS for LNN patients who 
had not received adjuvant systemic therapy included age, menopausal status, tumor size, 
grade, ESR1 and PGR mRNA levels. Survival curves were generated using the method of Ka­
plan and Meier. The log-rank test was used to test for differences between survival curves. 
Logistic regression was used for the association of DC-SCRIPT with clinical benefit. Computa­
tions were performed with the STATA statistical package, release 11.0 (STATA Corp., College 
Station, TX) and SPSS 15.0. All P-values are two-sided and P<0.05 was considered statistically 
significant.
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Table 1. A ssociations o f DC-SCRIPT w ith  clin icopathological a n d  b iological factors
No of DC-SCRIPT**
C haracteristic p a tien ts %* [reference  norm alized] (x102)
All p a tie n ts 1.505 100% 0,69 0,73
Age (years)
<40 192 13% 0,69 0,72
41-55 561 37% 0,70 0,74
56-70 498 33% 0,70 0,77
>70 254 17% 0,64 
P = 0.15*
0,64
M enopausal s ta tu s
premenopausal 637 42% 0,72 0,74
postmenopausal 868 58% 0,66 
P = 0.06§
0,70
Grade
poor 818 54% 0,64 0,74
unknown 452 30% 0,71 0,68
m oderate and good 235 16% 0,80 
P = 0.001»
0,70
T um or size
pT1, <2 cm 517 34% 0,81 0,84
>2 cm 988 66% 0,63 
P <0.001§
0,64
Lymph no d es involved*
no 837 56% 0,69 0,73
yes 668 44% 0,68 
P =0.64§
0,75
ESR1 mRNA status*
positive, >0.2 1176 78% 0,71 0,73
negative, <0.2 329 22% 0,61 
P = 0.004*
0,66
PgR mRNA status*
positive, > 0.1 949 63% 0,72 0,74
negative, <0.1 556 37% 0,61 
P < 0.001*
0,66
ESR2 mRNA status*
dichotomized high, > 0.005 741 49% 0,89 0,95
dichotomized low, <0.005 742 49% 0,54 
P < 0.001*
0,49
Invasive tu m o r cell co n ten tx
> 70% 719 48% 0,57 0,51
< 70% 786 52% 0,85 
P <0.001§
0,91
Histological type
DCIS + IDC 194 13% 0,82 0,89
ILC: infiltrating lobular carcinoma 135 9% 0,81 0,94
IDC: infiltrating ductal carcinoma 810 54% 0,66 0,69
mucinous 40 3% 0,56 0,65
medullary 31 2% 0,69 
P = 0.012»
1,18
In trin sic  b re a s t  can cer subtype* 308
normal-like 22 7% 1,43 1,19
ERBB2+ 63 20% 0,75 0,68
luminal A 76 25% 0,78 0,89
luminal B 65 21% 0,56 0,36
basal 82 27% 0,48 0,48
P <0.001»
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* Due to missing cases num bers to not always add up to 100%.
** Median level and p50 inter-quartile after normalization on the reference gene set.
t  With qPCR cut point for positive versus negative ESR1 and PGR, 0.2 and 0.1, respectively,
and for ESR2 at the median level of 0.005 (mRNA levels relative to reference gene set). 
x Dichotomized a t the m edian level of 70% invasive tum or cells (TC).
t  Intrinsic breast cancer subtypes assigned from Affymetrix microarray by hierarchical
clustering in 308 patients with LNN disease that did not recieve systemic adjuvant treatm ent. 
t  P for Spearman rank correlation test.
§ P for Mann-Whitney U test.
Ill P for Kruskal-Wallis test, including a Wilcoxon-type test for trend when appropriate.
Results
Associations of DC-SCRIPT with clinicopathological factors and histological 
and intrinsic breast cancer subtypes
In analogy w ith  our previous study, DC-SCRIPT mRNA expression  w as readily  
d etected  by quantitative RT-PCR in 5 norm al breast tissu es taken adjacent from 
tum or tissu e and 5 prophylactic breast tissu es (m edian [inter-quartile]: 0.063  
[0.015] and 0 .054  [0.035], respectively), w hile m edian levels w ere over 8-fold  
low er (P<0.05) in 1 ,505 invasive breast tum ors (0 .0069  [0.0074]). Table 1 show s  
the m edian expression levels and inter-quartile range o f DC-SCRIPT transcripts and 
relation w ith  patient and tum or characteristics for these 1 ,505 patients w ho were 
evaluable for prognosis. DC-SCRIPT levels w ere positively associated  w ith  tumor 
grade and ESR1, PGR and ESR2 steroid  horm one receptor expression  level and 
negatively w ith  invasive epithelial tum or cell content and tum or size. In addition  
ESR2 was higher expressed  in tum ors w ith  a higher percentage o f strom al cells (786  
tum ors w ith  30 to 70% invasive epithelial cells) and ESR1 w as higher expressed  in 
tum ors w ith a high percentage o f invasive epithelial cells (719 tum ors w ith  at least  
70% invasive epithelial cells), P<0.001 (data n ot show n). High levels o f DC-SCRIPT 
w ere found in breast tum ors w ith a DCIS com ponent or infiltrating lobular carcinoma  
com pared w ith  infiltrating ductal carcinom as (both P<0.01). Of 308  LNN tum ors 
intrinsic subtyping data w ere available [24]. In these tum ors, basal-like tum ors had  
the low est levels and norm al-like breast tum ors expressed  significantly higher levels 
o f DC-SCRIPT com pared w ith  the other intrinsic subtypes (P<0.001, Supplem entary  
Figure 1). Furthermore, lum inal A tum ors expressed  higher levels o f DC-SCRIPT and 
ESR2 but low er levels o f ESR1 com pared w ith  lum inal B tum ors (m edian levels in 
lum inal A versus lum inal B: 0 .0078  and 0 .056 for DC-SCRIPT, P=0.003, 0 .0095  and 
0.0023  for ESR2, P<0.001 and 6.1 and 13.6 for ESR1, P<0.001). This m ay at least  
partly be explained by the fact that in this cohort o f 308  LNN tum ors the lum inal B 
tum ors contained a higher percentage o f invasive epithelial cells [mean ± SD: 77±  
9% for the n=64 lum inal B tum ors versus 67±12%  for the n=71 lum inal A tum ors].
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Supplementary Figure 1. DC-SCRIPT 
mRNA expression in breast cancer sub­
types
The box-plot shows the five statistics (lower 
whisker is 5% minimum, lower box part is 
25th percentile, solid line in box presents the 
median, upper box part is 75th percentile 
and upper whisker is 95% maximum]. 
Figure depicts P for Mann-Whitney U test to 
identify significantly different expression of 
DC-SCRIPT in between subtypes.
DC-SCRIPT and tumor aggressiveness in univariate and multivariable 
analysis
In the analyses including all 1,505 M0 patients, increasing levels o f DC-SCRIPT 
mRNA w ere significantly associated  w ith  a favorable DFS, MFS and OS (HR 0.78, 0.74  
and 0.77, respectively, all P<0.001). To test for a relation b etw een  DC-SCRIPT mRNA 
levels and tum or aggressiveness, i.e. the natural course o f the d isease w ithout the 
confounding effect o f system ic adjuvant therapy, w e restricted our next analyses for 
MFS to those 837  patients w ith LNN d isease w ho had not received (neo)adjuvant 
system ic therapy. The significant relationships o f DC-SCRIPT as a continuous variable 
in these univariate analyses justified the use o f the previously identified cut-point of 
33.3% o f the patients w ith  low  levels and 66.7%  patients w ith  high levels o f DC- 
SCRIPT mRNA in their prim ary tum ors [7]. In univariate analysis, high levels o f DC- 
SCRIPT w ere significantly associated w ith a favorable prognosis HR 0.55, P<0.001, 
Table 2). W hen added to a multivariable base m odel for LNN d isease - which included  
the traditional prognostic factors age, m enopausal status, grade, PGR - stratified by 
ESR1 and tum or size to m eet the proportional hazards assum ption, the association  
of DC-SCRIPT w ith MFS rem ained highly significant (HR 0.60, P<0.001,Table 2). 
Adding ESR2 to the m odel did not significantly affect the prognostic value o f DC- 
SCRIPT in these analyses (Table 2).
Because the proportional hazards assum ptions w ere violated by ESR1 and tum or 
size and because DC-SCRIPT is a transcriptional co-regulator o f nuclear receptors
* Multivariable analyses were conducted in two blocks. First, a model including all established 
clinicopathological factors was fitted.
The Cox proportional hazards assumptions were checked and the analyses were stratified by 
tumor-size and ESR1 to m eet the PH assumption.
In a second block, the contributions of DC-SCRIPT and ESR2 (as continuous or dichotomized 
variables) were investigated.
I n t r in s ic  b r e a s t  c a n c e r  su b ty p e s
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Table 2. U nivariate  a n d  m u ltivariab le  analysis fo r MFS as a  func tion  of DC-SCRIPT in  LNN d isease
Factor No.
U nivariate  analysis M ultivariable analysis*
HR [95%  CI] P HR [95%  CI] P
837
Age (years)
<40 114 1 1
41-55 295 0,88 0,63 1,22 0,95 0,67 1,35
56-70 270 0,72 0,51 1,02 0,69 0,40 1,20
>70 158 0,53 0,35 0,81 <0.01 0,49 0,27 0,90 0,077
M enopausal s ta tu s
premenopausal 350 1 1
postmenopausal 487 0,78 0,62 0,97 0,028 1,08 0,70 1,66 0,731
Grade
poor 422 1 1
unknown 262 1,02 0,79 1,30 1,12 0,87 1,44
m oderate and good 153 0,49 0,34 0,71 <0.001 0,54 0,37 0,78 <0.001
PGR mRNA status*
negative, <0.1 312 1 1
positive, > 0.1 525 0,68 0,54 0,85 0,001 0,71 0,53 0,95 0,022
T um or size
<2 cm 378 1
>2 cm + unknown 459 1,26 1,00 1,59 0,047 Analyses stratified by tumor
size and ESR1 to m eet the
ESR1 mRNA s ta tu s ’ proportional hazards
negative, <0.2 199 1 assumption
positive, >0.2 638 0,77 0,59 0,99 0,040
Factor analyzed A dditions to th e  b ase  m odel
DC-SCRIPT
continuous 837 0,77 0,67 0,88 <0.001 0,80 0,70 0,92 0,001
33.3% low 277 1 1
66.7% high 560 0,55 0,43 0,69 <0.001 0,60 0,47 0,76 <0.001
ESR2 mRNA status*
continuous 820 0,88 0,79 0,99 0,034 0,86 0,76 0,96 0,011
dichotomized low, <0.005 410 1 1,00
dichotomized high, >0.005 410 0,80 0,63 1,00 0,052 0,75 0,59 0,94 0,014
DC-SCRIPT a n d  ESR2
com bined
both low 183 1 1
DC-SCRIPT low ESR2 high 91 0,74 0,51 1,08 0,71 0,49 1,04
DC-SCRIPT high ESR2 low 227 0,49 0,36 0,67 0,55 0,40 0,76
both high 319 0,50 0,38 0,67 <0.001 0,52 0,39 0,69 <0.001
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Table 3. DFS, MFS and OS as a function of continuous DC-SCRIPT in lymph node negative disease
Association with continuous 
DC-SCRIPT
Disease-free survival Metastasis-free survival Overall survival
Cohort No. HR [95% Cl] P HR [95% Cl] P HR [95% Cl] P
LNN 837 0,82 0,73 0,93 0,001 0,77 0,67 0,88 <0.001 0,82 0,72 0,94 0,005
ESR1 mRNA negative 199 0,94 0,76 1,17 0,59 0,93 0,73 1,18 0,53 0,88 0,70 1,11 0,30
ESR1 mRNA positive 638 0,79 0,68 0,90 0,001 0,72 0,62 0,85 <0.001 0,81 0,69 0,96 0,014
PGR mRNA negative 312 0,88 0,74 1,06 0,19 0,84 0,69 1,03 0,10 0,88 0,72 1,08 0,22
PGR mRNA positive 525 0,81 0,69 0,94 0,007 0,75 0,63 0,89 0,001 0,82 0,68 0,99 0,04
ESR2 mRNA low 410 0,76 0,64 0,91 0,003 0,69 0,56 0,84 <0.001 0,73 0,64 0,97 0,026
ESR2 mRNA high 410 0,93 0,78 1,11 0,43 0,89 0,73 1,09 0,26 0,92 0,75 1,13 0,41
tum or size <2 cm (pTl)* 378 0,74 0,61 0,89 0,001 0,67 0,54 0,83 0,000 0,73 0,59 0,91 0,005
tum or size >2 cm* 459 0,92 0,79 1,08 0,31 0,86 0,72 1,03 0,10 0,91 0,76 1,09 0,31
ESR1 mRNA positive, 
tum or size <2 cm 306 0,69 0,56 0,85 0,001 0,61 0,48 0,78 <0.001 0,72 0,56 0,93 0,010
ESR1 mRNA positive 
tum or size >2 cm 332 0,91 0,75 1,10 0,34 0,84 0,68 1,05 0,13 0,90 0,72 1,14 0,39
ESR2 mRNA low, 
tum or size <2 cm 175 0,57 0,43 0,76 <0.001 0,51 0,37 0,70 <0.001 0,60 0,44 0,83 0,002
ESR2 mRNA high, 
tum or size >2 cm 218 0,98 0,78 1,23 0,84 0,91 0,71 1,18 0,49 0,93 0,74 1,21 0,58
ESR1 positive and
ESR2 low, tum or size <2 cm 147 0,63 0,45 0,87 0,005 0,54 0,38 0,78 <0.001 0,63 0,43 0,92 0,017
ESR1 positive and
ESR2 low, tum or size >2 cm 181 0,94 0,71 1,24 0,66 0,94 0,68 1,29 0,69 1,03 0,73 1,45 0,89
ESR1 positive an d /o r 
ESR2 low, tum or size <2 cm 334 0,65 0,53 0,79 <0.001 0,57 0,46 0,71 <0.001 0,67 0,53 0,84 0,001
ESR1 positive an d /o r 
ESR2 low, tum or size >2 cm 386 0,90 0,76 1,08 0,25 0,81 0,66 0,99 0,037 0,87 0,71 1,07 0,20
t  With qPCR cut point for positive versus negative ESR1 and PGR, 0.2 and 0.1, respectively, and for ESR2 at the median level of
0.005 (mRNA levels relative to reference gene set).
* Interaction with continuous DC-SCRIPT (P<0.05).
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- including the for breast cancer biologically relevant steroid  horm one receptors
- w e next explored its prognostic value as continuous variable in subgroups of 
tum ors stratified by steroid  horm one receptor status and tum or size (Table 3 
and Figure 1). Subdividing the 837  prim ary LNN tum ors in ESR1-positive and 
negative [14] sh ow ed  that increasing levels o f  DC-SCRIPT w ere in univariate and
A: ESR1 negative primary breast tum ors
Patients at risk 
low DC-SCRIPT  88 
high DC-SCRIPT  111
B: ESR1 positive prim ary breast tum ors
Patients at risk 
low DC-SCRIPT  189 
high DC-SCRIPT  449
C: ESR1 positive  pT1 primary breast tum ors
D: ESR2 low  primary breast tum ors
Metastasis-free survival (months)
F: ESR2 low  pT1 primary breast tum ors
Patients at risk
low  DC-SCRIPT  82 69 47 35 22 68 54 37 25 15
high DC-SCRIPT  224 202 174 136 86 107 96 82 63 41
Figure 1. M etastasis-free  surv ival as a  function  o f d icho tom ized  DC-SCRIPT
MFS as a function of dichotomized DC-SCRIPT in 837 LNN primary breast cancer patients after subdividing 
patients according high and low ESR1 and ESR2 in the primary tum or and tum or size. qPCR cut points for 
high versus low DC-SCRIPT, 66.7% versus 33.3%[7]; for positive versus negative ESR1, 0.2[14]; and for 
ESR2 low versus high, at the median level of 0.005 (mRNA levels relative to reference gene set). Patients 
a t risk are indicated.
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m ultivariable analysis only associated  w ith  good  prognosis for the patients with  
ESR l-positive tum ors. Subdividing these LNN tum ors at the m edian level o f ESR2 
in high and low  revealed that, in contrast to ESR1, increasing levels o f DC-SCRIPT 
w ere in both uni- and m ultivariable analysis only associated  w ith  good  prognosis 
for patients w ith prim ary tum ors w ith  low  levels o f ESR2. W ith respect to tumor 
size, in uni- and m ultivariable analysis increasing levels o f DC-SCRIPT w ere only 
associated  w ith  good  prognosis for pT1 tum ors and n ot for larger tum ors. These 
and additional exploratory Cox univariate analyses are sum m arized in Table 3. The 
prognostic value o f DC-SCRIPT are v isualized  in Kaplan-Meier curves (Figure 1) 
as d ichotom ized variable in these b iologically relevant LNN ESR1 negative (Figure 
1A) and positive (Figure 1B) and LNN ESR2 high (Figure 1D) and lo w  (Figure 1E) 
subsets in com bination w ith  patients w ith  pT1 prim ary tum ors (Figure 1C and 1F).
DC-SCRIPT and response to first-line endocrine therapy
DC-SCRIPT expression levels w ere evaluated in 296  horm one-naïve ER-positive 
prim ary breast tum ors from patients w h ose relapse w as treated w ith  first-line 
tam oxifen monotherapy. These patients had n ot received (neo)adjuvant endocrine  
system ic treatm ent. In univariate analyses no statistically significant associations  
w ere observed b etw een  DC-SCRIPT as transform ed continuous variable and PFS 
or clinical benefit after start o f first line treatm ent w ith  tam oxifen (HR=1.08 [0.99­
1.18], P=0.07 and OR=0.88 [0.74-1.05], P=0.16, respectively).
Discussion
DC-SCRIPT has previously been  identified  as a key m odulator o f nuclear receptor 
activity that has prognostic value in breast cancer [7]. The clinical conclusions  
about DC-SCRIPT mRNA expression  as a prognostic marker in breast cancer were  
based  on nonrandom ized retrospective analyses in 3 sm all breast cancer cohorts 
from Nijmegen and still required in dependent validation. In this study, w e provide a 
higher level o f evidence as w e confirm  that mRNA expression  values o f DC-SCRIPT 
predict outcom e in an independent retrospective cohort o f 1 ,505 prim ary breast 
cancers from Rotterdam. In addition, w e confirm  that DC-SCRIPT mRNA expression  
is a pure prognostic marker as it predicts - independently o f  current clinical 
prognostic m arkers such as age, m enopausal status, grade, T-size and receptor status
- the occurrence o f d istant m etastasis in patients w ho did n ot receive any adjuvant 
system ic treatm ent. Because w e u sed  mRNA extracted from tum or tissu e using a 
different mRNA isolation  m ethod (RNA-B versus colum n-based), an independent
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real-tim e PCR assay to d etect DC-SCRIPT, a different type o f  m achine to am plify the 
transcript and other personnel from another institute, w e consider DC-SCRIPT a 
robust prognostic marker for early breast cancer patients. The patients described in 
this retrospective study entered  the clinic during 1 9 7 8 -2 0 0 0 , at w hich tim e disease  
w as d iagnosed  later and adjuvant therapy was n ot as w ide-spread as nowadays. 
But the latter w as at the sam e tim e the strength o f our cohort for the evaluation  
o f a prognostic marker. The data that em erged from this study thus validates the 
hypothesis that DC-SCRIPT is associated  w ith  good  prognosis in early disease, 
and supports the idea that DC-SCRIPT acts as a tum or suppressor in breast cancer 
progression [7].
Because o f the size o f this cohort and based  on the biological function o f DC- 
SCRIPT as a nuclear receptor co-regulator w e w ere able to include additional 
subgroup analyses to extend our insights into the clinical behavior and relevance 
o f m easuring DC-SCRIPT in prim ary breast cancers. High levels o f DC-SCRIPT mRNA 
in prim ary tum ors o f breast cancer patients w ere significantly related w ith  tumor 
characteristics that are associated  w ith  good  prognosis such as DCIS, infiltrating 
lobular carcinoma, breast tum ors o f the norm al-like and luminal A subtype, and 
sm all (pT1), w ell-differentiated, steroid  horm one receptor positive tum ors. While 
ESR1 is m ainly localized  in tum ors w ith  at least 70% invasive epithelial cells, 
(P<0.001), w e sh ow ed  for both ESR2 and DC-SCRIPT a positive correlation with  
tum ors w ith  <70%  invasive epithelial cells, (P<0.001). As norm al epithelial cells 
presen t in tum ors w ith  <70% invasive epithelial cells express the h ighest levels of 
DC-SCRIPT, they could be responsible for this correlation. Furthermore, infiltrating 
leukocytes in the strom a m ight have contributed in part to the detected  signal [4, 5]. 
Alternatively, or in addition, strom al cells m ay have played a role in the induction  
of DC-SCRIPT in the epithelial tum or cells. In analogy ESR2 is - apart from breast 
cancer epithelial tum or cells - also expressed  in adjacent infiltrating lym phocytes, 
fibroblasts and endothelial cells [3].
Interestingly, in tum ors that express relatively high ESR2 mRNA levels and which  
in general are tum ors w ith  a higher strom al content, DC-SCRIPT expression has 
little or no prognostic value. Thus, w hile in early ESR1 positive breast cancer DC- 
SCRIPT inhibits progression o f breast cancer, this effect appears to be neutralized  
in tum ors high in ESR2. Indeed, ESR2 has been  reported to be dom inant over ESR1 
and able to counteract the proliferation-inducing activities o f ESR1 [1, 2]. Unraveling 
the precise role o f DC-SCRIPT in the com plex genom ic and non-genom ic interplay  
b etw een  ESR1, ESR2 and their isoform s [25-27] m ight turn out to be rew arding for
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elucidating the “Yin-Yang” role o f these factors in breast cancer.
As DC-SCRIPT can inhibit ERa and PgR activity, a second  aim o f the study was 
to address w hether DC-SCRIPT affects the resp onse to endocrine therapy. In our 
previous study w e had already explored the value o f DC-SCRIPT mRNA expression  
to predict outcom e in a cohort o f breast cancer patients w ho received adjuvant 
tam oxifen [7]. However, in the adjuvant setting - that for ethical reasons nowadays 
only includes non-random ized patients am ong treated and untreated arms - one 
cannot discrim inate b etw een  tum or aggressiveness and resp onse to treatm ent 
[28]. The current retrospective study included horm one-naïve patients (i.e. not 
having received any (neo)adjuvant endocrine treatm ent) w ho received first-line 
tam oxifen treatm ent for their advanced d isease and w as therefore better suited to 
study a putative relation o f DC-SCRIPT and resp onse to therapy. Despite the positive  
association  o f DC-SCRIPT w ith  ESR1, DC-SCRIPT levels w ere unable to identify  
patients w ith  ESR1 positive prim ary tum ors at high or low  risk to progress if treated  
w ith tamoxifen. Thus, although DC-SCRIPT can m odulate the activity o f ESR1, it  does  
n ot affect the response to endocrine therapy w ith  tam oxifen in advanced breast 
cancer. The early loss o f DC-SCRIPT during cancer progression m ight explain this 
absence o f a resp onse in the m etastatic d isease setting.
Conclusions
This in dependent retrospective qRT-PCR study validates that high levels of 
DC-SCRIPT are associated  w ith  reduced tum or aggressiveness. The association  
is particularly strong for sm all tum ors w ith  high ESR1 an d /or low  ESR2 mRNA 
levels. Finally, desp ite the fact that DC-SCRIPT negatively regulates ESR1 and PGR 
activity, but in line w ith  DC-SCRIPT as an early marker for disease, DC-SCRIPT levels 
m easured in the prim ary tum ors are n ot associated  w ith  resp onse to first-line 
endocrine treatm ent for advanced disease.
Acknowledgements
We especially  thank the patients and surgeons, pathologists and internists for 
their assistance in collecting tum or tissu es and patient's clinical follow-up data. We 
also thank Joan Bolt, Marion Meijer, Mieke Timm ermans, Anita Trapman and Wendy 
van der Sm issen for their excellent technical support. This w ork was financially  
supported by VICI grant 9 1 8 -6 6 -6 1 5  (awarded to G.J.A.) from the Netherlands 
Organization for Scientific Research (NWO).
Clinical Significance of DC-SCRIPT in Breast Cancer | 89
References
1. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA: Estrogen receptor beta inhibits 17beta- 
estradiol-stim ulated proliferation of the b reast cancer cell line T47D. Proc N atl Acad Sci U S  A 2004, 
101(6):1566-1571.
2. Liu MM, Albanese C, Anderson CM, Hilty K, Webb P, Uht RM, Price RH, Jr., Pestell RG, Kushner PJ: Opposing action 
of estrogen receptors alpha and beta on cyclin D1 gene expression. J  Biol Chem  2002, 277(27):24353- 
24360.
3. Hartman J, Strom A, Gustafsson JA: Estrogen receptor be ta  in b reast cancer--diagnostic and therapeutic 
implications. Steroids 2009, 74(8):635-641.
4. Triantis V, Moulin V, Looman MW, Hartgers FC, Janssen RA, Adema GJ: Molecular characterization of the 
m urine homologue of the DC-derived protein  DC-SCRIPT. JL eukoc Biol 2006, 79(5):1083-1091.
5. Triantis V, Trancikova DE, Looman MW, Hartgers FC, Janssen RA, Adema GJ: Identification and 
characterization of DC-SCRIPT, a novel dendritic cell-expressed m em ber of the  zinc finger family of 
transcriptional regulators. J  Im m unol 2006, 176(2):1081-1089.
6. Lopez-Garcia J, Periyasamy M, Thomas RS, Christian M, Leao M, Jat P, Kindle KB, Heery DM, Parker MG, Buluwela 
L e t  al: ZNF366 is an estrogen receptor corepressor th a t acts through CtBP and histone deacetylases. 
Nucleic Acids Res 2006, 34(21):6126-6136.
7. Ansems M, Hontelez S, Looman MW, Karthaus N, Bult P, Bonenkamp JJ, Jansen JH, Sweep FC, Span PN, Adema 
GJ: DC-SCRIPT: nuclear receptor m odulation and prognostic significance in prim ary b reast cancer. J  N atl 
Cancer Inst, 102(1):54-68.
8. Ramadoss P, Marcus C, Perdew GH: Role of the aryl hydrocarbon receptor in drug metabolism. E xpert Opin 
Drug M etab Toxicol 2005, 1(1):9-21.
9. Osborne CK, Schiff R, Fuqua SA, Shou J: Estrogen receptor: curren t understanding of its activation and 
modulation. Clin Cancer Res 2001, 7(12 Suppl):4338s-4342s; discussion 4411s-4412s.
10. Code of Conduct of the  Federation of Medical Scientific Societies in the Netherlands. [http://www.federa. 
org/?s=1&m=99].
11. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: REporting recom m endations for tum or 
MARKer prognostic studies (REMARK). B reast Cancer Res Treat 2006, 100(2):229-235.
12. Jansen MP, Sieuwerts AM, Look MP, Ritstier K, Meijer-van Gelder ME, van Staveren IL, Klijn JG, Foekens JA, 
Berns EM: HOXB13-to-IL17BR expression ratio is related with tum or aggressiveness and response to 
tamoxifen of recu rren t b reast cancer: a retrospective study. J  Clin Oncol 2007, 25(6):662-668.
13. Sieuwerts AM, Look MP, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer 
AJ, de Weerd V, Portengen H e t al: Which cyclin E prevails as prognostic m arker for b reast cancer? Results 
from a retrospective study involving 635 lymph node-negative b reast cancer patients. Clin Cancer Res 
2006, 12(11 Pt 1):3319-3328.
14. Sieuwerts AM, Usher PA, Meijer-van Gelder ME, Timmermans M, Martens JW, Brunner N, Klijn JG, Offenberg
H, Foekens JA: Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein  are differentially 
associated with prognosis in prim ary b reast cancer. Clin Chem 2007, 53(7):1280-1288.
15. Foekens JA, Portengen H, van Putten WL, Peters HA, Krijnen HL, Alexieva-Figusch J, Klijn JG: Prognostic value 
of estrogen and progesterone receptors m easured by enzyme immunoassays in hum an b reast tum or 
cytosols. Cancer Res 1989, 49(21):5823-5828.
16. Sieuwerts AM, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, 
Portengen H, Klijn JG, Foekens JA: How ADAM-9 and ADAM-11 differentially from estrogen receptor 
predict response to tamoxifen trea tm en t in patients with recurren t b reast cancer: a retrospective 
study. Clin Cancer Res 2005, 11(20):7311-7321.
17. Dorssers LC, van Agthoven T, Brinkman A, Veldscholte J, Smid M, Dechering KJ: Breast cancer oestrogen 
independence mediated by BCAR1 or BCAR3 genes is transm itted  through mechanisms distinct from 
the oestrogen receptor signalling pathway or the epiderm al growth factor receptor signalling pathway. 
B reast Cancer Res 2005, 7(1):R82-92.
18. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD: Assessment of response to therapy 
in advanced b reast cancer: a project of the Programme on Clinical Oncology of the International Union 
Against Cancer, Geneva, Switzerland. Cancer 1977, 39(3):1289-1294.
C
ha
pt
er
90 | Chapter 4
19. Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van Gelder ME, Geurts-Moespot A, van der Kwast 
TH, Sweep CG, Klijn JG: High tum or levels of vascular endothelial growth factor predict poor response to 
systemic therapy in advanced breast cancer. Cancer Res 2001, 61(14):5407-5414.
20. Foekens JA, Look MP, Bolt-de Vries J, Meijer-van Gelder ME, van Putten WL, Klijn JG: Cathepsin-D in prim ary 
b reast cancer: prognostic evaluation involving 2810 patients. Br J  Cancer 1999, 79(2):300-307.
21. van Agthoven T, Sieuwerts AM, Meijer-van Gelder ME, Look MP, Smid M, Veldscholte J, Sleijfer S, Foekens 
JA, Dorssers LC: Relevance of b reast cancer antiestrogen resistance genes in hum an breast cancer 
progression and tamoxifen resistance. J  Clin Oncol 2009, 27(4):542-549.
22. Meijer-van Gelder ME, Look MP, Peters HA, Schmitt M, Brunner N, Harbeck N, Klijn JG, Foekens JA: Urokinase­
type plasminogen activator system in b reast cancer: association with tamoxifen therapy in recurren t 
disease. Cancer Res 2004, 64(13):4563-4568.
23. Martens JW, Nimmrich I, Koenig T, Look MP, Harbeck N, Model F, Kluth A, Bolt-de Vries J, Sieuwerts AM, 
Portengen H e t al: Association of DNA m ethylation of phosphoserine am inotransferase w ith response to 
endocrine therapy in patients with recurren t b reast cancer. Cancer Res 2005, 65(10):4101-4117.
24. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Martens JW: Subtypes of b reast cancer 
show preferential site of relapse. Cancer Res 2008, 68(9):3108-3114.
25. Lee LM, Cao J, Deng H, Chen P, Gatalica Z, Wang ZY: ER-alpha36, a novel variant of ER-alpha, is expressed in 
ER-positive and -negative hum an b reast carcinomas. A nticancer Res 2008, 28(1B):479-483.
26. Chen JQ, Russo PA, Cooke C, Russo IH, Russo J: ERbeta shifts from m itochondria to nucleus during estrogen- 
induced neoplastic transform ation of hum an b reast epithelial cells and is involved in estrogen-induced 
synthesis of m itochondrial respiratory chain proteins. Biochim B iophysA cta  2007, 1773(12):1732-1746.
27. Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L, Ellis IO, Robertson JF, Paish EC, Saunders 
PT e t al: Nuclear and cytoplasmic expression of ERbetal, ERbeta2, and ERbeta5 identifies distinct 
prognostic outcome for b reast cancer patients. Clin Cancer Res 2008, 14(16):5228-5235.
28. Jansen MP, Foekens JA, Klijn JG, Berns EM: Re: Limits of predictive models using m icroarray data for breast 
cancer clinical trea tm ent outcome. J  N a tl Cancer In st 2005, 97(24):1851-1852; author reply 1852-1853.


Chapter S
DC-SCRIPT: AR and VDR Regulator 
Lost upon Transformation of 
Prostate Epithelial Cells
Marleen Ansems 
Nina Karthaus* 
Saartje Hontelez* 
Tilly Aalders 
Maaike W. Looman 
Gerald W. Verhaegh 
Jack A. Schalken 
Gosse J. Adema
*Authors contributed equally
Submitted
94  | Chapter 5
N
uclear receptors (NR), including the Androgen Receptor (AR) and the 
Vitamin D Receptor (VDR) play an im portant role in prostate cancer etiology. 
We recently found that DC-SCRIPT is a prognostic marker in breast cancer 
and a unique NR coregulator differentially regulating different classes o f NRs. Here 
w e investigated the im portance o f DC-SCRIPT in prostate cancer. DC-SCRIPT mRNA 
expression, as m easured  by qPCR, w as readily detected  in norm al and m alignant 
prostate tissu e but could n ot be related to d isease stage. Im m unohistochem istry  
sh ow ed  that DC-SCRIPT protein w as found in m orphologically norm al prostate  
glands and in infiltrating im m une cells. Strikingly, DC-SCRIPT protein expression  
w as absent in m alignant prostate epithelial tissu e and prostate carcinom a cell lines. 
DC-SCRIPT protein expression  appears to be lo st prior to the basal cell marker HMW 
cytokeratin used  in prostate carcinom a diagnostics. The functional effects o f DC- 
SCRIPT on the transcriptional activity o f AR and VDR w ere a ssessed  by luciferase 
reporter assays and qPCR assays on endogenous targets o f AR and VDR. Our data 
dem onstrated that DC-SCRIPT repressed  transcription m ediated by w ild-type and 
m utated AR w hile enhancing VDR m ediated transcription. In addition, transient 
expression  o f DC-SCRIPT expression  in prostate carcinom a cells strongly repressed  
carcinom a cell growth. In conclusion, DC-SCRIPT is a key regulator o f nuclear 
receptors AR and VDR that play an opposite role in prostate cancer etiology and loss  
of DC-SCRIPT m ay be involved in the on set o f prostate cancer.
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Introduction
Prostate cancer is the m ost frequently d iagnosed cancer in the W estern m ale 
population. Initially prostate cancer can be successfully treated w ith  targeted  
therapies, including inhibiting the function o f the Androgen Receptor (AR), a 
m em ber o f the type I nuclear receptor (NR) family. Deregulation o f AR an d /or of 
AR coregulator expression or activity contributes to the transition to castration- 
resistant stage o f  the d isease in patients undergoing endocrine therapy [1-3]. The 
m ost frequently described  AR m utations in prostate cancer are substitutions at 
H 874 and T877. In addition to androgens that bind to the type I NR AR, also vitamin  
D3 that binds to the type II NR VDR (Vitamin D3 Receptor) plays an im portant role in 
the etiology o f prostate cancer. In 1997, Ingles e t  al. reported an association betw een  
variants o f  the VDR gene and prostate cancer [4]. Most studies on VDR and cancer 
have focused on VDR polym orphism s [5]. Functionally, the VDR ligand 1,25-(OH)2D3  
(vitD3) has b een  show n to reduce the grow th o f several prostate cancer cell lines in 
vitro , as w ell as tum or grow th in vivo  [6-12].
The activities o f NRs such as AR and VDR are tightly regulated by coregulators. 
The balance o f corepressors and coactivators determ ines NR transcriptional activity. 
Multiple studies have show n that in addition to alterations in NRs them selves, 
m alfunction o f coregulators o f NRs are im plicated in the developm ent o f cancer, 
including prostate cancer [13, 14].
In 2006 , w e identified  and characterized DC-SCRIPT that w ithin  the im m une 
system  is expressed  uniquely in the antigen presenting dendritic cells (DC) [15]. 
The C-terminal region o f DC-SCRIPT contains both a functional b inding m otif for 
the co-repressor protein CtBP and a LxxLL NR interaction m otif [15-17]. Recently 
w e have show n that DC-SCRIPT is an im portant coregulator o f m ultiple NRs and 
is expressed  by breast ductal epithelial cells. DC-SCRIPT expression  inhibited the 
activity o f  the type I NRs ER and PR, know n for their pro-proliferative and anti- 
apoptotic activities in breast cancer cells. In contrast, the transcriptional activities of 
the type II NRs RAR/RXR and PPAR/RXR, know n for their anti-proliferative and pro- 
apoptotic effects in breast cancer cells, w ere enhanced[18]. Interestingly, DC-SCRIPT 
mRNA expression  in breast cancer patients constituted  a strong and independent  
prognostic marker for breast cancer [18, 19]. These data su ggest that DC-SCRIPT 
acts as a tum or suppressor in breast cancer. W hether DC-SCRIPT also plays a role in 
other cancer types in w hich NRs play an im portant role, is currently unknown.
Herein w e investigated DC-SCRIPT expression  in norm al and m alignant prostate
C
ha
pt
er
96 | Chapter 5
tissu e and its relation w ith  AR and VDR, two NR family m em bers w ith  opposite 
functions in prostate epithelial cells.
Materials and Methods
Cells
Human embryonic kidney 293 (HEK293) cells were cultured in Dulbecco ' s modified Eagle 
medium containing GlutaMAX (Invitrogen, Breda, the Netherlands) supplemented with 10% 
heatinactivated fetal calf serum (FCS; Greiner Bio-one, Alphen a/d  Rijn, the Netherlands), 1% 
nonessential amino acids (Invitrogen), and 0.5% antibiotic -  antimycotic (Invitrogen). Hu­
man hepatocellular carcinoma Hep3B cells were cultured in Iscove's modified Dulbecco's me­
dium (Invitrogen), 10% heat-inactivated FCS, and 0.5% antibiotic -  antimycotic. LNCaP and 
22Rv1 prostate epithelial cancer cells were cultured were cultured in RPMI-1640 medium 
(Invitrogen), 10% heat-inactivated FCS, and 0.5% antibiotic -  antimycotic. All cell lines were 
originally obtained from American Type Culture Collection (Manassas, VA). Cells were regu­
larly checked morphologically to verify the identity of each cell line.
Co-immunoprecipitation assays
LNCaP and 22Rv1 were plated at 3,5*106 in 10 cm dishes 8 hrs prior to transfection. Cells 
were transfected with pHA-DC-SCRIPT using metafectene (Biontex, Germany) according to 
the manufacturers' protocol. Following transfection for 40 hrs, the cells were lysed in CHAPS 
buffer (1% CHAPS, 150mM NaCl, 10mM Tris-HCl pH 7,5 and 2 mM MgCl2 pH 7.5) containing 
the protease inhibitors leupeptin (Sigma), aprotinin (Roche) and PMSF (Sigma). Lysates of 
the LNCaP and 22Rv1 cells were used for immunoprecipitation (IP) of DC-SCRIPT using anti- 
DC-SCRIPT-coupled dynabeads (GE Healthcare). Isotype-coupled-dyna-beads were used as a 
control.
Hek293 cells were plated at 6*106 in 10 cm dishes 24 hrs prior to transfection. Cells were 
transfected with pDC-SCRIPT-EYFP or its control pEYFP and HA-tagged VDR using metafec­
tene (Biontex, Germany) according to the manufacturers' protocol. Following transfection 
for 24 hrs, the cells were lysed in RIPA buffer (50mM NaCl, 1% Triton, 0.1% SDS and 50mM 
Tris-HCl) containing the protease inhibitors leupeptin (Sigma), aprotinin (Roche) and PMSF 
(Sigma). Lysates of the Hek293 cells were used for immunoprecipitation (IP) of YFP-tagged 
proteins using anti-GFP coupled Protein G beads (GE Healthcare). Uncoupled beads were 
used as a control.
IPs were resolved in sample buffer placed at 95°C for 5 minutes, then cooled on ice. Proteins 
were subjected to electrophoresis on an 8% 37.5:1 acryl/Bisacrylamide gel and transferred 
onto Protan nitrocellulose transfer membranes (Schleicher and Schuell) overnight at 30 mA 
at 4°C. Blots were blocked in 1%Elk/3%BSA in PBST for detecting YFP-tagged proteins, DC- 
SCRIPT or AR and in 2%Elk/1%BSA in Phosphate-buffered saline with 0.01% Tween (PBST) 
for detecting HA-tagged VDR. DC-SCRIPT was detected with anti-DC-SCRIPT (R&D, 2,5 |ig/ml)
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and donkey anti-goat IRDye 800CW (1:5000 Li-cor biosciences) as secondary antibody. AR 
was detected with anti-AR (N20, santa cruz, 2 |ig/ml) and IRDye 800CW Goat Anti-Rabbit IgG 
(1:5000 Li-cor biosciences) as secondary antibody. Blots were probed with a mouse-anti-GFP 
(1:1000, Roche Applied Science) and IRDye 800CW Goat Anti-Mouse IgG (1:5000 Li-cor bio­
sciences) as secondary antibody, to detect YFP-tagged proteins. HA-tagged VDR was detected 
with a rat anti-HA (1:1000, 3F10, Roche) and goat anti-rat alexa fluor 680 (1:5000, Invitro- 
gen) as secondary antibody. After staining, the membranes were scanned using the Odyssey™ 
Infrared Imaging system to visualize the labeled proteins.
Transcription assays
pSVAR0, PSA85-luc, ART877A and ARH874Y were kindly provided by Prof. Dr. Trapman (Eras­
mus Medical Center, Rotterdam). pGL3-ARE-E1B-luc was kindly provided by Prof. Dr. Ber­
nards (Netherlands Cancer Institute, Amsterdam). AR was cloned in pHA-n1 (GFP sequence 
from pEGFP-n3 (clontech) has been replaced by an HA tag). MMTV-luc was kindly provided by 
Prof. Dr. Stunnenberg (Nijmegen Centre for Molecular Life Sciences). The vitamin D3 report­
ers were obtained from SABioscience. pCATCH, pCATCH-DCSCRIPT, pEYFP-DC-SCRIPT and 
pEGFP-DC-SCRIPT have been described [15].
Hep3b cells were plated (6x104) in 24-wells plates 8 hrs before transfection and transfected 
using the Calcium Phosphate precipitation method (Invitrogen). 22Rv1 cells were plated 
at (7,5x104) in 24-wells plates 8 hrs before transfection and transfected using metafectene. 
Transfected cells were stimulated with 1nM R1881 (sigma), 10nM DHT (sigma), 50nM vitD3 
(sigma), 1|iM AtRA (sigma), 10uM casodex, 10nM R5020 (PerkinElmer), 10nM E2 (sigma), 
or vehicle for 24 hrs. Cells were harvested 40 hrs after transfection and cell lysates were ana­
lyzed for luminescence according to manufacturer's protocol (Dual-Luciferase® Reporter as­
say, Promega) using a Victor3 luminometer (PerkinElmer). Relative light units (RLU) were cal­
culated after correction for transfection efficiency based on the activity of the co-transfected 
pRL-SV40 (Promega). The data are expressed as the mean activity of at least four independent 
experiments +/-s.d.
Target gene assays
For AR target gene experiments LNCaP cells were plated 3 days prior to transfection in RPMI, 
10% charcoal-stripped FCS, ultraglutamine and aa. 24 hrs prior to transfection cells were 
plated (400.000 cells) in 6-wells plates, cells were transfected with pHA-DC-SCRIPT or pHA as 
a control using metafectene according to the manufacturer’s protocol. Cells were stimulated 
with vehicle or R1881 for 24hrs. For VDR target gene experiments cells were plated (400.000 
cells) in 6-wells plates in RMPI, 10% FCS, ultraglutamine and aa, 24 hrs prior to transfection. 
Cells were transfected with pHA-DC-SCRIPT or pHA as a control using metafectene accord­
ing to the manufacturer's protocol. Cells were stimulated with vitD3 for 0 or 24hrs. RNA was 
isolated with the Quick-RNA MiniPrep kit (Zymoresearch).
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cDNA synthesis and Quantitative PCR
Total RNA was extracted from tissue sections or cell cultures using Trizol reagent (Invitrogen). 
RNA quantity and purity were determined on a NanoDrop spectrophotometer. Two micro­
grams of total RNA was DNase-I-treated and cDNA was synthesized using random primers 
and SuperScript II-MMLV reverse transcriptase (Invitrogen). Upon quantification of the RT- 
reaction, 10 ng of cDNA was used for PCR analysis.
mRNA levels for the genes of interest were determined with a Bio-rad CFX96 (Bio-rad) with 
SYBR Green (Roche) as the fluorophore. Reaction mixtures and program conditions were used 
that were recommended by the manufacturer (Bio-rad). Quantitative PCR data were analyzed 
with Bio-rad CFX manager version 1.6 (Biorad) and checked for correct amplification and dis­
sociation of the products. As a reference gene TFRC was used [20]. DC-SCRIPT levels relative 
to TFRC were calculated as: 2A- (Ct DC-SCRIPT - Ct TFRC). Primer sequences are available on request.
Immunohistochemical studies
Snap-frozen prostate specimens were embedded in Oct embedding matrix (CellPath), sec­
tioned at 5 |im intervals, placed on superfrost slides, fixed and incubated with 4 |ig/ml anti- 
DC-SCRIPT (R&D Systems) and stained with biotinylated Horse-anti-Goat (Vector), ABC-AP 
(Vectastain) and fast red (Sigma) was used for signal development. HMW cytokeratin was 
stained with 34bE12 (Dako) and stained with biotinylated Horse-anti-mouse (Vector), ABC­
AP and fast red. Isotype matched antibodies (gIgGs (R&D Systems) and mIgG1 (BD biosci­
ence) respectively) were used as controls. Sections were counter-stained with hematoxylin to 
visualize the nucleus of the cells and analyzed on a Leica DMLB microscope.
Prostate cancer patient tissue specimens
The use of patient material was approved by the local ethical committee of the Radboud 
University Nijmegen Medical Centre. Based on the pathology findings and the case records, 
patients with low grade (Gleason score < 7), high grade (Gleason score > 7), and castration- 
resistant prostate cancer were selected for this study. Normal prostate (NPr) and benign pros­
tatic hyperplasia (BPH) tissue specimens were used as non-malignant controls. Upon radi­
cal prostatectomy or transurethral resection of the prostate, specimens were snap frozen in 
liquid nitrogen. Normal, BPH and tumor prostatic tissues were selected and processed by step 
sectioning.
Statistical analysis
Differences in TFRC-normalized DC-SCRIPT mRNA expression levels between normal pros­
tate tissue and tumor tissue from the same patient and between target gene expression of 
VDR and AR in control and DC-SCRIPT transfected cells were assessed using paired t  tests. 
Two-sided P values less than .05 were a priori considered to be statistically significant.
DC-SCRIPT in Prostate Epithelial Cells | 99
A
C
B
III.
D
E
Pea GG<7 Pea GG>=7 CRPC
m r L i  f>w a1 >4 i -T'S
Isotype control DC-SCRIPT 40X
T it \  «
<  \
T . V ■ ’
Figure 1. DC-SCRIPT mRNA a n d  p ro te in  express io n  in  p ro s ta te  tissu e  sam ples
A) DC-SCRIPT mRNA levels in healthy tissues (black bars) and corresponding prostate tum or (white bars) 
tissue (n = 10 patients) relative to TFRC mRNA as determined by quantitative polymerase chain reaction.
B) DC-SCRIPT mRNA levels in 10 castration resistant prostate carcinoma, 10 low grade (<7) and 10 high 
grade (>=7) prostate tissue samples of prostate carcinoma patients. DC-SCRIPT mRNA levels relative 
to TFRC mRNA as determined by quantitative polymerase chain reaction. C) Immunohistochemistry 
staining of DC-SCRIPT and cytokeratine 340E12 on frozen morphologically normal prostate tissue D) 
Immunohistochemistry staining of DC-SCRIPT and the isotype control in frozen prostate tissue with 
well differentiated prostate carcinoma cells containing a region with tum or infiltrating leucocytes E) 
Immunohistochemistry staining of DC-SCRIPT and cytokeratine 340E12 on frozen prostate tissue with 
well differentiated prostate carcinoma cells
Results
DC-SCRIPT mRNA and protein expression in prostate epithelium
The bifunctional NR coregulator DC-SCRIPT that is expressed  in norm al breast 
epithelial cells and at low er levels in their m alignant counterparts represents a solid  
prognostic marker for breast carcinom a [18, 19]. Here w e investigated w hether DC- 
SCRIPT is expressed  by norm al and m alignant prostate epithelial cells in w hich NRs 
also play an im portant role. DC-SCRIPT mRNA expression  w as determ ined in normal
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and m alignant prostate tissu e specim ens from the sam e individual and in prostate  
carcinom a o f different grades. The data revealed the presence o f  DC-SCRIPT mRNA 
in prostate tissu e at levels com parable to those seen  in breast cancer specim ens, 
and a trend towards higher DC-SCRIPT expression  in norm al vs. tum or tissu e that 
did n ot reach significance (P=.1978) (Fig. 1a). The com parison o f DC-SCRIPT mRNA 
levels in 10 low  (Pca GG<7) grade patients, 10 high (Pca GG>=7) grade patients  
and 10 castration-resistant PCa patients did n ot reveal significant differences 
b etw een  the different subgroups (Fig. 1b). To confirm  DC-SCRIPT expression at the 
protein level, frozen prostate cancer tissu e sections w ere stained for DC-SCRIPT 
expression. The data sh ow ed  DC-SCRIPT expression  in the basal epithelial cell layer 
of m orphologically norm al prostate tissu e (Fig. 1c). Little or no expression  o f DC- 
SCRIPT w as observed in cancerous prostate epithelial cells o f patients w ith poorly  
differentiated prostate carcinom a (n=5) or w ith castration resistant d isease (n=4). 
As expected, DC-SCRIPT w as expressed  in cells w ith  DC m orphology in regions 
containing tum or infiltrating leukocytes (TIL) (Fig. 1d and data n ot show n). Of note, 
TIL are abundant in prostate carcinom a tissu e relative to healthy prostate tissue. 
These data dem onstrate that DC-SCRIPT is expressed  by norm al prostate epithelial 
cells and im ply that infiltrating DCs expressing DC-SCRIPT contribute to DC-SCRIPT 
mRNA expression observed in advanced prostate cancer tissue.
Subsequently, the expression  o f DC-SCRIPT was related to the expression  o f HMW 
(high m olecular w eight) cytokeratin (34ßE 12), w hich stains benign prostatic acini. 
Overall, DC-SCRIPT expression  paralleled the expression o f HMW cytokeratin in the 
basal prostate epithelial cells in healthy prostate tissu e (Fig. 1e). HMW cytokeratin  
negative glands also did n ot express DC-SCRIPT and all glands that expressed  DC- 
SCRIPT w ere also positive for HMW cytokeratin. More detailed  analysis sh ow ed  that 
DC-SCRIPT expression  in the basal epithelial layer w as lo st in 32% (15 out o f 36 
cases o f 19 pts) o f the cases that uniform ly (no focal d isruptions) expressed  HMW 
cytokeratin, w hile 53% (9 /1 7  cases o f 19 pts) o f the cases w ith  focal disruptions 
in HMW cytokeratin expression  w ere com pletely DC-SCRIPT negative. Since focal 
disruption is a pre-requisite for tum or progression /in vasion  [21], the loss of 
DC-SCRIPT expression  in glands w ith  focal d isruptions su ggest that DC-SCRIPT 
expression  is lo st early upon m alignant transform ation. In line w ith  this notion is 
the finding that no DC-SCRIPT mRNA expression  is observed  in all prostate cancer 
cell lines tested  so far (DU145, LNCaP, DuCaP, DuCaP+R1881, 22Rv1 and LAPC-4, 
data n ot shown).
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DC-SCRIPT interacts with and represses AR
As DC-SCRIPT is know n to affect the function o f m ultiple NRs [18], we 
investigated if  DC-SCRIPT m ay also act as a coregulator for NRs im portant in 
prostate biology. Therefore, w e first evaluated the interaction o f DC-SCRIPT with  
AR by co-im m unoprecipitation (co-IP) studies. For this, lysates w ere prepared from  
22Rv1 prostate carcinom a cells co-transfected w ith  cDNAs encoding DC-SCRIPT and 
w t AR. Im m unoprecipitated DC-SCRIPT w as readily able to co-IP w t AR, w hereas no 
AR could be detected  in the control IP (Fig. 2a). To further confirm  this interaction,
B
C
co -transfe ctedw t A R
a-D C-SCRIPT
a-AR
endogenous AR
a-DC-SCRIPT
a-AR
endogenous AR
9 0 k D a H
1 1 0 k D a -*  m
a-DC-SCRIPT
Figure 2. A ssociation of DC-SCRIPT w ith  AR in 
p ro s ta te  carc inom a cell lines
Protein of in the cell lysates were 
immunoprecipitated (IP) with anti-DCSCRIPT 
antibody -  or isotype control coupled 
beads. The IP-ed proteins were subjected to 
immunoblotting (WB) with anti-DCSCRIPT 
antibodies to detect IP-ed DC-SCRIPT or anti-AR 
antibodies to detect coimmunoprecipitated AR. 
Co-IPs were perform ed on A) lysates from 22Rv1 
cells cotransfected with DC-SCRIPT and with 
w t AR B) lysates from 22RV1 cells transfected 
with DC-SCRIPT and C) lysates from LNCAP cells 
transfected with DC-SCRIPT.
additional co-IP experim ents w ere perform ed w ith  DC-SCRIPT transfected 22Rv1 
and LNCaP prostate cancer cell lines that endogenously expressed  AR (Fig. 2b-c). 
Specific co-im m uniprecipitation o f endogenously  expressed  AR w ith  DC-SCRIPT 
w as observed  in both 22Rv1 and LNCaP cells. These data thus sh ow  the co-presence  
o f DC-SCRIPT in protein com plexes containing AR.
Next, w e a ssessed  the im pact o f DC-SCRIPT expression on the transcriptional 
activity o f  AR in luciferase reporter assays. Hep3b cells w ere transfected w ith  an 
androgen responsive MMTV-reporter construct. Upon provision o f the AR-ligands 
DHT or R1881 and ectopic expression  o f AR, they produced luciferase as expected. 
Introduction o f increasing am ounts o f DC-SCRIPT revealed a d ose-dependent  
repression  o f ligand-dependent AR m ediated  luciferase production (Fig. 3a). In 
addition, using another AR reporter construct, pGL3-ARE, w e confirm ed that DC- 
SCRIPT represses AR-mediated transcription in an AR ligand- and d ose-dependent 
m anner (Fig. 3b). Moreover, DC-SCRIPT specifically repressed  luciferase production  
from a reporter construct, PSA85luc [22], containing a genom ic fragm ent o f the AR
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Figure 3. Effect o f DC-SCRIPT expression  on AR-m ediated tran sc rip tio n
Hep3B cells were transfected with the firefly luciferase reporter plasmid MMTV-luc A), with the firefly 
luciferase reporter pGL3-ARE B), or with the firefly luciferase reporter plasmid PSA85-luc C). All 
experiments were performed in the absence or presence of a cotransfected AR expression plasmid and 
increasing amounts of DC-SCRIPT expression plasmid. The cells were treated for 24 hrs with vehicle (white 
bars),10 nM DHT(grey bars) or 1 nM R1881 (black bars). D) Hep3B cells were transfected with the firefly 
luciferase reporter plasmid pGL3-ARE in the absence or presence of a cotransfected wt, H874Y or T877A 
AR expression plasmid and increasing amounts of DC-SCRIPT expression plasmid. The cells were treated 
for 24 hrs with vehicle, 10 nM DHT, 1 nM R1881 , 10nM E2, 10nM R5020 or 10nM Dexamethason (dex) 
E) 22Rv1 cells endogenously expressing AR T877A were transfected with the indicated firefly luciferase 
reporter plasmids in and increasing amounts of DC-SCRIPT expression plasmid. The cells were treated for 
24 hrs with vehicle, 10 nM DHT or 1 nM R1881. F) 22Rv1 cells endogenously expressing AR T877A were 
transfected with the firefly luciferase reporter plasmid MMTV-luc and increasing amounts of DC-SCRIPT 
expression plasmid. The cells were treated for 24 hrs with vehicle, 1 nM R1881, 10uM Casodex or the 
combination of R1881 and casodex. (A-F) All data were corrected for transfection efficiency by dividing 
the firefly luciferase values by the value of a cotransfected Renilla luciferase reporter construct. Data are 
expressed as the mean values of a t least four independent experiments +/- SD.
responsive PSA-promoter (Fig. 3c). These data indicate that DC-SCRIPT specifically  
represses transcription m ediated by AR on 3 distinct prom oters containing androgen  
response elem ents in a dose and ligand dependent manner.
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Next w e investigated w hether DC-SCRIPT is able to repress the activity o f  the 
m ost com m on AR m utants, AR H874Y and AR T877A. These AR m utants exhibit 
m uch less ligand specificity as com pared to w ildtype AR, and can be activated by 
estrogens (AR H874Y and AR T877A) and p rogesterones (AR T877A) in addition to 
androgens [23]. Using the luciferase reporter construct pGL3-ARE in Hep3B cells, 
w e sh ow ed  that DC-SCRIPT suppresses the activity o f both AR-mutants in a dose 
and AR-ligand d ep endent fashion (Fig. 3d). Our data further sh ow  that DC-SCRIPT 
is also able to repress estrogen  E2 (H874Y and T877A) and progesterone R 5020  
(T877A) induced transcription by the AR-mutants. We also determ ined  w hether  
DC-SCRIPT could also repress transcription m ediated  by endogenously expressed  
T877A-AR in the prostate cell line 22Rv1. As show n in Fig. 3e DC-SCRIPT can repress 
transcription m ediated  by endogenously expressed  AR-T877A on MMTV-luc, pGL3- 
ARE as w ell as on PSA85luc reporter plasm ids in 22Rv1 cells. Casodex is an oral 
non-steroidal anti-androgen often u sed  in the treatm ent o f prostate cancer. Fig. 3 f  
show s that casodex indeed  inhibits luciferase production m ediated  by endogenous  
androgens p resen t in the culture m edium  (casodex treated 22Rv1 cells). Moreover, 
it inhibits luciferase production in R 1881 treated 22Rv1 cells to background levels. 
To assess w hether DC-SCRIPT function is affected by casodex, w e titrated different 
am ounts o f DC-SCRIPT in the luciferase reporter system . Increased expression  of 
DC-SCRIPT readily repressed  luciferase production m ediated by endogenous AR in 
R 1881 treated 22Rv1 cells. Moreover, the presence o f  DC-SCRIPT further decreased  
the R 1881 induced transcriptional activity o f endogenous AR in the casodex treated  
cells. These data indicate that DC-SCRIPT function is n ot affected by casodex, rather 
DC-SCRIPT is able to further decrease the AR-activity rem aining after casodex  
treatm ent.
TM PRSS2
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Figure 4. Effect o f DC-SCRIPT exp ress io n  on  TM- 
PRSS2 an d  SPDEF expression
OnM R1881 1nM R1881
P =  0.012 LNCaP cells were transiently transfected (efficiency 
10-20%) with a control or DC-SCRIPT expression 
vector and subsequently stimulated for 24 hrs with 
no or 1 nM R1881. SPDEF and TMPRSS2 mRNA levels 
are indicated relative to TFRC mRNA as determined 
by quantitative polymerase chain reaction. Data are 
expressed as the mean values of three independent 
experiments +/- SEM.
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Finally, w e investigated if DC-SCRIPT could also repress endogenous genom ic AR 
targets in prostate cancer cells. Therefore, DC-SCRIPT w as transiently transfected  
into the AR positive prostate cell line LNCaP and the expression o f the AR target 
gen es TMPRSS2 and SPDEF w as m onitored. Upon stim ulation o f control transfected  
cells w ith  the AR agonist R1881 the expression o f TMPRSS2 and SPDEF is clearly
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Figure 5. Association and functional effects of DC-SCRIPT on VDR function
A) Lysates from Hek293 cells cotransfected with YFP-DC-SCRIPT and with VDR-HA were 
immunoprecipitated (IP) with Anti-GFP to IP YFP-tagged DC-SCRIPT or the control protein YFP. The 
IP-ed proteins were subjected to immunoblotting (WB) with anti-GFP antibodies to detect IP-ed YFP- 
tagged DC-SCRIPT or GFP and anti-HA antibodies to detect coimmunoprecipitated AR. B) Hep3B cells 
were transfected with the firefly luciferase reporter plasmid VDRE-luc or control-luc, w ith different 
amounts of a VDR and RXR expressing vectors and increasing amounts of DC-SCRIPT expression plasmid. 
The cells were treated for 24 hrs with 0 nM (white bars) or 50 nM vitD3 (black bars). Luciferase data 
are expressed relative to luciferase production in cells transfected with VDRE-luc, 1ng/m l VDR/RXR, 
stimulated with vitD3 and in the absence of DC-SCRIPT. C) 22Rv1 cells were transfected with the firefly 
luciferase reporter plasmid VDRE-luc and increasing amounts of DC-SCRIPT expression plasmid. The 
cells w ere treated for 24 hrs w ith 0 nM vitD3 (white bars), 1nM R1881 (light grey bars), 1^M AtRA (dark 
grey bars) or 50 nM vitD3 (black bars). Luciferase data are expressed relative to luciferase production 
in cells transfected with VDRE-luc, stimulated with vitD3 and in the absence of DC-SCRIPT. All data (B- 
C) were corrected for transfection efficiency by dividing the firefly luciferase values by the value of a 
cotransfected Renilla luciferase reporter construct. Data are expressed as the mean values of a t least 
four independent experiments +/- SD D) LNCaP cells were transiently transfected with a control or DC- 
SCRIPT expression vector and subsequently stimulated for 0 or 24 hrs with vitD3. Cyp24A1 mRNA levels 
are indicated relative to TFRC mRNA as determined by quantitative polymerase chain reaction. Data are 
expressed as the m ean values of three independent experiments +/- SEM.
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upregulated (Fig. 4). R 1881 stim ulation o f LNCaP cells transfected w ith  DC-SCRIPT 
(10-20%  transfection efficiency) resu lted  in significantly low er expression  o f both  
AR target genes. These data thus dem onstrate that DC-SCRIPT can m odulate the 
function o f AR on genom ic targets in prostate carcinom a cells.
DC-SCRIPT interacts with and activates VDR
In contrast to the growth prom oting role o f AR, the type II NR VDR plays an 
im portant anti-proliferative and pro-apoptotic role in prostate cancer. As we 
previously sh ow ed  that DC-SCRIPT m odulates type II NRs in addition to type I NRs, 
w e investigated w hether DC-SCRIPT is able to affect the function o f  VDR. Therefore, 
w e perform ed co-IP experim ents using lysates prepared from HEK293 cells 
cotransfected w ith  constructs encoding YFP-tagged DC-SCRIPT or YFP- (control) 
and HA-tagged VDR. Although YFP-DC-SCRIPT and the control protein YFP were 
both effectively im m unoprecipitated w ith  anti-GFP antibody-coupled  beads, only in 
the YFP-DC-SCRIPT IP the HA-tagged VDR could be detected  (Fig. 5a), indicating a 
specific interaction b etw een  DC-SCRIPT and VDR.
To determ ine the effect o f DC-SCRIPT on the transcriptional activity o f VDR, 
luciferase reporter assays w ere perform ed in Hep3b cells. Hep3b cells transfected  
w ith a VDRE luciferase reporter construct sh ow  luciferase activity upon stim ulation  
w ith the VDR/RXRa ligand vitD3, con sistent w ith  the expression  o f endogenous  
VDR. Strikingly and in contrast to the repressive effect on the type I steroid  receptor 
AR, co-expression  o f increasing am ounts o f DC-SCRIPT resu lted  in a d ose-dependent 
increase in luciferase activity upon addition o f  vitD3 on both endogenous and 
ectopically expressed  VDR and RXR (Fig. 5b). Removal o f the VDR/RXR response  
elem ents in the reporter construct com pletely abolished the luciferase production, 
further dem onstrating that the activating function o f DC-SCRIPT is m ediated via 
binding o f VDR/RXR to its response elem ents. DC-SCRIPT w as also able to activate 
luciferase activity m ediated by endogenously  expressed  VDR in the prostate 
carcinom a cell line 22Rv1 (Fig. 5c). To dem onstrate that DC-SCRIPT enhances 
expression  m ediated  by VDR/RXR rather than RXR hom odim ers, cells w ere treated  
w ith the RAR/RXR ligand AtRA. As show n in Fig. 5c, DC-SCRIPT could only enhance 
luciferase production upon stim ulation w ith  vitD3 and n ot w ith  AtRA or with  
R1881. Moreover, w e sh ow  that DC-SCRIPT expression in LNCaP cells enhances the 
expression  o f vitD3 induced Cyp24A1 expression, the strongest know n endogenous  
genom ic target gene o f VDR (Fig. 5d). These data indicate that DC-SCRIPT can 
activate VDR m ediated  transcription in prostate epithelial cells.
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Figure 6. Effect of DC-SCRIPT expression on cell 
growth of 22Rvl prostate carcinoma cells
22Rvl cells were transfected with YFP, YFP-DC- 
y f p  SCRIPT or DC-SCRIPT-GFP. Cells were counted 
y f p -s c r ip t  24 jjrs an(j 72 hrs after transfection and analyzed
SCRIPT-GFP J
for YFP expression by means of FACS. Thereafter, 
the num ber of transfected cells was calculated. 
Number of cells plotted in the graph are relative 
to the num ber of YFP transfected cells. Data are 
expressed as the m ean of 3 experiments +/- SD.
DC-SCRIPT expression inhibits prostate carcinoma cell growth
Prostate tum or growth is highly dependent on androgens, w hereas vitD3 
is m ainly involved in the inhibition o f prostate cell growth. Our current findings 
that DC-SCRIPT can repress AR m ediated transcription and activates VDR m ediated  
transcription in prostate carcinom a cells im plies that DC-SCRIPT m ay be involved  
in m odulating the growth response o f prostate carcinom a cells to horm ones and 
vitam ins. To test this, w e transiently transfected DC-SCRIPT in 22Rv1 cells in com plete  
m edium  and m onitored their cell growth. As show n in Fig. 6, both C-terminally GFP 
tagged DC-SCRIPT and N-term inally YFP tagged DC-SCRIPT expression significantly  
represses cell grow th com pared to the YFP control transfected cells.
Discussion
Here, w e investigated the im portance o f DC-SCRIPT in prostate carcinoma 
biology. DC-SCRIPT mRNA expression w as readily detected  in norm al and m alignant 
prostate tissu e but could n ot be related to differentiation grade. DC-SCRIPT protein  
expression  w as found in the basal epithelial cells o f m orphologically normal 
prostate glands, and w as absent in m alignant prostate epithelial tissu e and prostate  
carcinom a cell lines. DC-SCRIPT protein expression appears to be lo st prior to 
the basal cell marker HMW cytokeratin in focally disrupted glands. Moreover, DC- 
SCRIPT repressed  transcription m ediated by AR w hile enhancing VDR m ediated  
transcription in prostate epithelial cells. Finally, transient expression  o f DC-SCRIPT 
in prostate carcinom a cells sh ow ed  that DC-SCRIPT strongly represses cell growth.
Prostate cancers are exquisitely d ependent on androgens for developm ent, 
grow th and survival [24-27]. Therefore, suppressing AR activity by androgen  
deprivation and the use o f  AR antagonists are at the forefront o f therapy regim ens in
DC-SCRIPT in Prostate Epithelial Cells | 107
prostate carcinom a for years [27-29]. Deregulation o f coregulators o f AR has often  
b een  associated  w ith  prostate cancer biology [30, 31] and dem onstrate that also 
coregulators o f AR play an im portant role in prostate carcinom a biology.
DC-SCRIPT w as previously show n to interact w ith  several proteins know n to be 
presen t in large m ultiprotein com plexes m odulating NR function [15, 17, 18, 32]. 
Here, w e dem onstrate that DC-SCRIPT is p resen t in a protein com plex together with  
AR and is able to repress the activity o f WT and m utated AR in luciferase reporter 
assays. Moreover, upon stim ulation w ith  androgens DC-SCRIPT repressed  the 
expression  o f several endogenous targets o f AR. Furthermore w e dem onstrate that 
DC-SCRIPT function was n ot affected by the anti-androgen casodex, it w as even able 
to further decrease the rem aining activity o f AR after casodex treatm ent.
DC-SCRIPT expression in hum an prostate tissu e w as m ostly confined to the basal 
epithelial cells. Although AR mRNA and protein expression has been  identified  in 
the basal cells [33, 34], AR activity in these cells has often been  described to be low. 
AR expression  and activity are m uch m ore pronounced in the lum inal cell layer in 
prostate glands [33]. The finding that DC-SCRIPT is m uch m ore abundant in the basal 
cells relative to the lum inal cells m ight therefore be part o f the explanation for the 
lo w  level o f AR activity in the basal cells. The observation that DC-SCRIPT regulates 
AR function and prostate cell growth, both o f w hich n eed  to be tightly controlled  in 
norm al prostate physiology, is indicative for a crucial role o f DC-SCRIPT in prostate 
biology. The exact m olecular m echanism  by w hich DC-SCRIPT inhibits AR activity in 
basal epithelial cells is currently unknow n and deserves further research.
Because DC-SCRIPT can m odulate AR function in prostate epithelial cells we 
hypothesized  that DC-SCRIPT m ay play a role in prostate cancer. Our data revealed  
the presence o f  DC-SCRIPT mRNA in prostate cancer tissu e and corresponding  
healthy tissue. However, DC-SCRIPT mRNA expression could n ot be related to disease  
stages. This m ay be explained by the fact that mRNA from the non-m icrodissected  
tissu e is n ot so le ly  derived from tum or cells, but also from adjacent norm al tissue, 
adipose tissue, b lood vesse ls  and im m une infiltrates, the latter o f w hich is known  
to express DC-SCRIPT. Im m unohistochem istry sh ow ed  that DC-SCRIPT protein is 
expressed  in the basal epithelial layer o f  m orphologically norm al prostate glands, 
but also in infiltrating DCs. In addition w e found that DC-SCRIPT protein expression  
parallels 340E12 expression. 340E12 is norm ally used  for the detection  o f basal 
cells o f  the prostatic acini and dem onstration o f this HMW cytokeratin in the basal 
cells o f prostatic acini is indicative o f benignity [35, 36]. Detailed analysis show ed  
that DC-SCRIPT expression in the basal epithelial layer was lo st in 32% o f the
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cases that uniform ly expressed  HMW cytokeratin, w hile 53% o f the cases with  
focal d isruptions in HMW cytokeratin expression w ere com pletely DC-SCRIPT 
negative. This indicates that the loss o f DC-SCRIPT expression  in basal epithelial 
cells precedes the loss o f HMW cytokeratin and that DC-SCRIPT expression is lost  
early upon m alignant transform ation. The basal cell population is the so le  source 
of several tum or suppressors [21, 37, 38], together w ith  the finding that DC-SCRIPT 
expression  in prostate carcinom a cell lines inhibits their cell grow th, it suggests that 
DC-SCRIPT m ay function as a tum or suppressor in prostate epithelial cells.
Recently w e have dem onstrated that DC-SCRIPT plays an im portant role in breast 
cancer via m odulating NR activity. DC-SCRIPT mRNA expression in breast cancer 
b iopsies positively correlated w ith  clinical outcom e. O verexpression o f  DC-SCRIPT 
inhibited the activity o f the type I NRs, ER and PR. In contrast, the transcriptional 
activities o f the type II NRs, RAR/RXR and PPAR/RXR, w ere enhanced [18, 19]. 
Functional crosstalk  o f  type I and II NRs in breast carcinoma, especially  betw een  
ER (estrogen  signaling) and RAR (retinoic acid signaling) has been  know n for 
years, but the m olecular m echanism  has only recently b een  elucidated [39-41]. ER 
has been  reported to exhibit m ainly pro-proliferative and anti-apoptotic activities 
in breast cancer cells [42-44], w hereas RAR m ainly has anti-proliferative and pro- 
apoptotic effects [42, 45]. For prostate cancer a sim ilar functional link b etw een  AR 
and the type II NR VDR has b een  described. In contrast to AR, VDR is associated  with  
anti-proliferative and differentiating actions on prostate cells [10-12]. Moreover, 
the grow th inhibiting effects o f VDR in prostate cells are m ost pronounced in the 
presence o f androgens [46-49], further supporting the crosstalk b etw een  AR and 
VDR.
Altogether, our data indicate that the reciprocal effect o f DC-SCRIPT on type I and
II NRs found in breast carcinoma, n ow  can be extended to prostate carcinoma.
DC-SCRIPT appears to be a key regulator o f the NRs AR and VDR, w hich exhibit 
opposite functions in prostate cancer cells. In conclusion, DC-SCRIPT represents a 
potential novel marker for NR-dependent tumors.
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Chapter 6
Crosstalk and DC-SCRIPT: 
Expanding Nuclear Receptor
Modulation
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N
uclear Receptors (NR) are intracellular receptors that execute a 
transcriptional program  upon binding to horm ones, vitam ins and m etabolic 
products. They are key regulators o f d istinct physiological processes, 
including growth and differentiation, m etabolism , and immunity. The im pact o f NR 
activation on a given cell can differ from  proliferation induction to program m ed  
cell death. NR m alfunction is associated  w ith  different d iseases, such as diabetes, 
chronic inflam m atory d iseases and cancer. Much progress has been  m ade towards 
understanding the transcriptional regulation by individual NR at the m olecular level. 
However, essentially  every cell expresses m ultiple NR and w ill encounter com plex  
m ixtures o f NR ligands during its life cycle. In this review, w e w ill focus on novel 
insights in balancing NR activity via NR crosstalk and DC-SCRIPT/ZNF366, a b i­
functional NR coregulator. The im pact on breast cancer developm ent and prognosis  
will be discussed.
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Introduction
In a physiological context cells are n ot alone; they com m unicate w ith  surrounding  
cells and interact w ith the extracellular m atrix (ECM1). W ithin their local environm ent 
they experience com plex m ixtures of com pounds and substrates, including growth  
factors, horm ones, vitam ins, organic constituents and their m etabolic products. 
These cellular cues and the nature o f the ECM offer a highly dynam ic setting for cells. 
To m aintain a healthy phenotype and avert m alignant cell growth, cells require strict 
regulation o f cell growth, -division and -death, p rocesses in w hich nuclear receptors 
(NR) play an im portant role. In fact, dysfunction o f NR can lead to uncontrolled  
proliferation and cell survival, allow ing for cancer developm ent.
The NR family o f ligand-inducible transcription factors recognize a diversity of 
ligands, including horm ones (e.g. estrogens, corticosteroids and androgens), vitam ins 
(e.g. vitam in A and D) and m etabolic products (e.g. fatty acids, eicosanoid  derivatives 
and oxidized lipids) [1]. In m en 48 family m em bers have been  described that all share 
com m on functional domains: they contain an am ino-term inal transactivation domain, 
a DNA binding dom ain (DBD) and a carboxy-term inal ligand-binding dom ain [2-4]. 
Based on their m ode o f action NR are divided into tw o main subclasses. Type I NR 
com prise the steroid  receptors, including the Estrogen Receptor (ER), Progesterone 
Receptor (PR), Androgen Receptor (AR) and Glucocorticoid Receptor (GR). Steroid  
receptors are classically sequestered  in the cytoplasm  of cells by binding to heat 
shock proteins. Upon ligand binding, they hom odim erize and translocate to the 
nucleus w here they bind to specific DNA sequences. Binding to these DNA response  
elem ents w ill lead to recruitm ent o f coactivator com plexes ultim ately resulting in 
transcriptional activation o f the target gene. Type II NR consists o f  the Retinoid X 
Receptor (RXR) heterodim ers. W ell-known m em bers o f this class are the Retinoic 
Acid Receptor (RAR), peroxisom e proliferator-activated receptors (PPAR) and the 
Vitamin D Receptor (VDR). In contrast to type I NR, type II receptors generally reside 
in the nucleus in the absence o f ligand. They bind to their response elem ents and are 
often com plexed w ith  corepressor proteins. Upon ligand binding, conform ational 
changes occur, corepressor proteins are released, coactivators are recruited and 
transcription is initiated. (For review s, see  [2-6])
Pathways affected by both type I and type II NR signalling in cells include those  
involved in apoptosis, cell cycle regulation and grow th factor signalling. This has 
b een  particularly w ell-studied  in the developm ent and progression o f breast cancer 
[7], w here the type I NR ER and the type II NR RAR exert opposing effects on these
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pathways. Typically, estrogens are referred to as pro-tum ourigenic, displaying  
proliferative and anti-apoptotic effects via ER activation, w hereas RAR stim ulation  
by retinoids is considered anti-tum ourigenic, repressing cell growth w hile inducing  
differentiation an d /or apoptosis. These observations indicate that balancing the 
activity o f NR is o f major im portance in keeping a healthy cell phenotype. The effects 
of a particular NR ligand on a cell w ill thus n ot only depend  on its ow n concentration, 
the expression  levels o f its receptor and its coregulators, but also on the presence or 
absence o f other ligands, other NR and their coregulators. Indeed, NR coregulators, 
like the coactivators SRC-1 (steroid  receptor coactivator 1) and AIB1 (am plified in 
breast cancer-1 also know n as SRC3) and NR corepressors (NcoRs) play a key role 
in regulating the cell’s resp onse to NR ligands and have been  associated  w ith  breast 
cancer [7, 8]. They play a central role in NR crosstalk, custom izing the effect o f NR to 
each target in relation to the local environm ent.
A protein term ed dendritic cell-specific transcript (DC-SCRIPT or ZNF366) 
w as first described in 20 0 6  and recently show n to act as a coregulator o f m ultiple 
NR [9]. DC-SCRIPT is a highly conserved  protein [10, 11] originally identified  in a 
unique im m une cell subset, the antigen presenting dendritic cells (DC) [12]. The DC- 
SCRIPT protein consists o f an N-terminal proline-rich region, 11 Cys2His2-type zinc 
fingers and a C-terminal acidic region. Beyond its zinc fingers, it shares no hom ology  
w ith proteins alike and has a restricted expression pattern, including epithelial 
cells. Remarkably, DC-SCRIPT could regulate the activity o f several subclasses  
of NR. DC-SCRIPT overexpression inhibited the activity o f ER and PR, know n for 
their proliferative and anti-apoptotic activities in breast cancer cells. In contrast, 
the transcriptional activities o f RAR/RXR and PPAR/RXR, m ostly know n for their 
anti-proliferative and pro-apoptotic effects in breast cancer cells, w ere enhanced  
by DC-SCRIPT. In this review, w e w ill focus on NR crosstalk and DC-SCRIPT. The 
im portance o f balancing NR activity in breast cancer developm ent and prognosis 
w ill be discussed.
Nuclear Receptor Coregulators
Balancing NR activity is o f major im portance in keeping a healthy cell phenotype. 
It is becom ing m ore and m ore apparent that the com position o f NR coregulator 
com plexes is crucial for m aintaining this balance, as these com plexes are essential 
for appropriate NR resp onses to ligands and other extra- and intracellular signals. 
Coregulator com plexes are involved in m ultiple transcriptional processes such as 
catalyzing the process o f chrom atin condensation and facilitating the com m unication
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w ith the general transcription apparatus at target gene prom oters [13]. Coregulators 
are classically divided into coactivators know n to enhance NR-mediated transcription  
and corepressors that dam pen the agonistic effect o f NR ligands. Coactivator 
proteins can be present in three different m ultiprotein com plexes, i) in the SWI/SNF 
com plex that is associated  w ith  ATP-dependent alteration in chrom atin structure, 
ii) in the p160/C B P com plex w hich is m ostly related to h istone acetylation and iii) 
in the m ediator com plex w hich is involved in the activation o f RNA polym erase II 
and the initiation o f transcription. Conversely, corepressors can inhibit NR-mediated  
transcription by interfering w ith  the access o f coactivators or by associating with  
HDAC (histone deacetylase) com plexes that repress transcription by catalyzing 
the condensation o f chromatin. Initially it w as thought that corepressors and 
coactivators reside in d istinct protein com plexes. However, current studies 
im ply that th ese  m olecules can ex ist in the sam e large com plexes suggesting that 
transcription repression  and activation are m ore closely integrated than initially  
su ggested  [14, 15]. Depending upon cell and signalling context, coactivators and 
corepressors can on occasion sw itch roles [16-19]. Evidence indicates that the 
operational definition b etw een  repressors and activators can be m odified by gene, 
cell, and signalling context for any one coregulator. Posttranslational m odification  
is an im portant m ode o f regulation. Phosphorylation, acetylation, ubiquitination, 
m ethylation an d /or sum oylation o f NR but also o f their coregulators have been  
reported to regulate the assembly, d issociation  and the content o f the regulatory  
protein com plexes. These m odifications allow  for the dynam ic m odulation and 
integration o f extracellular signalling pathways that w ill ultim ately enhance or 
decrease the transcriptional efficacy o f  NR-cofactor containing com plexes [13, 20]. 
The com plex netw ork o f coactivators and corepressors thus provides a balanced  
and sensitive control m echanism  to regulate NR target gen e expression.
A major b oost in understanding NR function has been  obtained by the 
introduction o f genom e w ide ChIP (Chromatin Im m unoPrecipitation) technology. 
This technique enables the identification o f specific transcription factors and  
the kinetics o f cofactor recruitm ent to a specific locus. The order o f recruitm ent, 
inform ation on the local chrom atin structure and the ep igenetic state can also  
be determ ined. Especially the ERa-m ediated transcriptional regulation has 
b een  elucidated by the use o f m ultiple ChIP profiling studies. Excellent review s  
detailing the recent advances in the identification o f the ERa-binding sites, their 
target gene netw ork and clinical applications can be found elsew h ere [21, 22]. A 
perfect exam ple for the identification o f  n ew  factors involved in ER transcriptional
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regulation using these n ew  techniques is the FoxA1 protein. FoxA1 is involved in 
ERa m ediated transcriptional regulation by acting as a p ioneer factor. Through its 
chrom atin-rem odelling activity, FoxA1 allows for the opening o f  genom ic regions in 
the absence o f horm one [23-26]. FoxA1 binds DNA adjacent to response elem ents  
for ER, thereby facilitating the local recruitm ent o f ER [27]. FOXA1/ER binding sites  
are often located in distal enhancers far from the transcription start site o f target 
genes. Gene transcription thus requires chrom atin looping to allow  physical contact 
b etw een  the protein com plexes b inding to the enhancer and the proxim al prom oter 
[27, 28]. Recently, FoxA1 binding w as suggested  to be required but n ot sufficient to 
trigger functional activity o f a given (cis)-regulatory region [29]. The cellular and 
physiological context co-determ ines w hether FoxA1-bound enhancers are active 
or inactive [29]. The num ber o f ER binding sites in MCF-7 cells identified  by ChIP 
that do contain a FOXA1 m otif has variably b een  estim ated  from less than 10%  to 
approxim ately halve o f the ER binding sites [23-26, 28, 30, 31]. The im portant role 
of FoxA1 in NR regulation is further em phasized  by the finding that also AR activity  
is regulated by this p ioneer factor [32, 33].
Functional impact of NR activation
NR activation induces a plethora of different proteins that take part in distinct 
biological pathways. Dysfunction o f NR an d /or their coregulators m ay affect one or 
m ore of th ese  pathways and can lead to uncontrolled proliferation and cell survival, 
allow ing for cancer developm ent. Dom inant pathways affected by NR in oncogenic 
cells include the apoptosis pathway, cell cycle regulation and growth factor 
signalling. These pathways have b een  particularly w ell studied  in the developm ent 
and progression o f breast cancer, w here the type I NR ER and the type II NR RAR 
exert opposing effects.
Estrogens proliferative effects are held  to be responsible for its role as a causative 
agent in breast cancer [34]. In the breast cancer cell line MCF-7, ERa induces the 
Gt- to S-phase transition, accelerating cell proliferation [35]. This is driven by the 
increased  activity o f the ERa responsive cell cycle-related genes c-myc, cyclin D1 
(CCND1), cyclin E1 (CCNE1) and E2 (CCNE2) [25, 34, 36]. siRNA m ediated  knock­
dow n o f either CCND1, CCNE1 or CCNE2 abrogates estrogen  induced proliferation in 
breast cancer cells [34]. Repressive cell cycle-regulators such as cyclin G2 (CCNG2) 
are also affected by ERa activation. Binding o f ERa to the CCNG2 prom oter initiates  
corepressor recruitm ent, negatively regulating expression  o f CCNG2 [37]. A potent
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feed forward loop has been  reported for the autocrine protein trefoil factor-1 (TFF1), 
a direct ERa target. TFFs are overexpressed  in several solid  tum ours including  
breast. They function in w ound  healing, w here they prom ote m igration and prevent 
apoptosis [38]. Forced TFF1 expression in MCF-7 and T47D breast cancer cells 
w as associated  w ith  up-regulation o f c-myc, CCND1 and CCNE1, and resu lted  in 
increased  proliferation and survival, as w ell as enhanced m igration and m etastatic  
properties. Enhanced expression o f several cyclins and c-myc also occurs through  
the Insulin-Like Growth Factor-1 (IGF-1) receptor system  [36] know n to stim ulate 
breast cancer m itosis, anti-apoptosis and m etastasis. ERa is critical in the activation  
o f this pathway, inducing expression  o f several IGF-1 family m em bers [39, 40]. Re­
expression  o f ERa in ER-negative MCF-7 breast cancer cell sub-lines also reactivated  
the IGF-1 pathway, w hich could be reversed w ith  ERa antagonists [41]. IGF-1R/ERa 
crosstalk  is also bi-directional, as IGF-1 induces transcriptional activity o f ERa and 
increases expression  o f estrogen-inducible genes. In hum an breast cancer cells ERa 
activity could be blocked w ith  IGF-binding protein-1 [42]. In addition, stim ulating  
MCF-7 cells w ith estrogens rapidly induces IGF-IR, EGFR and MAPK activation  
through non-genom ic ER signalling. EGF-R was was dem onstrated to act in a linear 
sequence dow nstream  o f the IGF-R pathway. Blocking this pathway dim inished  
estrogen  induced m itogenic and anti-apoptotic effects [43]. Furthermore, estrogens 
are p otent apoptosis inhibitors, in contrast to anti-estrogens that have a profound  
pro-apoptotic effect. ERa enhances the expression  o f several anti-apoptotic genes, 
including Bcl-2 and BclxL [44]. Moreover, the before-m entioned increased TFF1 
expression  also dow nregulates the pro-apoptotic genes BBC3 (PUMA) and MDM2 
[45].
W hile ERa skew s cancer cells towards highly proliferative and apoptosis resistant 
tum our cells, RAR is typically referred to as tum our suppressive. Remarkably, ER 
and RAR counteract each other in cell cycle control and apoptosis pathways. In 
v itro  studies have dem onstrated that RAR ligands effectively repress proliferation  
in norm al epithelial cells and ER positive breast cancer cells through G1 cell cycle 
arrest, associated  w ith  reduced cyclin D1 and -D3 expression  [46]. Additionally, 
retinoic acid (RA) triggers cell cycle arrest through im m ediate early RAR targets 
including the cell cycle regulator Btg-2. Induction o f Btg-2 by RA was accom panied  
by a m arked decrease in cyclin D1 expression, ham pering Gt- to S-phase transition  
[47]. Apart from cell cycle regulation, RAR also counteracts ER function in the 
apoptotic pathway. The anti-apoptotic protein Bcl-2 w as clearly downregulated  
in RA induced apoptotic cells, as was survivin, another suppressor o f apoptosis
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[48, 49]. In addition, RA-induced apoptosis in MCF-7 cells w as associated  w ith  an 
increased  expression  o f several pro-apoptotic genes including caspase 7 and 9. 
Opposite to caspase 7, caspase 9 harbors a retinoic acid response elem en t (RARE) 
and transcription is depended on RAR activation [50].
It is clear from th ese  functional studies that ER and RAR use sim ilar pathways and 
even genes to exert opposite effects. In m any studies breast cancer cells are usually  
treated w ith  single ligands. Since physiologically cells are constantly triggered by  
m ultiple NR ligands, crosstalk  b etw een  NR is inevitable. We n eed  to learn much  
m ore about the physiological settings in which m ultiple NR ligands are around to 
determ ine the effect o f their copresence on cell growth, -division and -d ea th  and the 
consequences for epithelial cell behaviour and breast cancer aetiology.
Crosstalk of ER & RAR at the Nuclear Receptor level
Crosstalk o f NR has been  su ggested  for years and m ay involve different steps 
in the pathway [3]. NR can share or com pete for ligands, DNA response elem ents, 
or binding partners. They can also regulate the expression o f other NR or behave 
as coregulators. Moreover, target gene products o f a certain NR m ay affect the 
functionality or b iosynthesis o f other NR ligands. The consequences o f crosstalk  
is that the expression  o f given se t of target genes expected  to be regulated by a 
given signalling pathway, is in fact dependent on the functioning of other signalling  
pathways [51]. Crosstalk b etw een  different pathways w ill ultim ately lead to an 
appropriate resp onse o f cells in a certain condition.
In breast cancer research the crosstalk  b etw een  RAR and ER has recently regained  
increasing attention. It is know n for long that estrogens can induce RAR expression  
[52, 53], w hereas RA induced RAR stim ulation in breast cancer cells correlates with  
the decreased  ERa expression [54]. In addition it has b een  show n that ER repressed  
the transcriptional activity o f RAR/RXR m ediated  transcription and this could be 
overcom e by the addition o f RA [55]. Recently, three relevant research papers were  
published that provide novel insight in the m echanism  o f crosstalk b etw een  ER and 
RAR in breast cancer cells [9, 56, 57].
Hua and colleagues [56] analyzed the genom ic actions o f  RA signalling through  
RAR in MCF-7 breast cancer cells. By genom e-w ide m apping o f RAR binding sites 
the authors found that RA signalling regulates the expression  o f m any gen es that are 
im plicated in breast carcinogenesis. They also found extensive colocalization o f RAR 
w ith ER DNA binding sites in the vicinity o f genes that are antagonistically regulated
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by estrogen  and RA. The majority o f RAR binding sites w ere found in intronic or 
prom oter-distal intergenic regions. As m any ER and RAR binding sites appeared  
as neighbouring or even (partially) overlapping elem ents, the authors propose  
NR com petition for the sam e closely spaced binding elem en t as one m echanism  
for the antagonistic regulation o f th ese  gen es upon RA treatm ent. Moreover, they  
dem onstrated that FoxA1 and GATA3 binding coincided w ith  RAR and ER binding, 
indicating that these transcription factors m ay also play an im portant role by  
coregulating ER and RAR on shared ER/RAR-binding elem ents. Hua et al. [56], 
postu late that ER and RAR are the “Yin and Yang” for the genetic regulation of 
proliferation and survival that are prom oted by ER and inhibited by RARs. The ER/ 
RAR antagonism  appears to regulate itse lf  through cross regulatory loops betw een  
ER, RARs and their cofactors. This balanced control o f gen e expression  regulates 
fundam ental cellular processes that w hen dysregulated can lead to cancer [56].
R oss-innes and colleagues [57] also m apped the RAR-binding events in MCF-7 
and did this in the presence o f the ER-ligand estrogen  instead  o f  RA. Moreover, these  
authors w ere the first to succeed  in m apping the endogenous RAR-binding events. 
Their data dem onstrated that RAR and ER can be part o f the sam e transcriptional 
com plex. Using Re-ChIp and co-im m unoprecipitation experim ents they sh ow  that 
RAR/ER co-occupancy does occur in a cooperative m anner in the presence of 
estrogen. Analysis o f the genom ic location o f the RAR binding events revealed that 
m ost binding events o f RAR occurred in intergenic regions. However, RAR could also 
bind to ER-binding regions and depended  in half o f th ese  sites on the presence o f ER. 
In contrast, ER binding to chrom atin w as in dependent o f the presence o f RAR; RAR 
rather functioned as a scaffold in the ER com plex for m aintaining cofactor interactions. 
Upon addition o f RA, the estrogen-E R-dependent role for RAR could be inhibited  
and could have antagonistic effects on ER transcriptional activity similar to as w hat 
has been  described by Hua e t  al. [56]. ChIP analysis o f horm one-depleted  MCF-7 
cells revealed that in estrogen  treated cells the co-presence o f RA did n ot perturb  
binding o f  either receptor. The co-presence o f RA rather dim inished the am ount of 
the cofactors p 300  and TRAP220 that are essentia l for effective transcription at ER/ 
RAR regulated genes. The authors postu late tw o in dependent functions for RAR. In 
resp onse to natural ligands such as RA it exerts its classical role as heterodim eric  
partner o f  RXR w hile during estrogen  treatm ent it can function as an ER-associated  
protein required for m aintaining cofactor interactions. Therefore, any shift betw een  
the classic and novel pathways m ay influence ER function in breast cancer cells. RA 
prom otes the classic role o f RAR at the cost o f Estrogen-ER function [57].
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The recen t identification of a novel NR m odulator, te rm ed  DC-SCRIPT, suggest 
th a t ER/RAR crosstalk  m ight n o t only take place a t the NR level, b u t also on the 
coregulator level. The 11 zinc fingers containing p ro tein  DC-SCRIPT also contains 
a functional CtBP1 binding m otif [10] and a putative LxxLL NR in teraction  motif. It 
has been show n th a t DC-SCRIPT can in terac t w ith m ultiple transcrip tion  regulatory 
proteins such as CtBP1, RIP140 and HDAC1, 3 and 6, suggesting th a t DC-SCRIPT is 
p resen t in very large m ultiprotein  complexes know n to be involved in NR regulation 
[9, 58-60]. DC-SCRIPT was show n to in terac t w ith m ultiple NR, including ER and 
RAR. DC-SCRIPT was able to rep ress transcrip tion  m ediated  by ER and surprisingly 
enhanced transcrip tion  m ediated  by RAR. Interestingly, exogenous DC-SCRIPT in 
MCF-7 was show n to opposingly regulate transcrip tion  m ediated  by m ultiple NR 
a t the sam e time. In the presence of m ultiple NR ligands, DC-SCRIPT was able, in 
a single cell, to rep ress transcrip tion  m ediated  by the type I NR PR and activate 
transcrip tion  m ediated  by the type II receptor RAR. To our knowledge, there  are 
currently  no coregulators know n th a t have such a distinct effect on type I and  type II 
m ediated  transcrip tion . So far, studies investigating crosstalk  betw een ER and  RAR 
have m ostly been perform ed in MCF-7. As this cell line and  all o ther cell lines tested  
so far are essentially negative for DC-SCRIPT, in con trast to b reast epithelial cells, 
the  effect of DC-SCRIPT on the estrogen and  RA signalling pathw ays in b reast cancer 
cells rem ains to be investigated. This m ay shed novel insight into the crosstalk 
betw een ER and  RAR.
Collectively, these  novel data are indicative for the high level of complexity in 
transcrip tional crosstalk betw een ERa, RAR and DC-SCRIPT (see figure 1). Upon 
estrogen or RA stim ulation, the  corresponding NR can exert the ir classical role or 
behave as a coregulator or cofactor of the other. D epending on cellular context, 
expression levels of DC-SCRIPT, different NR and the ir coregulators and the 
presence or absence of (m ultiple) ligands, cells are skew ed to a certain  genetic 
program . Extensive crosstalk betw een NR is essential to enable cells to fine-tune 
the ir response and  prom ptly  adap t to different environm ental situations.
Nuclear receptors, coregulators and breast cancer prognosis
The incidence of b reast cancer is know n to be affected by the horm onal m ilieu 
b reast cells experience over time. Im portan t horm one-related  risk  factors for 
b reast cancer include early m enarche, nulliparity  or late age a t first b irth  and  late 
m enopause [61]. The type I horm one-inducible NR play an im portan t role in the 
tum ourigenesis of b reast cancer. B reast tum our tissue expressing the type I NR,
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RARE ERE
Figure 1. T ran scrip tiona l c ro ssta lk  b e tw een  DC-SCRIPT, RAR an d  ER
Hypothesized model of the induction of an estrogen and retinoid responsive gene. RAR and ER binding 
sites have been shown to be in close proximity. RAR can function as a scaffold for ER binding or can act in 
its more classical role as heterodim eric partner of RXR. FOXA1 acts as a pioneering factor for ER binding. 
Both coactivators and corepressors regulate RAR and ER function. DC-SCRIPT can exert a dual role in 
this regulation. It represses ER function, and stimulates RAR function. The available ligands present 
will induce the crosstalk between DC-SCRIPT, NR, its regulators/cofactors and will ultimately lead to an 
appropriate cell response.
ER a n d /o r  PR, exhibit a w ell-differentiated phenotype indicating a good prognosis 
for the patient. Large scale expression profiling studies to classify tum ours [62-64] 
confirm ed th a t ER/PR positive tum ours are distinct from o ther b reas t tum our types 
on the basis of the ir gene expression pattern  [63, 65-67]. W ithin the ER/PR positive 
tum ours, two distinct types could be distinguished show ing a different prognosis; 
the histologically low-grade lum inal A subtype and the m ore often high-grade 
lum inal B subtype [63, 65, 68]. These data show  the im portance of ER/PR status 
for prognosticating of b reast tum ours. In addition, ER/PR sta tus is predictive for 
tamoxifen sensitivity, a highly effective anti-estrogen trea tm en t for b reas t cancer 
patients [69, 70]. These findings em phasize the im portance of m olecular signatures 
b u t also indicate th a t additional m arkers are needed to enhance the understanding  
of b reast cancer etiology and improve prognosis and trea tm en t selection.
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Besides the type I NR, also type II NR have clinical im plications in b reast cancer. 
Both low  vitam in D ingestion and  low  circulating 25-hydroxyvitam in D3 levels are 
associated w ith increased b reast cancer risk, indicating a protective role of the 
type II NR VDR in b reast cancer tum ourigenesis [71]. RARa mRNA expression has 
recently  show n to be associated w ith a good prognosis in endocrine trea ted  b reast 
cancer patien ts [57]. Moreover, Hua e t al. [56] w ere able to define a RA-induced gene 
expression profile associated w ith a favourable prognosis. Furtherm ore, increased 
expression of ano ther type II NR, PPARy, in the  prim ary  tum our also correlated 
w ith im proved survival [72]. Collectively, these  data imply th a t through their 
anti-proliferative and  pro-apoptotic effects the type II NR and  the ir ta rg e t genes 
are correlated  w ith a positive clinical outcome. Currently, no adjuvant trea tm en ts 
directed  a t type II NR are routinely available for b reast cancer. Stim ulation of the  NR 
RAR/RXR and PPAR/RXR has been explored [73, 74] and  synthetic RAR ligands have 
been show n to reduce second b reast cancers [75]. However, so far efficacy has been 
lim ited because of retinoic acid resistance acquired during cancer developm ent 
[76, 77]. Therefore, the  effect of RA in oncology has so far been limited. The only 
successful application of RA trea tm en t is in APL (Acute prom yelocytic leukemia) 
patien ts [78] w here it drives cell differentiation. W hether RA has a sim ilar effect in 
b reast cancer cells is no t known.
C onsistent w ith the finding th a t both  type I and  type II NR function are dependent 
on coregulators, several groups have repo rted  th a t NR co-regulator function is highly 
relevant for prognosis and  endocrine therapy  sensitivity in b reast cancer as well [7, 
79]. A w ell-studied example w ith relevance to b reast cancer is the  ER coactivator 
Amplified in B reast Cancer-1 (AIB1 or SRC3 [80]). O verexpression of AIB1 results 
in increased ER activity and  is generally associated w ith a poor prognosis in b reast 
cancer [81-83]. Some studies, however, do find a relation betw een AIB1 and a good 
prognosis [84, 85]. As AIB1, like o ther coactivators, is positively correlated  w ith 
ER status [86] it  m ight be indirectly associated w ith a good prognosis through 
association w ith the ER-positive lum inal subtype of b reast cancer. Possibly, w ithin 
this ER-positive lum inal subtype, ER coactivators m ight be associated w ith a 
relatively poor prognosis [87]. The am bivalent prognostic value of AIB1 in b reast 
cancer m ight thus be explained by the fact th a t these  ER/PR positive patien ts 
are m ost often trea ted  w ith adjuvant tam oxifen and th a t AIB1 is associated w ith 
tam oxifen resistance [82, 85]. Furtherm ore, coexpression of grow th factor receptors 
[82, 85] or the subcellular localization of AIB1 [84] has been suggested to affect its 
prognostic value in b reast cancer. Other cofactors th a t play a critical role in horm onal
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signalling, including the coactivators FOXA1 and  GATA3, appear to be m arkers 
of luminal A b reast cancers. Expression of these factors has show n to be related  
to good prognosis and  to endocrine therapy  sensitivity [88]. A nother coactivator 
w hose function in determ ining b reast cancer prognosis is unclear, is stero id  receptor 
coactivator 1 (SRC1 or NCOA1). SRC1 was originally described as denoting a good 
response to tamoxifen trea tm en t [89], then  found to be associated w ith poor survival 
and  poor response to tam oxifen [87, 90, 91]. More recently  it  has been found again 
to be associated w ith a good prognosis [86]. For SRC1, the  coexpression of other 
transcrip tion  factors such as Ets-1 and Ets-2 m ight be im portan t in determ ining 
its effect on prognosis [87, 91]. Corepressors like NR corepressor 1 (NCOR1) and 
-2 (NCOR2 or SMRT) w ere also found to be associated w ith a good response to 
tam oxifen [87, 91, 92], although these studies did n o t include a non-trea ted  cohort 
to distinguish a prognostic from predictive biomarker. Conversely, NCOR2 has also 
been show n to be associated w ith poor survival in a large b reast cancer cohort [86].
Approxim ately 300 coregulators have now  been identified, of which a t least 
165 have so far been directly associated w ith hum an diseases [33, 93, 94]. It will be 
im portan t to fu rther delineate the positive or negative effects on the transcrip tion  
factor pathw ays involved. Of note, m any coregulators are able to bind to, and  regulate, 
both  type I and type II NR [15]. Remarkably, m ost -if no t all- coregulators have either 
a stim ulatory  or inhibitory effect on both  type I and type II NR, w ith the notable 
exception of the newly discovered NR coregulator DC-SCRIPT [9]. DC-SCRIPT acts 
as a unique coregulator of m ultiple NR having opposite effects on type I vs type II 
NR. Recently, Ansems and  colleagues [9] evaluated DC-SCRIPT expression in b reast 
tissue and  show ed th a t DC-SCRIPT is expressed in b reast ductal epithelial cells. In 
addition it  was dem onstrated  th a t b reast tum ours expressed low er levels of DC- 
SCRIPT than  norm al b reast tissue from  the sam e patient. Moreover, quantification 
of DC-SCRIPT mRNA expression in th ree  cohorts of b reast cancer pa tien ts revealed 
th a t DC-SCRIPT mRNA expression is an independen t prognostic factor for good 
survival for b reast cancer patien ts w ith ER- a n d /o r  PR-positive tum ours [9]. The 
prognostic significance was m aintained in a cohort of tam oxifen trea ted  patients. 
Together w ith our finding th a t DC-SCRIPT inhibits cell grow th of b reast carcinom a 
cells our data  suggests th a t DC-SCRIPT can act as a tum our suppressor in b reast 
cancer developm ent (see figure 2). This m akes DC-SCRIPT an attractive ta rg e t for 
NR coregulator specific therapy  for either b reast cancer prevention or adjuvant 
therapy.
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Normal situation
Type I NR Type II NR
Anti-proliferation: 
CCND1/D3-, Btg2+ 
Pro-apoptosis : 
Bcl-2-, Survivin-, 
Caspase 7/9+
Pro-proliferation: 
C-Myc+, CCND1/E1/E2+, 
CCNG2-
Anti-Apoptosis :
Bcl-2+, BclxL+
DC-SCRIPT
high
■ V “
PPARy
RAR
Malignant Transformation & Tumor Progression
PPARy
RAR
DC-SCRIPT
PPARy
r a rER
d c-s c r ip t
dim
Bad prognosis Good prognosis
Figure 2. Balance of N uclear R eceptor function  by DC-SCRIPT expression
Hypothesized model of DC-SCRIPT function in ER+ breast epithelial cells. DC-SCRIPT represses the 
activity of the pro-tumourigenic type I NR ERa and PR and conversely enhances the anti-tumourigenic 
type II NR PPARy and RARa, thereby actively regulating the NR balance. During m alignant transform ation 
and tum our progression, higher DC-SCRIPT expression leads to a more balanced NR function resulting 
in a better prognosis, whereas low expression of DC-SCRIPT results in an imbalance in NR function and 
to a bad prognosis.
Future perspectives
Molecular and functional studies on individual NR are a t the forefront of life 
science research. They have led to novel insights into genom e-wide transcrip tion  
factor binding patterns and gene regulation. An em erging challenge is to unravel how  
NR family m em bers act in concert to regulate complex cellular processes in tissues 
w here m ultiple NR ligands are present. The examples presen ted  in this review, the 
crosstalk betw een ER and RAR and the action of the recently identified bi-functional 
transcrip tion  m odulator DC-SCRIPT, only provide initial insights in these processes. 
It will be in teresting  to fu rther unravel both  the genomic as well as non-genomic 
effects of NR on cellular behaviour and how  they relate to m alignant transform ation. 
Regarding its function as a type I and type II NR coregulator and its prognostic 
relevance in b reast cancer, it will be rew arding to investigate the im pact of DC-
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SCRIPT and  ER/RAR crosstalk in o ther horm one sensitive tum ours like p rosta te  and 
endom etrium  cancer. An im portan t question th a t rem ains to be answ ered is how  DC- 
SCRIPT genotype and  expression levels will affect the cell's response to horm ones, 
vitam ins and m etabolites and  w hether DC-SCRIPT m alfunction is sufficient to act as 
a prim ing event in m alignant transform ation.
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D
endritic cells (DC) are the professional antigen presen ting  cells of the 
im m une system  and  p roper function of DCs is crucial in eliciting an 
effective im m une response. Molecular understand ing  of DC biology will 
lead to m ore rational design of DC based  im m unotherapies for cancer patients 
and is vital for optim al clinical applications in vaccination settings. Over the years 
m any pro teins have been identified to be expressed by DCs. DC-SCRIPT (DC Specific 
transCRIPT) is one such molecule. Previously, its mRNA was found to be expressed 
by all DC subsets tested. In the cu rren t thesis we have applied a m ultidisciplinary 
approach to gain fu rther insight into the function of DC-SCRIPT. We have show n tha t 
DC-SCRIPT is a very versatile p ro tein  im portan t in DC biology and  we dem onstrated  
th a t its functionality extends beyond the  im m une system. DC-SCRIPT is also an 
im portan t factor in b reast and p rosta te  cancer. In this chapter our findings and 
potential im plications are fu rther discussed.
DC-SCRIPT
Human DC-SCRIPT mRNA was first discovered in 2006 and  is encoded by the 
ZN F366  gene. DC-SCRIPT was found to be expressed by hum an DCs, w hereas no 
expression was detected  in o ther cells of the  im m une system  [1]. Also in mice its 
expression in the im m une system  is restric ted  to DCs [2]. The ZNF366  gene is highly 
conserved betw een  species. The Fugu ru b r ip es  am ino acid sequence show s 58% 
identity  [3] and  the m ouse hom ologue of DC-SCRIPT is 80%  hom ologous to the 
hum an coun terpart [2]. The pred icted  am ino acid sequence of DC-SCRIPT contains 
an N-term inal proline-rich part, 11 zinc fingers and  an acidic region. Zinc fingers are 
know n motifs for DNA, RNA and  p ro tein  binding, while the acidic region contains a 
m otif th a t can in terac t w ith CtBP1 (C-terminal-Binding Protein-1), a global repressor 
of transcrip tion  [4]. Proline-rich and  acidic regions are know n to be directly involved 
in transcrip tion  by m ediating binding to o ther regulatory  proteins. Therefore, it 
has been suggested th a t DC-SCRIPT may function as a transcrip tion  factor [1]. In 
addition to the CtBP1 binding motif, DC-SCRIPT also contains a putative NR (nuclear 
receptor) interaction  motif.
DC-SCRIPT and nuclear receptors
It has previously been show n th a t DC-SCRIPT can in terac t w ith m ultiple 
transcrip tion  regulatory  pro teins such as CtBP1, RIP140 (Receptor interacting 
pro tein  140) and HDAC1, 3 and  6 (Histone Deacetylases). This suggests th a t DC-
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SCRIPT is p resen t in very large m ultiprotein  complexes know n to be involved in 
NR regulation [1, 4-6]. In this thesis, we extensively investigated the physical and 
functional in teraction  of DC-SCRIPT w ith different subclasses of NRs.
In chapter 3 and  5 we dem onstrate  th a t DC-SCRIPT can in terac t w ith the type 
I NRs, ER (Estrogen Receptor), PR (Progesterone Receptor) and  AR (Androgen 
Receptor) and  the type II NRs PPAR (Peroxisome Proliferator-activator Receptor), 
RAR (Retinoic Acid Receptor) and VDR (Vitamin D3 Receptor). Yeast-2-hybrid 
assays imply that, unlike binding to CtBP1, DC-SCRIPT does n o t b ind directly to NRs. 
The in teraction  is instead  m ediated  via o ther pro teins p resen t in these large protein 
complexes. Collectively, the  pro teins p resen t in these complexes tightly regulate the 
function of NRs, either activating or repressing  NR m ediated  transcrip tion . While 
m ost co-regulators have a distinct activating or repressing  function, co-repressors 
and  co-activators can occasionally sw itch roles, depending on the prom oter context 
[7-9]. Interestingly, we have show n th a t DC-SCRIPT is also a NR co-regulator having 
both  repressing  and  activating capabilities. T ranscription m ediated  by the type I NRs 
was inhibited by DC-SCRIPT, while the activity of the type II NRs was enhanced by 
DC-SCRIPT. Remarkably, although several co-regulators exist th a t have a dual effect 
on NR function, to our knowledge there  are currently  no co-regulators know n to 
have such a distinct effect on type I and  type II NR m ediated  transcription. The exact 
m echanism  by which DC-SCRIPT specifically m odulates type I and II NR activity is 
currently  unknow n and rem ains to be determ ined.
The presence of DC-SCRIPT in distinct transcrip tional complexes as well as its 
unique role as co-activator and co-repressor of different types of NRs implies th a t 
it  plays a fundam ental role in transcrip tional regulation (Figure 1). In chapter 6 
we review ed the complex crosstalk betw een ER, RAR and  DC-SCRIPT. However, to 
fully appreciate the regulatory  function of DC-SCRIPT on m ultiple type I and  II NRs, 
it  is of g rea t im portance to understand  the natu re  of the m olecular and  biological 
m echanism  responsible for the co-repressor versus co-activator activity of DC- 
SCRIPT
Repression and  activation of the  transcrip tion  of NR ta rg e t genes can be 
m ediated  via different m echanism s. Repression of transcrip tion  can be m ediated  
by co-repressor proteins th a t in terfere  w ith the access of co-activators to the  DNA. 
A nother possible m echanism  is the association of co-repressor pro teins w ith HDAC 
complexes th a t rep ress transcrip tion  by catalyzing the condensation of chrom atin 
[10, 11]. Interestingly, DC-SCRIPT has been show n to in terac t w ith m ultiple 
HDACs and the  global co-repressor p ro tein  CtBP1 [1, 5]. As HDACs are involved in
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Figure 1. H ypothetical m odel of th e  dual function  of DC-SCRIPT on NR m ed ia ted  tran sc rip tio n
Classically the type I NRs are sequestered in the cytoplasm by binding to chaperone proteins. Upon 
ligand binding the chaperone proteins dissociate, the NRs homodimerize, translocate to the nucleus 
and bind to their response elements. In the presence of DC-SCRIPT, transcription mediated by the type 
I NRs is repressed by the recruitm ent of HDACs and other co-repressor proteins. In the absence of their 
corresponding ligand, type II NRs bind to their response elements in the nucleus of the cells. In the 
presence of ligand, co-activator complexes are recruited facilitating transcription of their target genes. 
Upon expression of DC-SCRIPT transcription mediated by the type II NRs in enhanced. DC-SCRIPT can 
also possibly exert nongenomic actions. Although DC-SCRIPT is predominantly localized in the nucleus, 
its expression has also been detected in the cytoplasm of cells.
the condensation of the chrom atin th a t results in the inhibition of transcription, 
recru itm ent of these HDACs by DC-SCRIPT may be the explanation for its repressive 
effect on type I NRs. O ther m echanism s by which DC-SCRIPT may repress NR function 
include decreasing NR stability and interference w ith the translocation  of NRs from 
the cytoplasm  to the nucleus. Pilot experim ents show  th a t DC-SCRIPT expression 
does no t influence AR stability; how ever the effect of DC-SCRIPT expression on the 
stability of o ther NRs requires fu rther investigation. Interestingly, despite its nuclear 
localization motif, DC-SCRIPT expression in epithelial cells is not confined to the 
nucleus. In frozen p rosta te  carcinom a sections, DC-SCRIPT expression was mainly
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detected  in the cytoplasm  of the basal epithelial cells, w hereas DC-SCRIPT in the 
DCs p resen t in the  sam e section was predom inantly  localized to the nucleus. As 
NRs are also know n to shuttle  betw een the nucleus and cytoplasm, it  will be very 
in teresting  to investigate how  the localization of DC-SCRIPT affects NR localization 
and  subsequently  its function. Therefore, ongoing studies are aim ed a t studying DC- 
SCRIPT localization and the effect of this on the translocation  of NRs.
Further insight into the role of DC-SCRIPT as NR co-activator may be gained by 
studies focussing on the  identification of additional interacting  pa rtn e rs  in the  type II 
NR pro tein  complex. Based on the ir function, NR co-activators can be categorized to 
be p resen t in th ree  distinct m ultiprotein  complexes. 1) The SWI/SNF complex which 
is associated w ith ATP-dependent alteration  in chrom atin structure, 2) the p 1 6 0 / 
CBP complex, prim arily  re la ted  to histone acetylation and  3) the m ediator complex, 
involved in the  activation of RNA polym erase II and initiation of transcrip tion  [12, 
13]. The identification of additional in teracting pa rtn e rs  of DC-SCRIPT will shed 
m ore light on the m echanism  DC-SCRIPT utilizes to activate type II NR m ediated  
transcrip tion . The m ajor difference betw een  the type I and  type II NRs is th a t the 
type II NRs form heterodim ers w ith RXR, w hereas the  type I NRs do not. More 
com prehensive investigation of the in teraction betw een DC-SCRIPT and RXR may 
reveal novel insights into DC-SCRIPT’s activating and  repressing  capacities.
In this thesis, we have show n th a t DC-SCRIPT is p resen t in p ro tein  complexes 
containing different NRs and  th a t it  can regulate transcrip tion  of NR ta rg e t genes. 
Interestingly, prelim inary data  show  th a t DC-SCRIPT is also able to b ind directly 
to DNA (unpublished data, V. Triantis). Therefore, one may hypothesize th a t DC- 
SCRIPT m ay no t only affect gene transcrip tion  as p a r t of the  large NR protein 
complexes b u t m ay also directly influence transcrip tion  by acting as a cofactor by 
binding to prom oter regions of ta rg e t genes. Using genom e w ide ChIP (Chromatin 
Im m unoPrecipitation) DC-SCRIPT binding sites could be m apped and d irect targets 
of DC-SCRIPT can be identified. Furtherm ore, it  can then  be investigated as to 
w hether DC-SCRIPT binding coincides w ith NR binding or w hether DC-SCRIPT also 
has independen t targets.
T ranscription factors and  the ir co-regulators are im portan t pro teins in 
regulating gene expression. T ight regulation of the function of these factors is 
extrem ely im portan t for all biological processes in a cell. An im portan t m ode of 
regulation of protein  function is by post-translational m odifications (PTM), such 
as phosphorylation, acetylation, ubiquitination, m ethylation a n d /o r  sumoylation. 
These m odifications have been rep o rted  to regulate the  assembly, dissociation and
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conten t of regulatory  protein  complexes. PTMs allow for the dynam ic m odulation 
and in tegration of extracellular signalling pathw ays th a t will ultim ately enhance 
or decrease transcrip tion  of specific ta rg e t genes [14, 15]. Since DC-SCRIPT is an 
im portan t regulator of NR function, it  is of u tm ost im portance to investigate w hether 
the  function of DC-SCRIPT is also affected by PTM. Interestingly, bioinform atics data 
and prelim inary experim ental data  indicate th a t the DC-SCRIPT pro tein  is subjected 
to extensive PTM, including sum oylation and  proteolytic cleavage of the  100 kD 
m ature  DC-SCRIPT pro tein  into 90 kD and 60 kD proteins. Furtherm ore, DC-SCRIPT 
has several p red icted  serine, th reonine and  tyrosine phosphorylation sites (h t tp : / /  
w w w .cbs.d tu .dk /serv ices/N etPhos/ [16]). Mass spectrom etry  analysis of DC- 
SCRIPT may fu rther validate and identify PTMs of DC-SCRIPT possibly regulating its 
function. U nderstanding DC-SCRIPT pro tein  m odification m ay shed novel light on 
its unique function as a NR m odulator
In addition to fu rther investigating the m olecular m odifications and cellular 
functions of DC-SCRIPT, there  is also a clear need  to intensify research connecting 
the various dom ains of DC-SCRIPT w ith specific cellular function. In light of the 
different p rotein  dom ains th a t are p resen t in DC-SCRIPT, it  m ay be hypothesized tha t 
these  distinct dom ains are involved in different functions of DC-SCRIPT. Prelim inary 
data  indeed  imply th a t the functional effects of DC-SCRIPT on different NRs depend 
on different dom ains of DC-SCRIPT. W hereas repression  of transcrip tion  m ediated  
by AR mainly depends on the presence of the proline rich region of DC-SCRIPT, 
repression  of ER m ediated  transcrip tion  requires the presence of all dom ains of DC- 
SCRIPT These results dem onstrate  th a t the repressing  capacity of DC-SCRIPT is no t 
due to a single dom ain of DC-SCRIPT. Similarly, a single dom ain of DC-SCRIPT cannot 
be a ttrib u ted  to its activating function on type II NR m ediated  transcription. While 
the  presence of the  acidic dom ain of DC-SCRIPT is essential for activation of RAR 
m ediated  transcrip tion, all dom ains of DC-SCRIPT are requ ired  for full activation of 
PPARy. These observations illustrate the  complexity of NR regulation by DC-SCRIPT 
and dem onstrate  th a t single dom ains of DC-SCRIPT cannot be broadly assigned to 
the activating or repressing  function of DC-SCRIPT. Apparently, regulation of NR 
function by DC-SCRIPT depends on m ultiple dom ains and possibly PTMs of the 
different domains. Further research  is necessary  to fully elucidate the  function of 
the various dom ains and connect them  to specific cellular functions of DC-SCRIPT
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DC-SCRIPT in the immune system
Only a few putative ‘m aster’ transcrip tional factors have been identified to be 
im portan t in DC developm ent [17]. Genetic analyses have identified f.e. IRF4, relB 
and  PU.1, to be crucial for the developm ent of specific DC subsets in lym phoid 
organs. The lineage fate of hem atopoietic progenitor cells is determ ined  by ordered  
expression ofvarious transcrip tion  factors and  recep to r tyrosine kinases such as Flt3. 
However, the m olecular steps involved in the developm ent of specific DC subtypes 
from  com m on precursors, including m onocytes are n o t com pletely defined. [18­
22]. In v itro , hum an m onocytic differentiation into DCs can be induced by IL-4 and 
GM-CSF [23]. Various cell populations have been dem onstrated  to synthesize these 
cytokines, including Th2 cells, natu ral killer cells and  m ast cells [24-26].
DC-SCRIPT has previously been dem onstra ted  to be an early hallm ark of DC 
differentiation from  m onocytes [1]. Interestingly, m any transcrip tion  factors w ith 
a profound role in haem atopoiesis and DC biology, including Gfi, GATA-1, AP-1, SPi
B, NF-kb and c-Rel, have a high probability  of binding in the  proxim al prom oter 
region of DC-SCRIPT which is consistent w ith a prom inen t role of DC-SCRIPT in 
DCs [2]. These reports  suggest an im portan t role for DC-SCRIPT in DC function and 
immunobiology. In chapter 2 we fu rther characterized the expression dynam ics of 
DC-SCRIPT in DCs. We characterized its protein  expression during DC differentiation 
and  m aturation  as well as in different DC subsets. In addition, we investigated the 
im portance of DC-SCRIPT expression on the m aturation  capacities of DC. Our data 
show  th a t DC-SCRIPT is expressed early upon differentiation of m onocytes into DC 
and  is dependen t on IL-4. The early expression of DC-SCRIPT upon differentiation 
im plies an im portant, yet unknow n function during DC differentiation. DC-SCRIPT 
rem ains p resen t a t both  the mRNA and  protein  level during the com plete DC life 
cycle. Environm ental stim uli such as horm ones and vitam ins can greatly influence 
DC differentiation and  m aturation  [27]. Of the 48 NRs p resen t in hum an, 20 are 
rep o rted  to be expressed by hum an m onocyte derived DCs, indicating th a t NRs 
are likely to have functions in the differentiation and  function of DCs [28]. NRs and 
the ir co-regulators are know n to shuttle betw een  the cytoplasm  and the nucleus. 
Interestingly, in chapter 2 we show  th a t DC-SCRIPT in DC can also be localized to 
different cellular com partm ents. DC-SCRIPT was m ainly localized to the  nucleus of 
m onocyte derived and  myeloid DCs, w hereas in pDC its localization varied  betw een 
donors. It will be very in teresting  to understand  the underlying basis for the 
differential subcellular localization. DC-SCRIPT localization in a specific subset of DCs 
from  a single donor was hom ogenous, how ever localization betw een donors varied,
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suggesting th a t specific environm ental conditions could account for a particular 
subcellular localization. It may also be speculated th a t DC-SCRIPT expression and 
localization are controlled by the circadian rhythm  as this is also know n to influence 
NR expression and  localization. The intrinsic rhythm ic production  of m any horm ones 
and m etabolites w ithin the endocrine system  is instrum ental in controlling regular 
physiological processes such as im m une responses [29] and  m any NRs exhibit 
circadian-like pa tte rns of expression [30]. Elucidation of the regulatory m echanism s 
for DC-SCRIPT localization in DCs by the circadian rhy thm  and  external stim uli such 
as horm ones and  vitam ins will be im portan t for a be tte r understanding  of DC- 
SCRIPT function in DCs.
The function of DC-SCRIPT in the m aturation  of DCs was investigated using DC- 
SCRIPT knock-down. Reduced DC-SCRIPT expression led to a dim inished production 
of the pro-inflam m atory cytokines IL-12, IL-6 and TNF-a, w hereas secretion of the 
anti-inflam m atory cytokine IL-10 was unaffected. Therefore our results suggest tha t 
DC-SCRIPT expression is im portan t for TLR induced pro-inflam m atory cytokine 
production by DCs. One im portan t factor playing a key role in the  m aturation  of 
DCs and the production of cytokines is NF-kB. The NF-kB family of transcrip tion  
factors exist as e ither hom odim ers or heterodim ers of five distinct p roteins (p50, 
p52, RelA, RelB, and c-Rel). NF-kB activation occurs by nuclear translocation 
following inducible phosphorylation  of inhibitory IkB pro teins by the IKK0 (IkB 
k inase) complex. NF-kB has show n to be a key factor in DC m aturation  by, am ongst 
o ther factors, the  induction of pro-inflam m atory cytokine secretion [31-34]. NF-kB 
activation can potently  be inhibited  by glucocorticoids that, via the  induction of the 
IKBa inhibitory protein, traps activated NF-kB in inactive cytoplasm ic complexes [35­
37]. Interestingly, p relim inary  data indicates th a t DC-SCRIPT is also a co-regulator 
of GR and can regulate transcrip tion  of GR ta rg e t genes in DCs. Therefore one may 
hypothesize th a t DC-SCRIPT m odulates GR function in DC and  via this pathw ay 
influences NF-kB induced pro-inflam m atory cytokine production. If DC-SCRIPT can 
also act as a co-regulator of o ther NRs, the  exact m echanism  by which DC-SCRIPT 
regulates NR function and w hether it also reciprocally regulates type I and II NRs in 
DCs still needs fu rther investigation.
Taken together, the  exact function of DC-SCRIPT in DCs and  the  pathw ays DC- 
SCRIPT is involved in need  to be fu rther dissected to gain a m ore com prehensive 
insight into its role in DC biology. The DC-SCRIPT knock ou t m ouse th a t is being 
generated  will provide a useful tool in fully elucidating the exact role of DC-SCRIPT 
during DC developm ent, m aturation  and  in the different DC subsets.
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DC-SCRIPT and carcinoma
In this thesis we have identified DC-SCRIPT as an im portan t regulator of NRs. NRs 
and  the ir co-regulators are im portan t factors in the  aetiology of horm one dependent 
cancers, including b reast and  p rosta te  cancer. In chapter 3 and 4 we show  th a t 
DC-SCRIPT is a strong and independen t prognostic m arker in b reast cancer and in 
chapter 5 th a t DC-SCRIPT can also potentially  be used as a diagnostic m arker in 
p rosta te  carcinoma.
Breast cancer
B reast cancer is still one of the  leading causes of cancer death  in women. Prognostic 
and  predictive m arkers are of high relevance in therapeutic  decision procedures in 
o rder to individualize treatm ent. Classical clinicopathological features indicating 
pa tien t prognosis include tum our size, histological subtype and  grade and lymph 
node m etastases. O ther established biom arkers are ER, PR and  HER2 and  em erging 
biom arkers are Ki67, Cyclin D1, Cyclin E and ER0 [38]. In addition to single m arkers, 
recen t m olecular profiling has yielded genetic signatures for m any solid tum ours, 
including b reast cancer [39-41]. The identification of new  m arkers will lead to a 
m ore definitive insight into tum our biology and  will substan tia te  the  im portance of 
the existing biom arkers.
Currently, ERa is an im portan t biom arker in b reast cancer. Estrogens, the ligand 
for the type I NR ER, are w ell-known for the ir pro-proliferative effects in b reast 
cancer cells [42-45]. Therefore, endocrine trea tm en t w ith anti-estrogens, such as 
tamoxifen, has been a t the forefront of trea tm en t regim en for m any years [46]. In 
contrast, ligands for the  type II NRs are mainly associated w ith anti-proliferative 
effects in b reast cancer cells [47-50]. In line w ith the repressive activity of DC- 
SCRIPT on the type I NRs and the activating capacity on the type II NRs, ectopic DC- 
SCRIPT expression in a b reast carcinom a cell line has been show n to inhibit b reast 
cell proliferation. In addition we found th a t DC-SCRIPT expression had  statistically 
significant prognostic value for pa tien ts w ith ER- a n d /o r  PR-positive tum ours 
(c h a p te r  3)[51]. We show ed th a t DC-SCRIPT mRNA expression rep resen ts a solid 
prognostic m arker as it predicts - independently  of cu rren t clinical prognostic 
m arkers such as age, m enopausal status, grade, tum our size and recep to r status - 
the occurrence of d istan t m etastasis in patients who did no t receive any adjuvant 
system ic trea tm en t (c h a p te r  4)[52]. For a subset of ER-positive patien ts in which 
we determ ined  the DC-SCRIPT mRNA level, a global gene expression profile of the 
p rim ary  tum our was also available. Prelim inary gene ontology analyses show ed th a t
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high expression of DC-SCRIPT is negatively correlated  w ith m any cell cycle proteins. 
Intriguingly, this is precisely w hat one w ould expect of a protein  inhibiting the 
activity of the pro-proliferative type I NRs ER and  PR and stim ulating the activity 
of the mainly anti-proliferative NRs RAR and PPAR. In this context, we hypothesize 
th a t DC-SCRIPT expression may be associated w ith a gene expression profile tha t 
n o t only takes into account the  presence or absence of ER/PR and  RARa/PPARy/ 
RXRa them selves, b u t also the collective expression of the ir ta rg e t genes. Future 
experim ents are aim ed to fu rther study the association of DC-SCRIPT w ith cell cycle 
proteins. DC-SCRIPT expression itse lf m ay directly affect cell cycle progression, 
b u t it  is also possible th a t DC-SCRIPT is differentially expressed during the various 
stages of the  cell cycle and  as a consequence is negatively associated w ith different 
cell cycle proteins. Initial experim ents will be aim ed a t investigating the  effect of 
ectopic DC-SCRIPT expression on cell cycle progression in b reast cancer cells.To 
fu rther investigate its role as a prognostic m arker in b reast cancer, we have recently 
se t up an inducible DC-SCRIPT MCF-7 b reast carcinom a cell line model. So far, all 
(b reast cancer) cell lines we tested  do n o t express DC-SCRIPT, preventing us from 
perform ing knock dow n studies. The DC-SCRIPT inducible MCF-7 cell line allows 
for the expression of DC-SCRIPT upon stim ulation w ith doxycyclin. By varying the 
concentration of doxycyclin we can vary the DC-SCRIPT expression levels, enabling 
us to study cells expressing physiological levels of DC-SCRIPT. Ongoing experim ents 
have show n th a t this m odel is a useful tool in investigating the effect of DC-SCRIPT 
expression on b reast carcinom a cell growth. W hen physiological levels of DC-SCRIPT 
expression w ere induced by stim ulation of doxycyclin, grow th of the  cells in v itro  
was significantly inhibited. These resu lts w ere confirm ed in vivo. Initial experim ents 
dem onstra ted  th a t xenografts of the  DC-SCRIPT inducible cell line in nude mice 
resu lted  in a reduced  tum our cell grow th upon DC-SCRIPT expression, com pared to 
control inducible MCF-7 cells. DC-SCRIPT expression in the  tum our was confirm ed 
ex v ivo  by m eans of im m unohistochem istry (IHC). Taken together, our prelim inary 
data  shows th a t we now  have a system  th a t provides us w ith a unique m odel and 
an ideal tool to characterize and study the complex role of DC-SCRIPT (in both  the 
absence and presence of NR ligands) in b reast cancer biology in v itro  and in vivo.
Prostate cancer
Prostate cancer continues to be a frequent cause of m orbidity  and death  in males 
th roughou t the  w orld  [53]. The m ost w ell-known m arker for p rosta te  cancer is PSA, 
which has been used for detecting p rosta te  cancer since 1994. However, PSA is n o t a
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perfect marker, since it  lacks both  the sensitivity and  specificity to accurately detect 
the presence of p rosta te  cancer. Other prom ising m arkers for detecting p rostate  
cancer are hK2, uPAR, PSMA, EPCA and PCA3, how ever fu ture studies will need  to 
prove the ir usefulness [54].
In c h a p te r  5 we describe th a t DC-SCRIPT may also be a prom ising novel m arker 
for p rosta te  cancer detection. IHC on frozen sections of p rosta te  cancer patients 
revealed th a t DC-SCRIPT is expressed in m orphologically norm al p rosta te  glands 
and  th a t expression is lost in m alignant p rosta te  tissue. The use of IHC in the 
diagnosis of adenocarcinom a is a com m on practice in uropathology, and the use of 
antibodies against p63 and HMW cytokeratin has been recom m ended in confirming 
prosta tic  carcinom a in doubtful cases [55]. A rray-based screening approaches are 
w idely used to define tum our-specific aberration  p a tte rns of the  genom e and of 
gene expression in p rosta te  carcinoma. Currently, the lack of a suitable antibody 
for IHC on paraffin sections has restra ined  us from large scale screening studies of 
DC-SCRIPT protein  expression in paraffin tissue-m icroarrays of p rosta te  carcinom a 
patients. The availability of one w ould greatly facilitate future studies investigating 
its potential as a diagnostic tool in p rosta te  carcinoma.
Interestingly, we also found th a t DC-SCRIPT pro tein  expression in prostate  
carcinom a appears to be lost p rio r to the loss of the  basal cell m arker HMW 
cytokeratin th a t is frequently used in p rosta te  carcinom a diagnosis. The loss of 
cytokeratin is one of the m arkers of epithelial-m esenchym al transition  (EMT) [56]. 
EMT may be induced by several oncogenic pathw ays and is characterized by loss of 
cell adhesion, repression  of E-cadherin expression and  increased cell mobility. It is 
hypothesized th a t the  induction of EMT facilitates tum our cell invasion, spread  and 
m etastasis, and may rep resen t a m echanism  of tum our progression [57]. Since DC- 
SCRIPT is lost p rio r to cytokeratin, the loss of DC-SCRIPT expression may rep resen t 
an early m arker for EMT in p rosta te  carcinoma. This hypothesis may be extended to 
b reast carcinom a w here EMT is also suggested to play an im portan t role in cancer 
progression [58]. In b reast cancer, EMT preferentially  occurs in tum ours w ith the 
basal-like phenotype [59]. Remarkably, DC-SCRIPT expression was low est in b reast 
tum ours w ith this phenotype (c h a p te r  4), therefore it  is tem pting to speculate th a t 
the loss of DC-SCRIPT expression m ay also be associated w ith EMT in b reast cancer 
It is therefore of g reat in te rest to fu rther investigate the involvem ent of DC-SCRIPT 
expression or the  loss thereo f in the induction of EMT C
ha
pt
er
144 | Chapter 7
Tumour suppressor
In this thesis we have provided evidence th a t DC-SCRIPT is linked to cell 
proliferation and tum ourigenesis suggesting th a t it may function as a tum our 
suppressor in b reast and p rosta te  carcinoma. Tum our suppressor genes refer to the 
genes w hose function is to restra in  cells from  uncontrolled grow th and migration. 
W hen this gene is m uta ted  in a cell it may resu lt in loss or reduction  of its function 
and the cell can progress to cancer. Most loss-of-function m utations th a t occur in 
these  genes are recessive. Therefore, tum our suppressor genes generally follow the 
tw o-h it hypothesis, which implies th a t both  alleles of a tum our suppressor gene m ust 
be affected before an effect is m anifested [60-62]. This can either be via m utation 
b u t also via chrom osom al loss. Chromosomal loss is one of the m ost frequent genetic 
alterations detected  in a cancer cell. In some cases, there  may no t be a m utation 
of the tum our suppressor gene, b u t ra th e r som e o ther m echanism  th a t interferes 
w ith its expression or function. This may include m ethylation of the gene prom oter 
th a t suppresses its transcrip tion , an increased ra te  of proteosom al degradation, or 
abnorm alities in o ther pro teins th a t in terac t w ith the gene product [63]. Further 
study is needed  to determ ine the m olecular m echanism  th a t contributes to the 
loss of DC-SCRIPT expression and  to define DC-SCRIPT as a tum our suppressor 
gene. These studies may include single nucleotide polym orphism s (SNP) arrays 
th a t are aim ed a t detecting the loss of heterozygosity (LOH) of a gene and thereby 
may identify allelic im balance of the DC-SCRIPT gene. Further studies may also 
include the investigation of DC-SCRIPT prom oter m ethylation. Hyperm ethylation of 
tum our associated genes can be cancer cell specific and  can occur early upon cancer 
developm ent. H yperm ethylation of gene p rom oters can be reversed  by trea tm en t 
w ith dem ethylating agents. If DC-SCRIPT expression is lost due to prom oter 
m ethylation, trea tm en t w ith dem ethylating agents may lead to res to red  DC-SCRIPT 
expression and  thereby  possibly to grow th inhibition of the  cancer cells.
Thus, know ledge regarding the m echanism  of loss of DC-SCRIPT expression in 
epithelial cells may lead to m ore optim ized trea tm en t of cancer.
Conclusion
In summary, this thesis dem onstrates th a t the function of DC-SCRIPT extends 
beyond DCs. It is a unique co-regulator of NRs, im portan t in b reast and  prosta te  
epithelial cells and  possibly in DCs. Its exact function and  underlying m echanism  
as a prognostic m arker in b reast carcinom a and its potential as a diagnostic tool
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in p rosta te  carcinom a deserves fu rther research. The im portance of DC-SCRIPT in 
carcinom a may no t only be restric ted  to b reast and p rosta te  carcinoma, b u t may 
possibly extend to o ther carcinom as in which NRs play an im portan t role, such as 
ovarium  carcinoma. Ultimately, DC-SCRIPT m ay tu rn  ou t to be a fundam ental and 
essential factor in regulating cell grow th and  viability via m odulating the horm one 
and  vitam in balance in different cell types. Insights into the different pathw ays DC- 
SCRIPT is involved in, in both  DCs as well as epithelial cells, may lead to optim ization 
of DC based  vaccination strategies, bu t also to optim ization of existing and 
developm ent of new  trea tm en t strategies in different carcinomas.
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Samenvatting
Het m enselijk lichaam  w ord t dagelijks blootgesteld aan vele verschillende 
soorten  m icro-organism en en pathogenen, zoals bacteriën, v irussen en parasieten. 
Het im m uunsysteem  herken t een grote varië te it aan ziekteverw ekkers en bescherm t 
h e t lichaam  hiertegen, m aar kan ook onderscheid  m aken tussen  gezonde en 
kw aadaardige cellen. De enorm e verscheidenheid  aan cellen en de w isselw erking 
tussen  cellen van h e t im m uunsysteem  zorgen voor een hoog ontw ikkeld en complex 
systeem.
Het immuunsysteem
Het im m uunsysteem  bestaa t u it h e t aangeboren en h e t verw orven 
im m uunsysteem . Het aangeboren im m uunsysteem  reag eert heel snel en b estaa t uit 
o.a. granulocyten, macrofagen, dendritische cellen (DCs) en m onocyten. Deze cellen 
herkennen  specifieke onderdelen, de zogenoem de antigenen, van verschillende 
m icro-organism en en pathogenen en reageren  hierop door h e t uitscheiden van o.a. 
cytokines en antibacteriële eiwitten. Het verw orven im m uunsysteem  bestaa t u it de B 
en de T lymfocyten. In tegenstelling to t de cellen van h e t aangeboren im m uunsysteem , 
herkennen  de lymfocyten m aar één specifiek antigeen. Ze reageren hierop door he t 
uitscheiden van antistoffen tegen de pathogenen (B lymfocyten) of door h e t doden 
van virusgeïnfecteerde cellen of tum orcellen (T lymfocyten). Voordat de lymfocyten 
hierop kunnen reageren m oeten ze h e t antigeen gepresen teerd  krijgen door de 
zogenoem de antigeen p resen terende cellen (APCs). De belangrijkste en m eest 
efficiënte APC is de DC. Deze cel speelt h ierdoor een cruciale rol in h e t initiëren 
en stu ren  van een goede im m uunreactie. In h e t lichaam  zijn er veel verschillende 
soorten  DCs aanwezig. De tw ee belangrijkste soorten  DCs zijn de myeloïde en de 
plasm acytoïde DCs.
DCs die in de weefsels zitten zijn in een zogenoem de onrijpe s taa t en hebben 
een grote capaciteit om m icrobiële antigenen te herkennen  en te  vangen door 
m iddel van specifieke receptoren  die ze op h e t celm em braan hebben. T ijdens een 
infectie rijpen de DCs en veranderen  ze naar een antigeen p resen terende cel. Door 
deze veranderingen is de DC in s taa t vanuit de weefsels naar de lym feknopen te 
verplaatsen, w aar hij de antigenen kan p resen teren  aan de lymfocyten. DCs kunnen 
n ie t alleen lymfocyten activeren, m aar hij kan ze ook “to leran t” m aken zodat ze n ie t 
reageren op goedaardige bacteriën  en gezonde cellen. De omgeving van de DC is heel 
bepalend  voor de m anier w aarop een DC de lymfocyten stuurt. Niet alleen de micro-
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organism en die daar aanwezig zijn, m aar ook de hoeveelheid en soo rt vitam inen 
en horm onen die daar aanwezig zijn spelen daarbij een cruciale rol. H orm onen en 
vitam ines w orden in een cel herkend  door m iddel van de zogenoem de nucleaire 
receptoren  (NRs). DCs hebben een groot aantal van deze NRs.
Nucleaire Receptoren
NRs zijn eiw itten die door bepaalde liganden, o.a. horm onen en vitam ines, 
kunnen w orden geactiveerd en daardoor de expressie van belangrijke genen in de 
cellen kunnen reguleren. NRs zijn n ie t alleen belangrijk  in h e t im m uunsysteem , 
m aar spelen ook een belangrijke rol bij de ontwikkeling en de progressie van 
o.a. borst- en prostaatkanker. NRs spelen ook een belangrijke rol in fysiologische 
processen zoals em bryonale ontwikkeling, m etabolism e en hom eostase, m aar 
ook in pathologische situaties zoals in diabetes, reum atische artritis, astm a en 
kanker. Ze hebben  allem aal eenzelfde structuur. Ze hebben  een activerend domein, 
een DNA bindend  en een ligand bindend  domein. Op basis van hun w erking zijn 
de NRs ingedeeld in 2 hoofdgroepen. Tot de type I NRs behoren  de Oestrogeen 
Receptor (ER), de Progesteron Receptor (PR) en de Androgeen Receptor (AR), die 
respectievelijk oestrogenen, p rogesteronen  en androgenen binden. De type II NR 
bestaan  u it eiw itten die een interactie  aangaan m et de Retinoid X Receptor (RXR). 
Tot deze groep behoren  o.a. de Retinoic Acid Receptor (RAR) die actieve derivaten 
van vitam ine A bindt, de peroxisoom proliferatorgeactiveerde Receptoren (PPAR) 
m et als ligand o.a. vrije vetzuren en de vitam ine D3 Receptor (VDR). Niet alleen 
de NRs zelf, m aar ook de regulatoren van deze NRs spelen een belangrijke rol in 
bovengenoem de processen.
In 2006 is h e t eiw it DC-SCRIPT geïdentificeerd. Ook is aangetoond dat h e t mRNA 
van DC-SCRIPT in alle soorten  DCs aanwezig is. In d it proefschrift speelt DC-SCRIPT 
de hoofdrol. We hebben onderzocht w at de rol van dit eiw it is in h e t im m uunsysteem , 
m aar ook in borst- en p rostaa tkanker
In hoofdstuk 2 laten we zien d a t DC-SCRIPT zowel op mRNA als eiw itniveau 
aanwezig is in verschillende soorten  DCs. We laten  zien da t DC-SCRIPT binnen 2 
uur na de s ta rt van differentiatie to t expressie kom t en dat d it vooral afhankelijk 
is van de cytokine IL-4. DC-SCRIPT blijkt in m yeloïde DCs vooral gelocaliseerd te 
zijn in de kern van de cel, terw ijl in plasm acytoïde DCs DC-SCRIPT vooral in he t 
cytoplasm a van de cel aanwezig is. Om achter de rol van DC-SCRIPT te kom en in
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DCs, hebben we de expressie van DC-SCRIPT in deze cellen verlaagd. De resultaten  
laten zien da t DCs die m inder DC-SCRIPT to t expressie brengen ook m inder p ro ­
inflam m atoire (ontstekingsbevorderende) cytokines maken als ze gestim uleerd 
w orden m et antigenen. Dit w ijst erop dat DC-SCRIPT een belangrijke rol speelt in de 
juiste rijping van DCs.
Hoofdstuk 3 beschrijft de rol van DC-SCRIPT in borstkanker. Op basis van door 
bioinform atica verkregen aanwijzingen kon biochem isch w orden aangetoond dat 
DC-SCRIPT aanw ezig is in hetzelfde eiwitcomplex w aarin  ook de type I en type II NRs 
hun functie uitoefenen. Ook blijkt da t DC-SCRIPT de w erking van de pro-tum origene 
type I receptoren zoals PR en ER kan rem m en terw ijl DC-SCRIPT de w erking van de 
anti-tum origene type II receptoren RAR en PPARy ju ist kan stim uleren. We hebben 
ook aangetoond da t de borstkliercellen van epitheliale oorsprong h e t DC-SCRIPT
Gezond weefsel
T v p e1NR pp -
Stimulatie celgroei
PR
DC-SCRIPT ppARv Tvpe II NR 
RAR
k
Tumor ontwikkeling & progressie
PPARy
RAR
DC-SCRIPT
___________ Laag______________
Slechte prognose
PPARy
DC-SCRIPT „  *
PR nii *■ RAR ER Matig _
Goede prognose
Figuur 1. Model voor de w erk ing  van DC-SCRIPT
DC-SCRIPT regelt de balans in de activiteit van de type I ER en PR en de type II NRs RAR en PPARy 
DC-SCRIPT rem t de werking van de pro-tumorigene type I NRs en stim uleert de werking van de anti- 
tumorigene type II NRs. Na afschakeling van de DC-SCRIPT expressie zal de balans doorslaan naar de 
toegenomen activiteit van de pro-tumorigene type I receptoren.
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mRNA en eiw it to t expressie brengen, terw ijl maligne borstep itheel cellen m inder 
DC-SCRIPT to t expressie brengen. Het afschakelen van DC-SCRIPT-expressie in 
borstcellen op h e t m om ent d a t deze een tum or gaan vorm en, p ast bij de rol van DC- 
SCRIPT als regelaar van de balans in de activiteit van type I en type II NRs (Figuur 1).
Om na te  gaan of DC-SCRIPT inderdaad  een rol speelt bij de ontw ikkeling en 
h e t verloop van borstkanker w erd  de hoeveelheid DC-SCRIPT mRNA gem eten in 
tum orw eefsel van patiën ten  m et borstkanker. Patiënten die weinig of geen DC- 
SCRIPT to t expressie brachten in hun prim aire  borsttum or, hadden  een significant 
kortere  ziektevrije overleving dan de patiën ten  w aarvan de tum or grotere 
hoeveelheden DC-SCRIPT to t expressie brachten. De prognostische w aarde van 
DC-SCRIPT is vooral aanwezig in ER e n /o f  PR positieve patiënten. Patiënten die 
adjuvant behandeld  w erden m et de ER antagonist tamoxifen lieten precies dezelfde 
prognostische w aarde van DC-SCRIPT zien als patiën ten  die geen adjuvante therapie 
kregen. DC-SCRIPT expressie had  dus geen invloed op h e t effect van Tamoxifen. 
Statistische testen  m et uni- en m ultivariate analyses lieten uiteindelijk zien d a t DC- 
SCRIPT een prognostische factor is onafhankelijk van andere  standaard  klinische en 
pathologische param eters.
In hoofdstuk 4 hebben we de resu lta ten  die we hebben verkregen in hoofdstuk 
3 gevalideerd in een groter en onafhankelijk cohort van 1505 borstkankerpatiënten . 
Uni- en m ultivariate analyses lieten ook in d it cohort zien, d a t de hoeveelheid DC- 
SCRIPT mRNA in tum orw eefsel corre leert m et zowel ziektevrije overleving, m etastase 
vrije overleving en totale overlevingsduur en dus inderdaad  een onafhankelijk 
prognostische factor is voor ER e n /o f  PR positieve borstkankerpatiën ten . Bovendien 
laa t deze studie zien da t DC-SCRIPT mRNA hoeveelheden vooral inform atief zijn voor 
h e t klinische verloop van ERa positieve e n /o f  ER0 lage tum oren  van <2 cm (pT1). 
DC-SCRIPT hoeveelheden in de prim aire  tum or konden n ie t gecorreleerd  w orden 
m et h e t effect op eerstelijns endocriene therap ie  voor gevorderde borstkanker
Hoofdstuk 5 rich t zich op h e t effect van DC-SCRIPT in prostaatkankercellen. 
Ook in prostaa tkanker spelen verschillende NRs een belangrijke rol. Vooral 
van de type I NR AR (Androgeen Receptor) en de type II NR VDR (Vitamine D3 
Receptor) is bekend dat ze de groei van prostaatcellen  kunnen beïnvloeden. In 
d it hoofdstuk laten  we zien da t DC-SCRIPT mRNA to t expressie kom t in norm aal 
en m aligne p ro staa t weefsel, m aar n ie t gerela teerd  kan w orden aan verschillende 
stadia van prostaatkanker. Im m unohistochem ische kleuringen tonen aan dat
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DC-SCRIPT to t expressie kom t in m orfologisch norm ale basaal epitheliale cellen 
van de p rostaatk lieren  en in de infiltrerende im m uuncellen. Opvallend is dat 
DC-SCRIPT afwezig is in maligne p ro staa t epitheliaal weefsel en in alle geteste 
prostaatcellijnen. De eiw itexpressie van DC-SCRIPT lijkt eerder verloren  te  gaan dan 
de basale celm arker HMW cytokeratine die vaak gebruik w ord t in de diagnose van 
prostaatkanker. Om dat we eerder hadden  laten zien dat DC-SCRIPT een rem m end 
effect had  op de type I NR en een activerend effect op de type II NR, hebben we in 
deze studie onderzocht of DC-SCRIPT hetzelfde effect heeft op de protum origene 
NR, AR en de voornam elijk antitum origene NR, VDR. Biochemische experim enten 
tonen  aan dat DC-SCRIPT in eenzelfde eiwitcom plex kan zitten als AR en VDR. Ook 
laten  de resu lta ten  zien d a t ook in prostaatcellen  DC-SCRIPT de werking van de type 
I NR AR kan rem m en en de w erking van de type II NR VDR kan activeren. Bovendien 
vertraag t DC-SCRIPT de groei van prostaatkankercellen  aanzienlijk. Sam envattend 
laa t deze studie dus zien d a t DC-SCRIPT een belangrijke regulator is van de NRs AR 
en VDR die in p rostaatkanker een tegengestelde rol spelen en dat h e t verlies van 
DC-SCRIPT expressie in prostaatcellen  betrokken zou kunnen zijn bij h e t ontstaan 
van prostaatkanker.
In hoofdstuk 6 beschrijven we de com plexiteit van w erking van NRs. Van veel 
NRs is bekend dat ze invloed op elkaar kunnen uitoefenen (“crosstalk”). Vooral van 
de crosstalk  tussen  ER and RAR w ord t steeds m eer bekend in borstkankercellen. 
Ze kunnen in hetzelfde eiwitcom plex zitten, m aar ook elkaar reguleren. Het is 
een uitdaging om precies uit te  zoeken hoe deze NRs sam enw erken om complexe 
processen te  reguleren  in een omgeving w aar m eerdere horm onen en vitam ines 
aanwezig zijn. Bovendien is h e t heel in te ressan t om uit te zoeken hoe DC-SCRIPT 
precies betrokken is bij deze crosstalk en hoe h e t de type I NR kan rem m en en de 
type II NR kan activeren. Een belangrijke vraag die nog onbeantw oord is, is hoe 
h e t genotype en de expressie niveaus van DC-SCRIPT de reactie  van een cel op 
verschillende horm onen en vitam ines kan beïnvloeden en of een verstoorde w erking 
of expressie van DC-SCRIPT genoeg is voor cellen om te transform eren  naar maligne 
cellen.
In hoofdstuk 7 w orden de resu lta ten  van h e t onderzoek beschreven in dit 
proefschrift sam engevat en bediscussieerd.
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Toekomstperspectieven
In dit proefschrift hebben we laten zien da t DC-SCRIPT n ie t alleen een rol speelt 
in dendritische cellen m aar ook in andere  cellen. Het is een unieke co-regulator van 
verschillende NRs die een belangrijke rol spelen in borst- en p ro staa t epitheliale 
cellen. De exacte functie en h e t onderliggende m echanism e van zijn w erking als 
prognostische factor in borstkanker en zijn potentiële rol als diagnostische factor in 
prostaa tkanker verdienen verder onderzoek. De belangrijke rol van DC-SCRIPT zou 
ook kunnen gelden voor andere  tum oren  w aar NRs ook een belangrijke rol spelen 
zoals ovariumkanker. Uiteindelijk zou verder onderzoek u it kunnen wijzen d a t DC- 
SCRIPT een fundam entele en essentiële factor is in h e t reguleren  van celgroei en 
celviabiliteit via h e t m oduleren van de balans tussen  de verschillende horm oon- en 
v itam inereceptoren  in verschillende celtypes. Verdere inzichten in de verschillende 
“pathw ays” w aar DC-SCRIPT een rol blijkt te spelen, in zowel dendritische cellen 
als epitheliale cellen zou kunnen leiden to t de optim alisatie van dendritische cel 
gebaseerde vaccinatiestrategieën, m aar ook to t de optim alisatie van bestaande en 
de ontw ikkeling van nieuw e therap iestrateg ieën  tegen verschillende soorten  kanker.
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Eindelijk dan....het dankw oord....
Natuurlijk ten  eerste  Gosse, zonder jouw  ongelooflijke vertrouw en en steun 
tijdens m ijn aio-tijd zou h e t natuurlijk  nooit gew orden zijn zoals h e t n u  is. Ik ben 
heel blij m et de m anier w aarop je mij begeleid hebt. Ik kon altijd bij je binnenlopen 
en vond h e t altijd leuk om m et je over data  te  discussiëren, ook al w aren en zijn we 
h e t n ie t altijd eens... Jouw onophoudelijke enthousiasm e m aakte h e t altijd leuk om 
over DC-SCRIPT te praten. En natuurlijk  enorm  bedank t da t je me nog een tijdje rond 
w ilt laten lopen op h e t TIL.
Op een gedeelde eerste  plaats m et Gosse wil ik natuurlijk  M aaike bedanken. W at 
vorm en wij een goed team  sam en zeg. Vanaf h e t begin was h e t leuk om  m et jou 
sam en te werken. Jij gaat er helem aal voor. Het is nooit een probleem  als h e t eens 
een keertje w at later wordt. Ook was je er altijd om mij een beetje af te  rem m en, w at 
ik  regelm atig nodig had  als ik  w eer eens een beetje overenthousiast was. Gelukkig 
kunnen we n ie t alleen op h e t w erk  goed sam en opschieten m aar ook daarbuiten!!! 
Ik hoop da t we d it nog heel lang volhouden en d a t je heel gelukkig blijft m et Bas en 
Levi.
Mijn andere paranim fje, M arjolijn ... ~ 4  oktober 2008 was h e t zover.. toen is onze 
liefde opgebloeid :)... Dankzij jou  was h e t altijd een plezier om iedere dag om  7.00 te 
b e g in n e n .. Eerst even m et Marjo kletsen en dan pipetteren!! Het is ech t ongelooflijk 
hoeveel wij kunnen p ra ten  en lachen...ik denk  d a t anderen  er soms wel een beetje 
m oe van w erden...En zelfs als we elkaar heel de dag gezien hadden, konden we 's 
avonds nog m akkelijk 2 uur m et elkaar b e l le n . h e t is ech t altijd gezellig! Bedankt dat 
je zoveel naar mijn verhalen heb t gelu isterd  toen ik  h e t nodig had!! Ik vind h e t heel 
jam m er d a t je w eer weg b en t gegaan uit Nijmegen en w eer te rug  naar Waddinxveen. 
Ik hoop en denk da t we nog steeds veel contact zullen houden, w an t ik  wil Megan 
natuurlijk  wel op zien groeien! Ik mis onze vrijdagavonden nu  wel h o o r ! ..  Maar ik 
w ens jou, Franklin en Megan natuurlijk  een geweldige tijd  in Waddinxveen!
En dan kom en natuurlijk  de andere tw ee scriptm eisjes: S aa rtje  en Nina! W at 
hebben  wij een leuk groepje m et zijn 4-tjes en gelukkig n ie t alleen op h e t lab, m aar 
ook daarbuiten. SHO h e t is echt heel gezellig om naast jou te  zitten. Ik denk  dat 
we ongeveer n e t zo vaak aan h e t lachen zijn als da t we aan h e t w erk  z ijn ..d a t  
klinkt natuurlijk  heel in effic ien t..m aar je m oet je inspiratie  toch ergens vandaan 
halen :). Ook onze tijd in Kroatie was fa n ta s tisc h .w e  hebben elkaar toch w at 
be ter leren kennen en zelfs na 6 dagen sam en op 1 hotelkam er bleven we la c h e n .
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en de re s t van de verhalen over Kroatie die kan ik  h ier be ter n ie t opschrijven 
natuurlijk..;)...En dankzij jou heeft ook Diggy Dex een speciaal plekje in mijn hart! 
En Nina, w at superleuk  da t jij ook in ons scriptgroepje zit. Eerst heb je een half 
jaar proefkonijn m oeten zijn, w an t je was natuurlijk  de eerste  s tu d en t w aarvan ik 
stagebegeleidster werd. Stiekem vond ik dat wel een beetje  spannend natuurlijk, 
w an t ik  voelde m ezelf ook nog een studentje. Maar gelukkig ging h e t goed en was he t 
erg  leuk. Buiten h e t onderzoek hebben we ook even een soo rt N ederlandse cursus 
gedaan in de vele uren  da t we sam en hebben gewerkt. Gelukkig is h e t pro ject w at je 
geschreven h eb t om  bij ons aio te  w orden toegekend en hoor je w eer helem aal bij 
ons!! M alou, jij ho o rt natuurlijk  ook een speciaal plaatsje te  krijgen in d it dankwoord. 
Je was de 2e s tu d en t w aarvan ik  stagebegeleidster m ocht zijn. Ongelooflijk d a t jij 
n ie t gek b en t gew orden bij ons. Je zou de nobelprijs voor volhardendheid  m oeten 
krijgen...de hoeveelheid kloontjes die wij geprik t hebben sam en...m aar h e t is n iet 
voor niets geweest.. h e t KWF-project d a t we nu  geschreven hebben, is gebaseerd  
op kloon S29 en S36!!! Ik ben er nog steeds van overtuigd dat we een enorm  goed 
zangduo zouden kunnen w orden, n e t zoals we in h e t viruslab deden. F itsu m  and 
Jo sh u a  ju st before I finished my PhD you becam e students in our scriptgroup, thanks 
for everything and the funny talks we had  and the nice Dutch singing!
Dear A nna, no t a scrip t girl, bu t anyway you belonged to us! In the beginning 
w hen you s ta rted  as a PhD student, we w orked together a lo t and got to know  each 
o ther very well. It was very nice th a t you also lived in the  aquarium ! Sometimes 
you w ere a b it “pittig”, b u t always honest and I very m uch appreciate that!! I'm very 
happy th a t you show ed m e how  it is to celebrate a tru e  Polish wedding, it  was a great 
weekend!! And although you’re  n o t w orking in the  lab anym ore, we luckily see each 
o ther very often. I w ish you and  P a tr ic k  all the  b e s t and  a g rea t tim e in London!! 
A m y'tje, my yeti b est friend from Australia. In the first few m onths you w orked at 
the TIL, we didn’t  really know  each other...but everything changed in 2010. I have 
never had  a friend which ditched m e so often and  I could so easily ditch w henever 
o ther things cam e around w hich w ere or seem  to be m ore im portant. I liked all our 
talks about OCs and  everything th a t had som ething to do w ith that...o r abou t other 
things. Thanks a lo t for all your su p p o rt in the sum m er of last year! And I’m  happy 
th a t we still ta lk  a lo t and  th a t our w eek in Norway will now  be followed w ith a w eek 
in Switzerland.
Paul, hartelijk  bedank t voor al je hulp m et ons JNCI stuk  en onze review. Jij heb t 
al de berekeningen gedaan, de tabellen en Kaplan-Meiers gem aakt en m e eindeloos 
SPSS uitgelegd als ik h e t w eer eens n ie t begreep. Ongelooflijk w at jij daar allemaal
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vanaf weet! En dankzij jou hebben we nu  een m ooie sam enw erking lopen m et 
Rotterdam. A nieta, hartstikke bedank t voor de fijne sam enw erking die we hadden 
bij h e t valideren van de prognostische rol van DC-SCRIPT in borstkanker. Voordat ik 
je een m ailtje had  gestuurd, had  je er ongeveer al een teruggestuurd , d a t was echt 
heel p re ttig  samenwerken!! En natuurlijk  John  en John, bedank t voor de vruchtbare 
besprekingen die we hebben gehad. John  M. hartstikke leuk dat we een KWF- 
pro ject hebben geschreven over DC-SCRIPT, laten  we hopen d a t h e t toegekend gaat 
worden! Jack, G erald  en Tilly hartstikke bedank t voor jullie hulp bij de DC-SCRIPT/ 
prostaatpaper. Tilly ik vond h e t heel fijn d a t jij de scoring van alle coupes heb t willen 
doen!! Ik wil natuurlijk  ook graag alle andere  coauteurs bedanken voor hun bijdrage 
aan de artikelen.
A le ssa n d ra  en R u u rd  bedank t voor jullie hulp toen Gosse er een tijdje n ie t was. 
Zonder jullie hulp bij de rebu tta l w eet ik n ie t zeker of ons verhaal geaccepteerd zou 
zijn gew orden bij JNCI. Natuurlijk wil ik ook D agm ar, Bas, F ried e riek e , M aaike vH., 
B arb a ra , E s th e r en P au l G. bedanken voor hun inpu t en discussies tijdens de DLMs 
en daarbuiten. Salva H erre ro , M aria  F o rlenza  and  A n n em iek  vS, my internship 
supervisors, you show ed m e for the  first tim e how  g reat science can be and you 
all encouraged me to do a PhD, thanks a lo t for that, I have never reg re tted  it!! Ook 
iedereen  van h e t TIL; de staf, h e t secretariaat, de patiëntengroep, de adhesiegroep, 
TTT en de m uizengroep, bedank t voor alle discussies en gezellige p raatjes tijdens
o.a. alle TIM m eetings en tijdens de koffie. Maar ook voor alle leuke m om enten 
buiten  werktijd, zoals op kerstavonden, dagjes uit, pokeravonden etc. vooral W endy, 
M arjo le in , M igiechel, S tefan, 10-us, De D u itse r, G erm an n e tje , Jessica, Nicole, 
B en en Jori zonder jullie zou mijn aio-tijd een stuk  m inder gezellig zijn geweest! 
E ric v an  D. ik vond h e t superleuk  om sam en m et jou en Koen h e t binnenhalen van 
de derde ster van Ajax te  vieren op h e t M useumplein d it jaar!! En M elissa zonder 
jou zou de barbecue van dit jaar een stuk  m inder (of ju ist m e e r .)  “m em orabel” zijn 
g e w e e s t.;) . Ik hoop d a t we nog vaak zullen gezellig avonden zullen hebben!!
En dan de m eisjes van W ageningen, Kim, N ienke en Cindy. We doen allemaal 
iets anders nu, m aar heel erg bedank t da t jullie altijd naar mijn geklaag over he t 
prom overen en hoe d ruk  h e t was aan w ilde horen. Ik hoop da t we vaak af blijven 
s p re k e n . w an t ik denk  d a t ik nog lang n ie t klaar ben m et klagen :).
U iteraard wil ik  ook mijn vrienden  u it Bladel bedanken, ondanks da t we iedereen 
veel m inder zagen toen we verhuisden naar Nijmegen, was h e t toch altijd gezellig 
als vanouds als we w eer eens kwamen. Ik wil speciaal S an d ra  en P e tra  bedanken, ik 
ben blij d a t we elkaar nog regelm atig zien, sam en carnaval vieren, bij kunnen kletsen
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en vooral gaan winkelen! En Jeroen , jij hoo rt natuurlijk  ook een speciaal plekje te 
krijgen in d it dankw oord. Je ben t er een g root gedeelte van mijn prom otie altijd voor 
m e geweest! Soms kon ik m e een beetje verliezen in m ijn werk, m aar je w ist me 
altijd op h e t goede m om ent te  rem m en w anneer h e t n e t iets teveel werd! Ik ben je 
daar echt heel dankbaar voor!
Dan h e t verplichte gedeelte .. .mijn fam ilie .:). Maar natuurlijk  n ie t m inder terecht! 
P ap  & A njo lie  en m am  & Paul, tw ee paar ouders, dus dubbel geluk!! Hartstikke 
bedank t voor alles! Jullie hebben altijd achter elke keuze gestaan die ik  gem aakt 
h eb t en hebben  er bovendien voor gezorgd da t elke keuze ook echt mogelijk was. 
Dat is altijd een heel p re ttig  gevoel geweest!! En nu  is h e t dan eindelijk zo v er.w ie  
had  d a t nu  g e d a c h t.m ijn  prom otie. En dan Emmy, mijn kleine stoere z u s je .  je vond 
h e t altijd zo verschrikkelijk om naar mijn verhalen over m ijn w erk  te lu isteren. en 
ik  snapte  niets van jouw  verhalen  over de koeltechniek. Maar gelukkig is h e t toch 
altijd...oké d a n .m e e s ta l .h e e l  leuk samen! Toch nog iem and die een beetje snapt 
d a t h e t hebben van deze ouders som s b est een beetje lastig is ;)!!
Koen, ongelooflijk w at jij h e t laatste  jaar voor mij gedaan hebt. En dan heb ik  he t 
natuurlijk  n ie t alleen over h e t m aken van de cover en h e t layouten van de re s t van 
m ijn boekje (w aar ik  overigens natuurlijk  wel enorm  blij m ee ben :)). Maar ik  ben 
vooral blij m et alle leuke dingen die we sam en doen en al gedaan hebben. Ik hoop 
d a t de p lannen die we gem aakt hebben gaan lu k k e n . !!
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The Versatile Role of the Nuclear Receptor Co-Regulator 
DC-SCRIPT in Dendritic Cell and Cancer Biology
1. DC-SCRIPT is a universal dendritic cell marker and regulator of TLR-induced 
cytokine production. ( th is  th esis)
2. The function of DC-SCRIPT extends beyond dendritic cells. It can regulate the 
function of nuclear receptors important in cancer biology. (th is  th esis)
3. DC-SCRIPT can inhibit the function of the protumorigenic type I nuclear 
receptors ER, PR and AR, in contrast it can stimulate the function of the 
antitumorigenic type II nuclear receptors RAR, PPAR and VDR. ( th is  thesis)
4. DC-SCRIPT expression is lost upon malignant transformation of breast and 
prostate epithelial cells. ( th is  thesis)
5. DC-SCRIPT represses cell growth of breast and prostate epithelial cells. (th is  
thesis)
6 . DC-SCRIPT is an independent prognostic marker for ER and/or PR positive 
breast cancer patients. (th is  thesis)
7. Opinion is the medium between knowledge and ignorance. (P la to )
8 . Het wil niet zeggen dat mensen die veel praten veel te zeggen hebben.
9. Een wereldrecord lijkt een grote stap voor een mens, de mensheid komt er niet 
door van haar plaats. Die blijft gemiddeld op hetzelfde niveau. Tegenover die 
ene uitschieter in hoogspringen staat ergens in de bevolking een nieuwe 
kampioen laagspringen. Gemiddeld is de mensheid geen millimeter 
opgeschoten. (M idas D ekkers)
10. In the middle of difficulty lies opportunity. (A lb er t E instein)
11. Schoenen hoeven niet te zitten, als ze maar staan. (B r ig itte  H ou gardy)
12. Hormonen en vitamines demonstreren dat kleine dingen grootse effecten 
kunnen hebben.
